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Abstract 
Genetic toxicity testing is the assessment of compounds, and their respective metabolites, 
potential to cause DNA damage either directly or indirectly. There are many genetic 
toxicology screening assays designed to assess the DNA damaging potential of chemicals in 
early drug development to help identify promising drugs that have a low risk potential of 
causing damage leading to cancer in humans. Despite this, in vitro tests generate a high 
number of miss-leading positives, the consequences of which lead to unnecessary animal 
testing and abandoning promising drug candidates. Understanding chemical Mode of Action 
(MoA) is vital in identifying true genotoxic potential of substances. Here I demonstrate a 
simple robust protocol for optimised staining of fixed human lymphoblast P53 proficient TK6 
cells with the antibodies; Anti-ɣH2AX, Anti-P53 and Ant-pH3S28 along with DRAQ5™ DNA 
staining in a whole cell multiplex system that is suitable for analysis via microscopy or 
imaging flow cytometry. Use of the Amnis FlowSight® and ImageStream X Mark II® platform 
provided a high content high throughput acquisition platform with the sensitivity of flow 
cytometry and accuracy of image analysis. Using both optimal and suboptimal lasers for 
fluorophore excitation demonstrated that a multiplex system for DNA damage assessment 
including MN was possible in un-lysed cells. IDEAS 6.2 template generation allowed for 
batch processing of data samples extracting the following metrics: Cell Cycle, Micronucleus 
(MN), ɣH2AX, P53, PH3, G1 ɣH2AX, G1 P53, S ɣH2AX, S P53, G2 ɣH2AX, G2/M P53, Prophase, 
Metaphase, Anaphase and Abnormal mitosis. Furthermore, high content nature of the 
platform using imagery allows for identification of rare cellular event assessment 
particularly preliminary data on biomarker signal found within MN. The system found 
differences in the biomarker metric responses between the chemicals; MMS, Carbendazim, 
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Chapter 1 – Introduction 
1.0 – Background 
Genetic toxicity testing is the assessment of compounds, and their respective metabolites, 
potential to cause DNA damage either directly or indirectly. The Organisation for Economic 
Co-operation and Development (OECD) offers recommended regulatory guidance for 
genetic toxicology testing approaches in an attempt to unify assay standards across industry 
and academia world wide. One of the mandated tests for the assessment of chromosome 
damage, is the in vitro micronucleus (MN) assay, (OECD., 2014; Fenech et al., 2003). In this 
test, damage to the chromosomes (clastogenicity) and chromosomal segregation machinery 
(aneugenicity) can be evaluated via MN formation in cells that have undergone mitosis 
(Schmid., 1975). Typically, each cell type within the MN assay is identified using microscopy, 
via either manual scoring or semi-automated image classifiers, but more recently, flow 
cytometry approaches have been utilised. These approaches can be highly laborious or 
potentially lead to misleading positive or negative outputs, through over- and under-scoring 
respectively (Johnson et al., 2014; Verma et al., 2017). The main challenges with the in vitro 
tests, including the various incarnations of the MN assay, at this time, are related to the high 
number of misleading positives that are reported, especially when using mammalian cells 
(Fowler et al., 2012). False positives in this context are found by subsequent animal tests 
which cannot confirm the genotoxicity reported with in vitro studies. The consequence of 
this situation results in unnecessary animal tests and or the abandonment of promising 
substances that otherwise are safe. Further testing is required to characterise the Mode of 
Action (MoA) that has driven the MN formation.  
Conventionally, the presence or the absence of centromeric labels within the MN is used to 
discriminate between aneugenic or clastogenic Mode of Actions respectively (OECD., 2010). 
Recently, molecular markers have proven useful in identifying MoA, for example, the 
increase in phosphorylated Histone 3, linked to aneuploidy, and phosphorylated histone 
variant H2AX (ɣH2AX) linked with clastogenicity (Audebert et al., 2010; Cheng et al., 2015; 
Bryce et al., 2016). Histones are proteins made up of two of each of the following sub-units, 
H2B, H2A, H3 and H4 in addition to a single H1 linker protein (Hans et al., 2001). Post 
translational modifications of tail residues of these proteins, are responsible for a cells 
progression through the cell cycle and the condensing of chromosomes (Nowak et al., 2004; 
Hans et al.,2001; Zhou et al., 2006). The H2A histone is a highly conserved protein across 
many species, with the ɣH2AX foci occurring in a 1:1 ratio with regard to DNA damage 
(Hoeller et al., 2009; Zhou et al., 2006; Watters et al., 2009). Phosphorylation of H2AX, on 
serine 139 of the SQEY tail, upon double strand breaks results in the activation of the DNA 
damage repair (Watters et al., 2009). Chromosome condensation is accompanied by 
phosphorylation of the H3 protein, at two different serine residues, S10 and S28, to ensure 
movement through mitosis (Doerig et al., 2015; Hans et al., 2001). Phosphorylation of H3 at 
the S28 position begins at prophase and by late anaphase has been completely 
dephosphorylated (Hans et al., 2001). H3 phosphorylation is affected by the amount of DNA 
damage found within the cell as it passes through the cell cycle, especially by chemically 
induced DNA damage (Ozawa., 2008). These characteristics of pH3 and ɣH2AX, used in 
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combination with immunofluorescent antibodies (AB), enables the use of flowcytometry 
based platforms to determine the clastogenic/aneugenic potential of compounds (Smart et 
al., 2011; Bryce et al., 2016). Past the direct assessment of histone tail modifications 
additional biomarkers in combination with pH3 and ɣH2AX aid in MoA assessment of 
chemicals one such biomarker is the tumour suppressor protein P53. P53 often referred to 
as the guardian of the genome has multiple functions including but not limited to; Cell cycle 
progression and maintenance, DNA damage repair initiation and induction of apoptotic 
pathways (Lavin & Gueven., 2006). P53 response to DNA damage and cellular stresses is 
mediated by complex pathways and phosphorylation of different protein residues 
dependant on the mechanism of DNA damage induction (Lavin & Gueven., 2006). Due to 
P53 intrinsic nature related to DNA damage pathways regardless of aneugenicity or 
clastogenisity it offers a biomarker for overall assessment of DNA damage induction (Bryce 
et al., 2016). 
The following work attempts to build on work by Khoury et al., 2016 and Bryce et al., 2016 
pH3 and pH2AX genotoxicity screening assay and MultiFlow® assay respectively using the 
Imaging flow cytometry platform for unlysed cell assessment of the Biomarkers ɣH2AX, pH3-
S28, P53 (unphosphorylated) individually and in relation to the cell cycle combined with the 
genotoxic endpoint MN assessment.  
1.0.1 – Toxicology Terminology  
In terms of colloquial communications within genetic toxicology circles, the terms 
‘Mode’ and ‘Mechanism’ as well as ‘Endpoint’ and ‘Biomarker’ are often used 
interchangeably. 
Here ‘Mode’ in Mode of Action (MoA) refers to the overriding way in which a chemical 
has induced damage to the DNA. Direct physical breakage of the DNA is a Clastogenic 
MoA. DNA loss due to interactions with the cell division machinery is a Aneugenic MoA. 
The ‘Mechanism’ in terms of mechanism of action is referred to as the underlying 
detailed steps of the MoA, for example, a chemical has a clastogenic MoA caused by the 
mechanism of DNA alkylation. In short, the MoA is the effect and mechanism of action 
the how.  
The term ‘Endpoint’ is the physical conclusion of the MoA. The MN is the conclusion of 
the MoA whether it be by clastogenic or aneugenic means. A biomarker here is referred 
to as a measurable transient signal that occurs along the biochemical pathway that 
allows for an indication of MoA. With the potential for allowing mechanistic assessment.  
Understanding the MoA can help determine testing strategy within safety assessment 
whilst knowing mechanism can help make decision on compound progression through 
the drug development pipeline and impact of DNA damage repair pathways on a 





1.1 – DNA: Structure, Function, Damage and Repair 
Deoxyribose Nucleic Acid (DNA) is the hereditary information of all living organisms, and it is 
found within the nucleus of mammalian cells and as a circular chromosome in bacteria. DNA 
is the biological molecule that contains the genetic blue print of life. This set of instructions 
is contained within every cell and is passed down from parents to offspring, in the case of 
mammals half from the father and half from the mother. The DNA fingerprint is specific to 
each individual because of this combining of hereditary information.  
DNA was first isolated in 1869 by Swiss biochemist Freidrick Miescher but the structure and 
importance of this polymer was a relative mystery (Dahm, 2008). Not until James Watson 
and Francis Crick in 1953 pulling pieces of the puzzle together from other scientists was the 
true structure of DNA realised. Phoebus Levene in 1919 put forth the ‘polynucleotide’ model 
of nucleic acids, that they contained one of four nitrogen containing basis, a sugar molecule 
and phosphate group. Oswald Avery and his team in 1944 demonstrated that genes 
composed of DNA were the hereditary units. Erwin Chargaff a few years later published in 
1950 that no matter the organism the basis (Adenine (A), Thymine (T), Guanine (G) and 
Cytosine (C)) of DNA remain the same and that A and T are found in similar ratios, likewise 
for C and G, this known as ‘Chargaffs rule’(Chargaff, 1950; Avery, 1944). The final piece of 
the puzzle was provided by Rosalind Franklin (unbeknownst to her) in 1952 when her X-ray 
diffracted image of DNA, that showed the three dimensional structure of DNA to be a 
double helix, was shown to Watson and Crick. This information along with previously 
published knowledge of the structural chemistry of the basis allowed Watson and Crick to 
suggest the structure of two opposing strands of DNA wound in a right handed helical 
structure allowing for the base pairing of Purines with Pyrimidines and stabilised by 
hydrogen bonds.  
Elucidation of the structure of DNA allowed for the understanding of DNA replication and 
the passing of hereditary events as well as potential impact of mutation.   
1.1.1 – DNA Structure & Function 
Whilst simple in design the structure and packaging of DNA can be thought of in three 
levels of increasing complexity: Primary, Secondary and Tertiary. Figure 1.1 
demonstrates the three levels of structure the DNA macromolecule passes through to 















Figure 1.1: Primary, secondary and tertiary stages of Deoxyribose Nucleic Acid (DNA) 
structure. DNA is a polymer made up of a long sequence of deoxyribose nucleotide bases 
bound together by phosphodiester covalent bonds. Hydrogen bonds form between the 
specific base pairs Guanine:Cytosine and Thymine:Adenine stabilising the two strands of 
DNA into a helical structure referred to as a double helix (Watson & Crick, 1953; Chargaff, 
1950; Pierce, 2012). DNA strands wrap 1.65 times around histone octamer protein core 
consisting of H2A, H2B, H3 and H4 dimmers, this is referred to as a nucleosome. H1 protein 
stabilises the structure and is known as a chromatosome, forming beads on a string 
(Carruthers et al., 1998; Pierce, 2012). Nucleosomes fold together to form a 30nm DNA and 
protein fibre. Further folding generates 300nm long loops that compact to 250nm wide 
coiling fibres that form 700nm wide chromatid arm (Lodish et al., 2000; Lodish et al., 2004 
Dorigo et al., 2004; Pierce, 2012). The metaphase chromosome consists of two sister 
chromatids joined at the centromere, telomeres being at the very end of each chromatid 
arm, the chromosome is roughly 1400nm in width. Figure adapted from Pierce, Benjamin. 



































DNA is a polymer made up of multiple repeating nucleotide units linked together to 
form a long molecule termed, a macromolecule. A single DNA macromolecule makes up 
one chromosome (Alberts et al., 2002; Pierce, 2012). The nucleotide monomers DNA is 
made up of are composed of the following: 
- Pentose sugars composed of five carbons 1’ through to 5’ and has a hydrogen 
atom bound to the second carbon giving its name deoxyribose. 
- Nitrogen containing base (nitrogenous base), which is either purine or 
pyrimidine. A and G are purines, they are formed of a six sided ring attached to 
a five sided ring and differ based on the positions of double bonds in the 
structure and adjacent groups. C and T are 6 sided pyrimidines that differ again 
based on double strand positioning and associated chemical groups. The 
nitrogenous base forms a covalent bond with the 1’ carbon of the sugar. 
- Phosphate group consisting of a phosphorus atom bound to four oxygen atoms, 
carrying a negative charge, and is bound to the 5’ carbon of the sugar.  
DNA nucleotides are properly known as deoxyribonucleotides and are the primary 
structure of DNA (Pierce, 2012).  
The secondary structure refers to the 3D alpha double helix formed of two 
complimentary polynucleotide strands wound around one another, running anti parallel, 
with the sugar phosphates being on the outside fused to the neighbouring monomer by 
phosphodiester bond (Watson & Crick, 1953). At the 5’ end of each strand there is a free 
phosphate and at the 3’ end a free hydroxyl group. The associated bases of the structure 
are on the inside, like rungs on a ladder (Watson & Crick, 1953; Pierce, 2012). The 
structure is stabilised by the Watson and Crick base pairs C and G forming three 
hydrogen bonds with each other and A and T forming two hydrogen bonds, along with 
stacking forces between neighbouring bases (Watson & Crick, 1953; Chargaff, 1950; 
Pierce, 2012), refer to figure 1.1. These interactions whilst not as strong as covalent 
bonds have a purpose to their weakness. The frailty of the bonds and interactions allows 
for the separation of the strands by cellular machinery for DNA replication and 
transcription during Ribonucleic Acid (RNA) synthesis (Pierce, 2012; Alberts et al., 2002). 
As genetic information resides in the base sequence of DNA, transcription to RNA allows 
the code to be read and translated into amino acids that form proteins generating the 
cellular phenotype (Avery, 1944; Watson & Crick, 1953; Pierce, 2012). This is why when 
DNA is lost or mutated due to damage or error, the expression of genes and therefore 
proteins can be faulty or missing completely, in the case of loss of the protein P53 this 
can potentially result in initiation of cell malignancy.  
The tertiary structure of DNA is a dynamic system, supercoiling between its most 
condensed chromosome state during mitosis and more relaxed chromatin state 
consisting of DNA and proteins during interphase where genes for transcription and 
translation need to be accessed and replication to occur (Li et al., 2007; Woodworth & 
Holloway, 2017; Pierce, 2012). This more relaxed state of active DNA access is referred 
to as euchromatin, heterochromatin is the more condensed form of chromatin and is 
mainly found at the centromeres and telomeres of chromosomes (Woodworth & 
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Holloway, 2017). Proteins in the chromatin are positively charged histones that attract 
the negatively charged DNA. There are five main histones; H1, H2A, H2B, H3 and H4. As 
seen in figure 1.1, DNA wraps around a octamer core consisting of H2A, H2B, H3 and H4 
dimers forming a nucleosome (Luger et al., 1997). H1 stabilises the nucleosome 
structure. The core nucleosome combined with H1 is referred to as a chromatosome 
(Carruthers et al., 1998; Pierce, 2012). Chromatosomes are connected to one another by 
linker DNA of about 30-40 base pairs forming beads on a string. Histone tails project out 
from the nucleosome core, and whilst offering a site for a number of modifications from 
initiation of gene transcription to the DNA repair pathway, they also interact with tails of 
neighbouring nucleosomes facilitating compaction (Bednar et al, 1998; Lodish, et al., 
2000; Fischle et al., 2003; Pierce, 2012). This is a higher order of chromatin structure 
making a fibre about 30nm wide (Dorigo et al., 2004; Pierce, 2012). This fibre further 
compacts forming 300nm long loops anchored at their base by proteins. Additional 
folding and compressing occurs forming 250nm wide fibre that folds into the 700nm 
wide chromatid arm of the metaphase chromosome (Bednar et al., 1998; Pierce, 2012). 
The metaphase chromosome consists of two sister chromatids held together at the 
centromere and a multiprotein complex termed the kinetochore at each chromatid 
centromere (Pierce, 2012). The kinetochore facilitates binding of the spindle fibres to 
the sister chromatids in preparation for the chromatid separation in anaphase of 
mitosis. It is during this process that aneuploidy or polyploidy may occur due to a 
nondisjunction event resulting in the miss segregation of chromosomes.  
1.1.2 – DNA Damage 
Consisting of 2.9 billion base pairs the human genome is simultaneously complex and 
simple (Venter et al, 2001). Simple in that its base components are only made up of 4 
bases, complex in the packaging and maintenance mechanisms in place to preserve its 
integrity. Occurring at a rate of up to 105 lesions per cell per day both exogenous and 
endogenous agents can result in DNA damage (Lindahl, 1993). Exogenous 
(environmental) sources include ultraviolet (UV), radiation as well as chemicals 
introduced to a system. Whereas endogenous chemical genotoxins are as a result of 
normal metabolic activity, hydrolytic and oxidative reactions with water and reactive 
oxygen species (Chatterjee & Walker, 2017; Lindahl, 2000). It is predominantly these 
reactions that lead to spontaneous cancers and hereditary diseases (Chatterjee & 
Walker, 2017; Perrone et al., 2016). Predominantly DNA damage occurs at the primary 
level of DNA structure. These can result in bulky adducts and chemical bonds forming at 
the base level that disrupt the secondary helical structure of DNA. Due to the dynamic 
nature of DNAs’ tertiary or ‘superstructure’ moving between heterochromatin and 
euchromatin for gene expression, this higher form of packaging does not confer 
additional protection from DNA damaging agents (Lodish et al., 2004). Damaging agents 
can cause harm to DNA in a number of ways, the most common of which are 
summarised in figure 1.2 along with the repair mechanisms and potential 
consequences): DNA strand breaks, both single and double; Oxidative; Base alkylation; 
Abasic site generation; Bulky adduct formation and DNA crosslinking (Hoeijmakers 2001; 




1.1.2.1 – Oxidative Damage 
Reactive oxygen species (ROS) such as hydroxyl radicals (.OH) can be produced by 
ultraviolet (UV) and ionizing radiation or from metabolic reactions (Galano et al., 
2018). Guanine is the most easily oxidised nucleic acid and reactions with .OH forms 
8-oxo-7,8-dihydrogeanine (8-oxoG). 8-oxoG is one of the most prevalent DNA lesions 
and is considered a biomarker for oxidative stress (Poetsch, 2020; Galano et al., 
2018). Replication of DNA containing 8-oxoG results in the incorporation of Adenine 
opposite these modified Guanines. Upon conclusion of replication 8-oxoG is excised 
during DNA repair and Thymine used to replace it due to the A incorporation on the 
opposite strand resulting in a mutational event (Galano et al., 2018).  
1.1.2.2 – Base Alkylation 
Alkylating agents introduce legions that can be cytotoxic, mutagenic or neutral to the 
cell. Alkylating chemicals can modify any Oxygen and Nitrogen external to the rings 
Figure 1.2: DNA damaging agents, DNA damage, resultant repair and outcomes. A) Top - 
Common DNA damaging agents; Middle - examples of DNA lesions induced by these agents. 
Cisplatin (cis-Pt) and mitomycin C (MMC) are crosslinking agents. 6–4 photoproduct ((6-4)PP) and 
cyclobutane pyrimidine dimer (CPD) are induced by UV; Bottom - most relevant DNA repair 
mechanism responsible for the removal of the lesions. There are two main types of 
recombinational repair that fix DNA double strand breaks, Homologous recombination (HR) and 
Non Homologous End Joining (NHEJ). B) DNA damage effects on cell-cycle progression, leading to 
G1, S, G2 and M phase arrest, resulting in inhibition of DNA processing. Consequences of DNA 
injury include permanent changes in the DNA sequence, mutation and chromosomal aberrations 







of the pyrimidine/purine structure as well as ring nitrogen’s (Chatterjee & Walker, 
2017; Eker et al., 2009). However, the amount of site modification depends on the 
alkylating agent and position of the DNA. Mutagenic lesions result in the miscoding 
of newly synthesised DNA, the most common modification of alkylation being 
methylation. The products formed include N7-methyl guanine, N3-methyladnenine 
and O6-methylguanine. Blocking of replication, interruption of transcription or 
apoptotic pathway activation are signs of cytotoxic legion induction (Eker et al., 
2009). Base alterations also occur spontaneously such as the spontaneous 
deamination of 5-methylcytosines. These occur at varying rates dependant on the 
position in the DNA i.e., within a nucleosome turn or on linker DNA (Tomkova & 
Schuster-Bockler, 2018). Upon deamination cytosine converts to thymine resulting in 
a G to T. Both MMR and BER play a role in the correction of these errors (Poulos et 
al., 2017; Walsh & Xu, 2006).  
1.1.2.3 – Abasic Sites  
Abasic sites, apurinic/apyrimidinic (AP) sites are different terms for ‘Base Loss’. AP 
sites are formed due to unstable hydrolysis of DNA. This is where neither a purine or 
pyrimidine base has been incorporated on one of the strands of the DNA leaving the 
opposing base without a partner (Lindahl, 1993; Lindahl & Barnes, 2000). This may 
happen spontaneously or be due to DNA damage. AP sites may also occur as a 
intermediate step in the Base Excision Repair (BER) pathway (Lindahl, 1993; Lindahl 
& Barnes, 2000). Abasic sites by nature are unstable and convert into single strand 
breaks (SSBs) due to targeting of 3′ phosphodiester bond of the remaining 
deoxyribose by a β-elimination reaction (Bailly & Verly, 1988; Chan et al., 2013) 
1.1.2.4 – Bulky Adducts 
Biologically active chemicals may form covalent links with molecules such as DNA 
with molecules such as DNA, creating bulky adducts or appendages that branch off 
from the main molecule. Benzo[a]pyrene, a polycyclic aromatic hydrocarbon found 
in burnt meat and tobacco smoke, is one such chemical that when metabolically 
activated forms a epoxide that preferentially binds with Guanine residues to form a 
bulky adduct (Chatterjee & Walker, 2017; Wiencke, 2002). If this adduct is not 
repaired a Adenine base will be inserted opposite the adduct during replication. 
Excision of the bulky adduct after replication will result in a thymine insertion 
causing a G-T transversion mutation (Chatterjee & Walker, 2017). Additional 
examples of bulky adducts are Cyclobutane Pyrimidine Dimers (CPDs) and                  
(6-4)Pyrimidine-pyrimidone photoproducts at dypyrimidine sites that form due to UV 
exposure (Besaratinia et al., 2005; Chatterjee & Walker, 2017). 
1.1.2.5 – DNA Crosslinking  
DNA crosslinking occurs when a reactive agent interacts with two nucleotides 
forming covalent link between them. This may happen on the same strand 
(intrastrand) or opposite strands (interstrand) (Chatterjee & Walker, 2017; Clauson 
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et al., 2013). DNA replication and transcription are often affected by these adducts. 
UV radiation can cause crosslinks to occur between pyrimidines and often 
neighbouring thymines, chemicals such as cisplatin and mitomycin C generate 
interstrand crosslinks often between guanine residues (Hoeijmakers, 2001; Clauson 
et al., 2013). These inter and intra strand adducts cause a kink to occur in the helical 
structure of DNA, if uncorrected inhibition of polymerases can occur causing 
misreading during transcription or replication and may lead to replication arrest 
(Hoeijmakers, 2001; Clauson et al., 2013). DNA intrastrand crosslinking is often fixed 
by Nuclear Excision Repair (NER) and interstrand crosslinks by Homologous 
recombination and Non homologous end joining (Hoeijmakers, 2001; Clauson et al., 
2013).  
1.1.2.6 - DNA Strand Breakage 
Ionising radiation i.e. X-rays, due to high energy, can cause both single and double 
strand brakes directly. Chemicals that cause crosslinking of bases can also induce 
strand breakages if the damaged DNA undergoes replication (Hoeijmakers, 2001). 
During replication and transcription of DNA Topoisomerase (Topo) enzymes are used 
to relieve the helical tension, crosslinks cause Topo to stall remaining covalently 
bound to the DNA (Morimoto et al., 2019). This process, abortive catalysis, leads to 
the formation of single strand breaks in the case of Topo1 and double strand breaks 
in the case of Topo2. Generation of these breaks during transcription may help to 
signal DNA damage response pathway initiation (Morimoto et al., 2019; 
Hoeijmakers, 2001).  
1.1.3 – DNA Repair 
Eukaryotic cells have developed a series of mechanisms to preserve genome integrity, 
predominantly, DNA damage checkpoint activation and DNA damage repair (Chatterjee 
& Walker, 2017; Ding et al., 2020). In terms of DNA damage response two outcomes are 
prevalent, cells either undergo cell cycle arrest to allow damage repair and re-enter the 
cell cycle or the apoptosis (cell death) pathway is initiated (Ding et al., 2020; 
Hoeijmakers, 2001). Cell cycle progression and segregation of chromosomes into 
daughter cells is a highly regulated process and is separated into four distinct phases, 
multiple checkpoints are in place to ensure correct transition into each of the phases, 
see section 1.2 below. Upon incidence of DNA damage detection, the cell cycle is halted 
by cyclin-dependant kinase inhibitors (Ding et al., 2020). This is a complicated cascade 
with a series of downstream effects. DNA damage sensors in addition to blocking cell 
cycle progression are responsible for initiating repair pathways that are specific for each 
type of DNA damage (Ding et al., 2020; Hoeijmakers, 2001; Chatterjee & Walker, 2017). 
Single strands DNA breaks are repaired by Base Excision Repair (BER), Bulky adducts and 
crosslinks are repaired by Nucleotide Excision Repair (NER), smaller nucleotide 
mutations such as alkylation’s are repaired by Mismatch Repair (MMR). Double strand 
breaks can be repaired by two different mechanisms; Non homologous End Joining 




1.1.3.1 – Base Excision Repair  
Single strand breaks are repaired by the BER pathway as are oxidised bases. Oxidised 
bases are removed from the DNA by BER enzymes. The 8oxoG lesion is excised OGG1 
(8-Oxoguanine DNA glycosylase) leaving a AP site. AP sites are then processed 
further, AP-endonuclease 1 nicks the backbone inducing a single strand break 
(Poetsch, 2020; Galano et al., 2018). This AP site can be repaired in one of two ways. 
The first is long patch base excision repair, the AP site along with additional bases 
are replaced by the activity of polymerase δ and ε with proliferating cell nuclear 
antigen (PCNA) (Poetsch, 2020). The old strand is removed by flap endonuclease one 
and ligase one reseals the backbone. The second is short patch BER, here Polymerase 
β replaces the single missing base, LigaseIII and X-ray repair cross complementing 
protein one complex sealing the backbone (Poetsch, 2020).  
1.1.3.2 – Nucleotide Excision Repair  
The NER process excises DNA fragments of 24 to 32 nucleotides long that contain the 
damage lesion with high accuracy. Then the undamaged strand is used as a template 
and repaired sequence ligated into the DNA, repairing the break that occurred as a 
result of the cross link/ bulky adduct damage excision (Petruseva, 2014; Hanawalt, 
2002). Determined by initial type of damage recognition there are two potential NER 
routes. Global Genome Nucleotide Excision Repair (GG-NER) identifies and removes 
bulky lesions from the entire genome. Transcription Coupled Nucleotide Excision 
Repair (TC-NER) is initiated when damage to the DNA that is being transcribed 
inhibits RNA polymerase II transcription (Petruseva, 2014; Hanawalt, 2002). XPC- 
hHR23B protein identifies damage in GG-NER it is not required in TC-NER. After the 
initial detection of damage, the continued progression of the NER pathway is the 
same for both GG-NER and TC-NER (Petruseva, 2014; de Laat et al., 1999). Involved 
in RNA polymerase II activation, NER and cell cycle regulation TFIIH is a 9 subunit 
complex (de Laat et al., 1999). TFIIH bind the DNA near the site of the bulky addict 
creating a 10 to 20 nucleotide opening in the DNA complex. Additional proteins: RPA, 
XPG, XPA, ERCC1 are recruited to the site (Petruseva, 2014; Gillet & Schärer, 2006; 
Fousteri & Mullenders, 2008). XPA bind the damaged nucleotides, RPA to the 
undamaged strand (Shivji et al., 1995; de Laat et al., 1999). The repairasome is fully 
stabilised by XPG which makes the three prime incision on the DNA backbone. 
ERCC1-XPF makes the second incision on the five prime side of the lesion (Shivji et 
al., 1995; de Laat et al., 1999). Once the lesion has been removed proliferating cell 
nuclear antigen (PCNA) and Replication Factor C (RFC) aid polymerase δ to perform 
patch repair (Shivji et al., 1995). DNA ligase then re-seals the DNA backbone. 
1.1.3.3 – Mismatch Repair  
Mismatch repair helps maintain genome stability through correction of mismatched 
bases and modified bases such as alkylation. The major source of mismatch base 
pairs is replication error. The E-coli MMR machinery is able to identify the DNA 
template strand due to its methylated state compared to the new strand which is 
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unmethylated, it is possible that this also occurs in eukaryotes (Fukui, 2010). Post 
replicative MMR is performed by the long patch MMR mechanism, here a long 
portion of oligonucleotide is excised during repair removing the lesion. In eukaryotes 
mutSα and mutSβ identified the mismatch (Fukui, 2010). PCNA, RFC, mutLα and 
mutLγ perform the strand incision, RPA single stranded binding protein and Exo1 
exonuclease excised the nucleotide sequence with the lesion (Fukui, 2010). DNA 
polymerase δ fills the gap and ligase repairs the backbone nicks (Fukui, 2010). 
1.1.3.4 – Double Strand Break Repair 
Induction of a Double Strand Break (DSB) in the DNA is a highly toxic lesion, and 
unresolved DSBs are linked to various cancers and human diseases (Jackson & 
Bartek, 2009). Non homologous end joining (NHEJ) and Homologous recombination 
(HR) are the two major pathways of DSB repair. The first step that signals DSB 
induction is chromatin modifications that trigger cascading events for recruitment of 
the DNA damage repair machinery, this include but are not limited to: 
Ataxia-telangiectasia mutated (ATM) kinase activation, H2AX phosphorylation, MDC1 
recruitment along with 53BP1 and BRCA1 (Panier & Boulton, 2014; Liu et al., 2014; 
Chatterjee & Walker, 2017).  Phosphorylation of serine 139 on the histone H2AX 
variant, referred to as ɣH2AX, through both direct and indirect mechanisms serves in 
both the NHEJ and HR pathways to aid in scaffold and retention of effector proteins 
(Cully & Xie, 2013; Chen et al., 2019; Collins et al., 2020). The NHEJ pathway for 
repair of DSBs can take place at any phase of the cell cycle whereas HR can only 
occur in the S and G2 phases of the cycle (Krajewska et al., 2015). NHEJ is the 
simplest and widest used mechanism of DSB repair, the process simply reseals the 
two broken ends regardless of base sequence homology, this means the process is 
error prone. In contrast HR is extremely accurate in maintaining sequence homology 
by predominantly using the sister chromatid as a template for repair (Krajewska et 
al., 2015; Hoijmakers et al., 2001). The two pathways compete to perform the 
repairs. The MRX complex, composed of MRE11/RAD50/XRS2 is recruited to the 
ends of the DNA DSB and plays a role in both NHEJ and HR (Decottignies, 2013).  
1.1.3.4.1 – Non Homologous End Joining  
For initiation into the NHEJ, Ku70/Ku80 heterodimer inhibits the 5’-3’ 
exonuclease activity by binding the DNA ends, which prevents initiation of the HR 
pathway. The DNAPKcs, complexes with XRCC4 and binds to the Ku70/Ku80 
stabilising the NHEJ complex and initiating recruitment of further proteins 
(Jackson, 2009; Panier & Boulton, 2014). This stabilising scaffolding complex 
allows Artemis, PNKP, APLF, WRN, APTX to initiates DNA end processing, this 
removes blocking groups and resecting the naked strands (Jackson, 2009; 
Chattergee & Walker, 2017; Panier & Boulton, 2014). The gaps left behind by 
resection are filled by specific polymerases (POLµ or POLλ) and DNA ligase IV 
joins and seals the ends (Panier & Boulton, 2014; Lieber, 2010). NHEJ low fidelity 
usually results in nucleotide deletions or insertions at the repair junction 
(Decottignies,2013; Chattergee & Walker, 2017).  
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1.1.3.4.2 – Homologous Recombination  
Due to the lack of a sister chromatid in G1 the HR pathway is largely inhibited, 
not until the synthesis phase of the cell cycle where two copies of the DNA 
become available does HR become active (Johnson & Jasin, 2000; Krejci et al., 
2012). HR does not have one unique mechanism but many potential routes: 
Synthesis-Dependent Strand Annealing (SDSA), double Holliday junction 
resolution (also known as Double Strand Base Repair (DSBR)) and single-strand 
annealing (SSA). The common theme in each of these mechanisms is the 
generation of single stranded DNA and can be classified into presynapsis, 
synapsis and postsynapsis (Chattergee & Walker, 2017; Li & Heyer, 2008 ). The 
presynapsis and synapsis stages are the same for SDSA, DSBR and SSA, it is not 
until postsynapsis that distinct divergence of mechanisms occurs (Li & Heyer, 
2008).  
The MRN complex consisting of MRE11/RAD50/NBS1 initiates HR where it 
recognises and binds to the DNA at the DSB site (Stracker & Petrini, 2011; 
Chatterjee & Walker, 2017). During presynapsis ATM and TIP60 are recruited to 
the DNA, TIP60 activates ATM which phosphorylates H2AX which provides 
anchoring for MDC1 across the DSB site (Riches et al., 2008; Panier & Boulton, 
2013; Collins et al., 2020). Upon recruitment ATM phosphorylates MDC1 which 
acts as a scaffold for the ubiquitin E3 ligases RNF8 and RNF168. The E3 ligases are 
then able to ubiquitinate H2AX which then acts as a docking site for BRCA1 and 
53BP1 (Riches et al., 2008; Altmeyer and Lukas, 2013; Panier & Boulton, 2013;) 
BRCA1 inhibits 53BP1 helping to commit the system to the HR pathway (Panier & 
Boulton, 2013). RPA and RAD51 join the scaffolding complex on the DNA and end 
resectioning occurs via the endonuclease activity of MRN and EXO1 or BLM 
where 5’-3’ nucleolytic degradation results in 3’ nucleotide overhangs, the 
system is now fully committed to the HR pathway (Chen et al., 2008; Nimonkar et 
al., 2011; Panier & Boulton, 2013; Chatterjee & Walker, 2017). The next step 
‘synapsis’ is entered, and RPA is dislodged from the 3’ overhang by RAD51 
generating a nucleoprotein filament when combined with BRCA2 and PALB2 
(Zhang et al., 2009; Holloman, 2011). This nucleoprotein filament then invades 
near by duplex DNA forming a D-loop (Krajewska et al., 2015; Li & Heyer, 2008).  
After formation of the d-loop intermediate the HR pathway diverges commits to 
one of the three mechanisms during postsynapsis. A summary of the DSBR 
mechanism shall be focussed on here. On invasion of the template DNA RAD54 
and 54B remove RAD51 allowing the 3’OH group to activate by Polymerases δ, κ 
and ν ready for synthesis (Li & Heyer, 2008; Mazin et al., 2010; Sebesta et al., 
2013; Punatar et al., 2017). DNA synthesis occurs filling the gaps at which point 
second end capture occurs resulting in the formation of double Holliday 
junctions (Punatar et al., 2017). The BLM helicase-TopoisomeraseIIIα-RMI1-RMI2 
(BTR) complex catalyses the dissolution of the Holliday junctions. GEN1 
endonuclease, MUS81/EME1 and SLX1/SLX4 complexes may also process the 
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junctions (Cicca et al., 2008; Fekairi et al., 2009; Rass et al., 2010; Punatar et al., 
2017).  
 
1.2 – Cell cycle  
 
The biomarkers ɣH2AX, pH3, P53 and genotoxic endpoint of micronucleus formation cannot 
be discussed without first having an understanding of the cell cycle and its checkpoints. This 




Cell cycle Interphase is split into G1, S and G2 stages. Mitosis is the last stage of the cell cycle 
and is split into: Prophase, Metaphase, Anaphase and Telophase contributing to an equal 
division of DNA into two daughter cells (Poehlmann et al., 2010). G1 (Gap phase 1) of the 
Figure 1.3: Depicts the main stages of the cell cycle; Interphase consisting of G1, S and G2. Mitosis 
consisting of:  Prophase; condensing of chromosomes. Metaphase; Chromosomes aligned along 
metaphase plate. Anaphase; Cohesins binding chromatids are degraded spindles contract pulling 
chromatids apart and Telophase; Daughter nuclei begin to form and cell starts to divide (Tyson et al., 
2002). H2AX phosphorylation at checkpoints on the induction of SSBs and or DSBs result in DNA 
damage repair to occur, allowing the cell cycle to continue. Phosphorylation of H3 Serine residues 
signal prophase initiation, global phosphorylation at metaphase and progression into anaphase (Hans 
et al.,2001). Figure adapted from Tocris., 2015. 
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cell cycle is characterised by increase of cell size through accumulation of proteins, energy, 
and nucleotides ready for nuclear content duplication (Schafer., 1998; Vermeulen et al., 
2003). The S (Synthesis) phase of the cell cycle immediately follows G1 and is named as such 
as DNA replication occurs during this phase of the cell cycle. Here centrosomes also 
duplicate. At the end of this phase the nuclear DNA will have doubled 1n to 2n (also referred 
to as 2n to 4n) (Schafer., 1998; Sclafani et al., 2007). The second Gap (G2) phase, also 
referred to as the rest phase, the cell makes preparations to enter mitosis. Protein synthesis 
for chromosome manipulation and organelle duplication occurs here (Vermeulen et al., 
2003; Norbury & Nurse., 1992). Once the cell is prepared it will enter mitosis. The first phase 
of mitosis is prophase, here chromosome condensation begins, spindle fibres start to 
develop from the centrosomes and the nuclear envelop disappears (Poehlmann et al., 
2010). Prometaphase and metaphase stages consist of continuation of chromosome 
condensation microtubule and kinetochore assembly, centrosomes move to opposite poles. 
This is followed by chromosomes being lined up along the metaphase plate and full mitotic 
spindle assembly with centrosomes at opposite poles of the cell (Poehlmann et al., 2010; 
Cheeseman & Desai., 2008). At entry to anaphase the sister chromatids bound together at 
the centromere kinetochore complex, are completely attached to one spindle fibre 
emanating from opposite centromeres at the cell poles. Cohesin proteins connecting the 
centromere of the two sister chromatids break down and are separated by contracting 
microtubules at the kinetochore interface (Poehlmann et al., 2010; Cheeseman & Desai., 
2008). The newly defined chromosomes move to the cellular poles the cell lengthening and 
becoming oval in shape. Once chromosomes have arrived at the opposite poles the cell has 
entered telophase. The DNA structure begins to relax and the mitotic spindle breaks down, 
the nuclear envelope reforms. A cleavage furrow then separates the daughter cells before 
individual cytoplasmic membranes are formed generating two identical daughter cells 
(Poehlmann et al., 2010. Vermeulen et al., 2003). The mechanisms that aid mitosis include 
the epigenetic modifications of histone tails on histones such as Histone 3 and Histone 2A 
variant X (Ichijima et al., 2005). Daughter cells then enter Go phase, this is a holding pattern 
state where cells are inactive. External signals trigger the onset of G1 (Vermeulen et al, 
2003; Foster., 2008). 
 
During the G phase, S phase and G2/M phases of the cell cycle information is continually 
being collected to determine cellular readiness to pass into the next cell cycle stage 
(Norbury & Nurse., 1992). These are termed checkpoints. The main checkpoints are G1/S, 
Inter S phase, G2/M and Spindle Assembly Check Point (SAC) (Elledge., 1996; Tyson et al., 
2002; Poehlmann et al., 2010).  Checkpoint control is mediated through Cyclin dependant 
kinases (CdK) and Cyclins, the DNA either passes the checkpoint into the next phase or the 
cell cycle is arrested (Tyson et al., 2002; Poehlmann et al., 2010; Otto et al., 2017). This 
occurs through induction of tumour suppressing factors such as P53 and DNA damage repair 
pathway mediators such as ATM kinases upon Double Strand Breaks (DSB) and 
Ataxia-telangiectasia and Rad3 related (ATR) Kinases on Single Strand Breaks (SSB) figure 1.3 
(Tocris., 2015; Lord & Ashworth., 2012). The maintenance of these checkpoints, cyclin 
complexes and monitoring of the genome for DNA damage and therefore having a crucial 
role in genome maintenance, is P53 (Schafer., 1998; Lavin & Gueven., 2006). P53 signalling 
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pathways in turn lead to recruitment of DNA repair complexes signalled by epigenetic 
modifications of histones such as H2AX phosphorylation.  
1.3 – Genetic Toxicology and testing strategy 
Genotoxicity tests can be defined as in vitro and in vivo assays designed to detect 
compounds that induce genetic damage by various modes and mechanisms. These tests 
enable hazard identification with respect to damage done to DNA and potential risk 
(Dearfield et al., 2017; Hartwig et al., 2020; Thybaud et al., 2007). Genotoxic chemical 
compounds can be divided into 3 categories:  
 Mutagens – Compounds that react with DNA causing mutation.  
 Clastogens – Compounds that react directly or indirectly with the DNA resulting in 
DNA breaks. 
 Aneugens – Compounds that disrupt the cell division apparatus leading to miss 
segregation of the chromosomes.  
In terms of safety assessment for human exposure, genetic toxicology tests are used across 
several industries from chemical and environmental to fashion, food and pharmaceuticals. 
Within the drug development pipeline specifically there are approved guidance’s available 
on appropriate testing strategies, namely International Conference on Harmonisation (ICH) 
S2(R1) and the various in vitro and in vivo Organisation for Economic Co-operation and 
Development (OECD) testing guidelines. A combination of assays, referred to as a test 
battery, are used to assess the potential for carcinogenesis due to the vast spectrum of 
genetic damage mechanisms (ICH S2(R1), 2011; OECD, 2017; MacGregor et al., 2000; 
Dearfield et al., 2017; Hartwig et al., 2020). The recommended tests focus predominantly on 
gene mutation and chromosome damage endpoints because they have been identified as 
molecular events that are critical in tumour initiation.  
There are two predominant pathways suggested in the ICH and OECD guidelines for an 
appropriate battery of genetic toxicology good laboratory practice (GLP) package prior to 
first time in human that provide a robust platform for the identification of potential risk to 
the human population for promising drug candidates (ICH S2(R1), 2011; OECD, 2017). The 
first pathway consists of two in vitro assays, one being the bacterial reverse mutation assay 
(‘Ames’ test) the other a mammalian cell assay usually the Mouse lymphoma L5178Y cell 
thymidine kinase gene mutation assay (MLA) or Micronucleus Test/Assay (MNT). The in vitro 
assays may also include a +S9 arm in an attempt to mirror in vivo metabolism of the drug 
compound (ICH S2(R1), 2011; Kirkland et al., 2005) . These in vitro tests are followed by a 
single end point in vivo rodent micronucleus study using either peripheral blood or bone 
marrow. The second pathway again includes an Ames test but excludes the in vitro 
mammalian option for a dual endpoint in vivo study, taking samples for both micronucleus 
assessment and Comet analysis (ICH S2(R1), 2011; OECD, 2017; Kirkland et al., 2019).  
1.3.1 – Ames assay 
Salmonella typhimurium reverse mutation assay developed by Bruce Ames et al., 1973, 
which may be combined with the Escherichia coli (E.Coli) reverse mutation assay, Green 
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& Muriel, 1976, is colloquially referred to as ‘The Ames Assay’. The assay detects gene 
mutations, specifically base pair substitutions and frameshift mutations, using bacterial 
test strains modified at specific histidine or tryptophan loci that may or may not contain 
a plasmid (Gatehouse, 2012): 
 - Salmonella typhimurium – TA1535, TA100, TA1538, TA98, TA1537, TA97, TA102 
 - Escherichia coli – WP2uvrA(pkm101), WP2uvrA 
The salmonella typhimurium strains each differ in that they have a different mutation in 
the histidine operon (Ames, 1975; Maron, 1983). The E.Coli strain carries a AT base pair 
at the critical mutation site within the trpE gene blocking tryptophan biosynthesis 
(Bridges et al., 1967; Green & Muriel, 1976;  Mortlemans & Roccio, 2000). These 
different mutations act as sensitive sites where reversion to the parent wild type for 
histidine/tryptophan synthesis are possible. These mutations in the amino acid synthesis 
genes make the bacteria auxotrophic, so they require the presence of the histidine and 
tryptophan amino acids to grow (Ames, 1975; Maron, 1983; Mortlemans & Zeiger, 2000; 
Gatehouse, 2012). In the presence of a genotoxic mutagen the bacteria will revert back 
to the wild type prototrophic strains, meaning they are able to grow in the absence of 
amino acids (Gatehouse, 2012). An increase of large bacterial colony growth compared 
to that of untreated controls identifies true revertants and a positive response indicating 
the test compound is a mutagen (Ames, 1975; Green & Muriel, 1976; 1967; Maron, 
1983; Gatehouse, 2012). Not all treated bacterial strains may give a positive response 
and this is due to the sensitive sites in each of the different strains detect different types 
of mutation mechanism i.e. base pair substitution or frameshift (Maron, 1983; Wilcox et 
al. 1990; Yamada et al., 1995; Gatehouse, 2012). Different combinations of bacterial 
strains are used in an attempt to cover the array of potential mutations that may occur 
in the presence of a potentially genotoxic compound (Gatehouse, 2012).   
1.3.2 – Mouse Lymphoma Assay  
The MLA is a mammalian cell culture assay used to evaluate chemicals for their potential 
to induce genetic mutation and/or chromosomal damage which result in the formation 
of mutant colonies (i.e. it is a clonal mutation assay) (Lloyd & Kidd, 2012; Cole et al., 
1983; Moore et al., 1985; Applegate et al., 1990). The Thymidine Kinase (TK) locus is 
used as a genetic biomarker of gene mutation and is an indicator of chemically induced 
mutagenesis in mammalian genome, the assay is performed using mouse lymphoma 
L5178 Y (TK +/-) cell line. TK is an enzyme involved in a salvage pathway for 
incorporating thymidine bases into DNA. TK converts free thymidine to thymidine 
monophosphate to be used in DNA synthesis (Lloyd & Kidd, 2012). Once cells have been 
incubated with the test compound and the inclusion of Trifluorothymidine (TFT) during 
plating, this allows for the identification of cells that have undergone a forward 
mutation to TK -/- due to cell colony survival (Moore-Brown, 1981; Cole, et al., 1983). 
TFT is a thymidine nucleoside analogue and is lethal to the cell when it becomes 
incorporated into the DNA in the presence of the active TK protein (Lloyd & Kidd, 2012). 
The premise of the assay is if a test compound results in a mutation at the TK locus or 
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damage to the chromosome resulting in conversion from a functional (+) gene to mutant 
(-), the cell will use an alternate pathway for the incorporation of thymidine 
monophosphate for DNA synthesis resulting in cell survival (Lloyd & Kidd, 2012; Cole et 
al., 1983; Moore et al., 1985). As L5178Y cells are negative for P53 activity there is 
reduced repair and apoptosis which results in the creation and survival of more mutant 
cells i.e. TK-/- cells. An increase of cell colony growth in treated cultures compared to 
that of untreated identifies potential mutagens and clastogens (Lloyd & Kidd, 2012; Cole 
et al., 1983; Moore et al., 1985). The assay is able to identify both through the size of the 
cell colonies, large colonies are indicative of small point mutations or deletions whereas 
smaller colonies are more likely to be as a result of larger chromosome 
rearrangements/deletion/breaks (Applegate et al., 1990; Moore et al., 1985).  
1.3.3 – Comet  
Physical DNA Breaks may be repaired (no effect), may be lethal (cell death), or may be 
fixed into a mutation (permanent damage). The Comet assay detects global DNA strand 
breaks (clastogenicity) in somatic tissues at that moment in time, it also has the 
potential to detect DNA crosslinking chemicals (Sasaki et al., 2000). Under alkaline 
conditions this assay detects single, double strand breaks as well as alkali-labile sites 
(Singh et al., 1998). Comet can be performed with any tissue sample that can be made 
into a single cell suspension, with minimal processing avoiding damage to cells (Singh et 
al., 1998; Sasaki et al., 2000). A cell suspension volume mixed with low melting point 
agarose, is placed on normal melting point agarose dipped slides. Once set, cells are 
lysed leaving the nuclear contents held within the agarose matrix, the slides are then 
electrophoresed (Fielder et al., 1992; Lovell et al., 1999; Hartman et al., 2003; Hartman 
et al., 2004]. Pieces of DNA that have become ‘broken’ move through the agarose from 
the negative terminal to the positive, given the negative charge of the DNA molecules, 
away from the main nuclear body ‘head’ creating a ‘tail’ (Olive et al., 1990; Singh et al., 
1998). Slides are then stained before being visualised and quantified via microscope 
using specialised image analysis software. The assay measures DNA fragment migration 
following electrophoresis; the length of migration is proportional to the amount of DNA 
strand damage (Olive et al., 1990).  
1.3.4 – Micronucleus Test 
Use of MN as a measure of chromosomal damage was first suggested by Evans et al in 
1959. However, MN were not used as a established genetic toxicology assay until after 
1971 when Matter and Schmid developed the in vivo mouse bone marrow MN test. 
Following this in 1976 an in vitro version of the MN assay using cultured human 
lymphocytes for short term carcinogenicity testing was developed by Contryman & 
Heddle, 1976.  
The Micronucleus Test (MNT) is a straightforward cytogenetic assay based on scoring 
small portions of DNA whether they be whole chromosomes, acentric chromatids or 
chromosome fragments that have not been incorporated into the daughter cells’ 
nucleus during cell division. Micronuclei (MN) are produced when whole chromosomes 
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or DNA fragments are unable to attach to the spindle at mitosis appearing during the 
next interphase as small bodies adjacent to the daughter nucleus. The MNT assesses 
DNA loss in cells through either Clastogenicity (structural chromosomal changes – 
caused by DNA strand breaks, DNA adducts, or genome instability) or Aneugenicity 
(numerical chromosomal changes – caused by mitotic infidelity and/or genome 
instability) (Tsuchimoto, 1979; Yamamoto, 1980). In essence, MNT detects non-lethal 
gene mutations and structural chromosome damage in mammalian cells, using 
fluorescence whether that be microscopy or flow cytometry (Bryce et al., 2008; Diaz et 
al., 2007). This test can be performed in vitro or in vivo and is considered an important 
assay in the assessment of risk following the dogma ‘one point of DNA damage results in 
one mutation that will then result in cancer’. There are multiple versions of the MNT, 
but one rule is the same for all, it must be performed in actively dividing cells i.e., a 
nuclear division must occur (OECD 474, 2016; OECD 487,2016).  
1.3.4.1 – In Vivo  
In vivo assessment of MN allows for the consideration of factors of in vivo 
absorption, distribution, metabolism, and excretion of drugs and also mammalian 
DNA-repair processes (OECD 474, 2016). The tissue most often assessed for 
frequency of micronuclei is bone marrow. The bone marrow is readily accessible to 
chemicals that are present in the blood. Peripheral blood using flow cytometry 
analysis can also be used to assess MN response (OECD 474, 2016; Richold et al, 
1990). Due to the high proliferating nature of liver tissue when damaged, the liver 
MN assay can also be performed, however use of this version of the assay is rare.  
For the bone marrow MN assessment animals (usually rats or mice) are dosed twice 
24 hours apart and are sacrificed 24 hours later (OECD 474, 2016). The femur is 
removed, and bone marrow aspirated. The sample is smeared onto microscope 
slides and stained with acridine orange before being analysed by fluorescence 
microscopy (Schmid, 1975; Matter, 1976; Tsuchimoto & Matter 1979). The immature 
red blood cells, polychromatic erythrocytes, stain orange due to the RNA content 
whilst normochromatic (mature) erythrocytes stain green as the RNA content has 
been removed as the cell matures (Hayashi et al., 1990; Kasamoto et al.,2013). If 
DNA damage has occurred a small piece of DNA remains in the polychromatic or 
normochromatic erythrocytes after the main nuclear body has been expelled during 
erythropoiesis (MacGregor et al.,1980; Hayashi et al., 1990; Kasamoto et al.,2013). 
The nuclear content stains bright yellow. With all biological systems there is a 
background frequency of DNA damage, this is no different for the MN endpoint and 
therefore a positive response to a test compound is indicated by a increase of MN 
induction compared to control (normal) levels (OECD 474, 2016).  
1.3.4.2 – In Vitro 
The in vitro MNT is predominantly used to help identify MoA. The addition of 
cytogenetic staining techniques allows the differentiation between aneugenicity and 
clastogenicity to be made (Doherty et al., 1996; Lynch and Parry, 1993; Hoshimoto et 
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al., 2012). The in vitro assay can be performed on human peripheral blood 
lymphocytes and different mammalian cell lines including but not limited to; L5178Y 
(TK+/-) Mouse Lymphoma cells, Human Lymphocyte TK6 cells, Chinese Hamster Cho-
K1 cells and Human HepG2 hepatoma cell line. The in vitro MNT can include a 
number of treatment regimens (OECD,2016; Fowler et al., 2012; Hoshimoto et al., 
2012; Doherty, 2012): 
- long treatment (24 hours in the absence of S9-mix), with the option of 
a 12 hour recovery period 
- short treatment (3 hours in the presence &/or absence of S9-mix) 
The profile of treatments conducted usually depends on the information required 
from the compound being tested e.g., short acting genotoxin requiring metabolic 
activation would require a 3 hour treatment in the presence of S9 (OECD, 2016; 
Doherty, 2012). Whilst the time points of compound exposure may change, as well 
as the cell line used, the time it takes for a MN to be generated is roughly 1.5-2 cell 
cycles (OECD, 2016). There are two versions of the MN assay the Mononucleted 
(mono) and the Bi-nucleated (Bi) assay. The main difference between these two 
assays is the Bi-MNT requires the addition of Cytochlasin B (CytoB) (Fenech & 
Morley, 1986; OECD, 2016). CytoB is a actin inhibitor that prevents cytokinesis at the 
end of mitosis from occurring. As a result, a binucleate (a cell containing two distinct 
nuclei) is generated. This demonstrates the cell has divided when in the presence of 
the test compound and often makes it easier to identify MN as well as other nuclear 
abnormalities such as neoplasmic bridges (Fenech & Morley, 1986; Fenech, 2007; 
Fenech, 2020). In the Bi-MNT only micronuclei in cells with two nuclei are counted 
whereas in the Mono-MNT MN are only counted in cells with one nucleus.  
In the event a test compound indicates a positive MN response, cytogenetic staining 
techniques such as Fluorescence In Situ Hybridisation (FISH) and Kinetochore 
staining have been traditionally used for the assessment of chemical MoA (Doherty 
et al., 1996; Lynch & Parry, 1993). Both these techniques allow for the assessment of 
whole chromosome presence. The idea being the presence of a 
centromere/kinetochore is indicative of a whole chromosome being present as it is 
unlikely that fragmentation of a chromosome would result in 
centromere/kinetochore loss from the nucleus. Therefore, it is reasonable to suggest 
that presence of a MN containing a centromere/kinetochore fluorescence signal 
would have likely occurred due to some nondisjunction event i.e., aneugenic MoA 
and lack of signal would imply a clastogenic MoA (Doherty et al., 1996; Lynch & 
Parry, 1993). The main difference between FISH and Kinetochore labelling is FISH 
allows specific chromosome identification due to fluorescently labelled DNA probes 
binding to unique DNA centromere sequences that are specific for each 
chromosome during a heating, denaturing, hybridisation process (Doherty, 2012; 
Hoshimoto et al., 2012). In binucleated cells this also allows for a more specific 
analysis of non disjunction events. Kinetochore staining indirectly assesses whole 
chromosome presence as a specific anti-kinetochore antibody binds to the 
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kinetochore protein. The antibody will bind to the kinetochore regardless of 
chromosome number i.e., chromosome 2 will stain the same as chromosome 11. 
Whilst kinetochore staining does not require the same denaturation and 
hybridisation protocol as FISH it is still an extra, time consuming processing step 
(Doherty, 2012; Hoshimoto et al., 2012).  
1.3.5 – Genetic Toxicology Summary 
Due to the Ames test concordance with rodent carcinogenicity study data (Zeiger, 1987; 
Ashby & Tennant, 1988) if a positive response is recorded for a compound using this 
assay it usually goes no further in the development process unless the compound is 
known to have specific bactericide properties (ICH, 2011). In the event of a in vitro 
mammalian positive, the pipeline may still continue but requires a dual endpoint in vivo 
study to confirm or overrule the in vitro mammalian positive result. The reasoning 
behind this flexibility is there is less concordance with in vitro mammalian assays and in 
vivo carcinogenicity data compared to that of Ames and is often overly sensitive i.e., the 
hazard does not often translate into risk in vivo (ICH S2(R1), 2011; OECD, 2017; Kirkland 
et al., 2019; Kirkland et al., 2014; Kirkland et al., 2008).  
Whilst there may be weaknesses to in vitro GLP safety assessment, use of these assays 
as screening tools not only help mitigate hazard translating to risk in the human 
population and potential financial fall out due to late stage attrition but also reduce 
animal usage in line with the NC 3Rs principles (Kirkland et al., 2005; Kirkland et al., 
2014). Screening assays provide the ability to reduce the pool of drug candidates down 
to the most promising options whilst having safety at the forefront of the strategy. 
Understanding the chemical Mode of Action leading to potential insights into the 
mechanism can aid in an informed decision process and understanding of threshold and 
point of departure metrics of dose responses (Dearfield et al., 2017; Hartwig et al., 
2020). Providing more information prior to in vivo studies can help us understand the 
biological system capacity for tolerance and a threshold at which hazard translates to 
risk in a compounds potential for initiating tumorigenesis (Jenkins et al., 2010; Thomas 
et al., 2015; Chapman et al., 2021).   
  
1.4 – Biomarkers 
1.4.1 – P53 
P53 is a tumour suppressor transcription factor that plays a vital role in both the 
regulation of cell cycle checkpoints and apoptotic induction. Due to the interlinked 
pathways of cell cycle maintenance and apoptosis, mutation and or loss of the P53 gene 
can lead to cancer. The cell cycle consists of 4 main phases; Cell growth 1 (G1), DNA 
synthesis (S), Cell growth 2 (G2) and Mitosis (M). Each phase has a checkpoint of control 
that the cell is arrested at if DNA damage is detected to allow time for repair. The main 
checkpoints are; G1/S, G2/M, intra S-phase and Mitotic as shown in figure 1. P53 on the 
induction of DNA damage can halt the progression of the cell cycle into the next phase, 
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this allows time for DNA Damage Repair (DDR) pathways to be initiated and instigate any 
DNA adduct removal (Lord & Ashworth., 2012). If the damage at these checkpoints is 
excessive P53 will then upregulate the apoptotic pathway via transcription of apoptotic 
transcription factors which initiate the caspase cascade (King & Klidowski., 1998).  
At the G1/S checkpoint active un-phosphorylated Cdc25A, dephosphorylates Cdk2-Cyclin 
E complex keeping it in its active form and phosphorylated CDK4-Cyclin D 
phosphorylates Rb (Retinablastoma protein)  causing it to release E2F. The active Cdk2-
Cyclin E and E2F drives the cell forward into S phase (Moll & Petrenko., 2003; Ma et al., 
2015). Upon DNA damage ChK1/ChK2 phosphorylates Cdc25A inducing either its 
degradation or binds 14-3-3 and can activate the MPF pathway (Nag et al., 2013. Otto et 
al., 2017). BRCA1 binds Rb and E2F which recruits HDAC deacetylating histones causing 
nucleosome formation. P53 is phosphorylated on Ser-15 by BRCA1/BARD1 complex 
resulting in the release of MDM2 stabilising P53, P53 accumulation activates DNA 
damage repair (DDR) pathways and initiates arrest through upregulation of P21 
suppressing Cdk2-Cyclin E and Cdk4-Cyclin D from phosphorylating Rb (Moll & Petrenko, 
2003; Lavin & Gueven, 2006). At G2/M checkpoint dephosphorylation of Cdk1-CyclinB1 
is the initiation for mitotic entry. A positive feedback loop of activated Cdk1-CyclinB1 
activating Cdc25C pushes the cell cycle into mitosis (Otto et al., 2017). If DNA damage 
has occurred at this checkpoint P53 mediated activation of CHK1 results in 
phosphorylation of Cdc25 and dephosphorylating Cdk1 induces arrest, here P53 can also 
be activated by ChK1/ChK2 inducing P21 which prevents the CdK1-CyclinB1 complex 
forming. It is the arrest at this checkpoint that allows the DDR pathway to enter 
homologous repair (HR) (Lord & Ashworth, 2012; Lavin & Gueven, 2006). Loss of P53 and 
or BRCA1 function compromises P21 and Chk1 induction therefore checkpoint arrest 
would not occur and lack of nucleosome formation means transcription is no longer 
inhibited leading to continued proliferation (Hartwell & Kastan, 1994).  
1.4.2 – ɣH2AX  
At the cell cycle checkpoints it is the phosphorylation of H2AX on the induction of strand 
breaks that results in the activation of the DNA Damage repair mechanism (Watters et 





The H2A histone is a highly conserved protein across species, the H2AX variant being a 
specific and sensitive biomarker for DNA damage repair and is very much in a 1:1 ratio 
with regard to DNA damage and ɣH2AX foci generation (Zhou et al., 2006; Watters et al., 
2009). It is these qualities and the availability of ɣH2AX antibodies that enables the use 
of flow cytometry platforms. Positive results i.e., identifying potential clastogens, are 
Figure 1.4: Demonstrating the role of phosphorylated H2AX known as gamma-H2AX 
(ɣH2AX) in the DNA damage repair pathway with regard to double strand breaks (Hoeller 
et al., 2009). The phosphorylation of serine-139 on the SQEY tail leads to the generation 
of ɣH2AX foci, and is a universal cellular response to DNA strand breaks, providing a 
scaffold and retention role aiding formation of repair DNA protein complexes (Zhou et 
al., 2006; Watters et al., 2009) 
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classed positive if ɣH2AX signal is above a 1.5 fold change over negative control levels 
(Smart et al., 2011). 
Phosphorylation of the H2AX molecule is a useful biomarker in the identification of 
chemicals that cause physical strand breakage (Clastogens) through an increase of ɣH2AX 
levels in terms of fluorescence intensity over that of standard cell cycle and DNA 
maintenance ɣH2AX i.e., control ‘normal’ cells. However apoptotic cells have a 
widespread phosphorylation event, so it is important to identify true cellular DNA 
damage linked with the chemical rather than falsely identifying cytotoxicity with 
genotoxicity (Huang et al., 2006). Healthy mitotic cells also undergo pan nuclear 
phosphorylation of H2AX meaning a global phosphorylation of the variant ɣH2AX occurs 
during healthy mitosis alongside H3 serine 10 and serine 28 phosphorylation’s (Ichijima 
et al., 2005). Use of the anti P53 antibody is one way to confirm true DNA damage has 
occurred in response to chemically induced strand breakage and presence of healthy 
mitotic cells can be confirmed by the presence of both ɣH2AX and pH3.  
 
1.4.3 – pH3 
During the mitotic phase of the cell cycle chromosome condensation is accompanied by 
phosphorylation of H3, occurring in a stepwise manner. During this global 
phosphorylation two different serine residues, S10 and S28, on the H3 tail (figure 1.5) 
occur to condense the chromosome and ensure movement through stages of mitosis 
(Doerig et al., 2015; Hans et al., 2001).  
 
S10 H3 phosphorylation begins in late G2 phase in the pericentromeric and 
heterochromatin as the chromosomes begin to condense. This phosphorylation then 
Figure 1.5: Demonstrates the nucleosome consisting of histone octamer with DNA and the H3 
tail along with the most well-known sites of post-translational covalent modifications (Nowak et 
al., 2004; Hans et al., 2001). The kinase/phosphatase system is responsible for phosphorylation 









spreads through the whole chromosome continuing through prophase and maintained 
through metaphase, de-phosphorylation starts in anaphase (Hans et al., 2001; Nowak et 
al., 2004). Phosphorylation of H3 at the S28 position begins later than S10 
phosphorylation, initiating at prophase maintained through metaphase and by late 
anaphase has been dephosphorylated (Hans et al., 2001). It has also been suggested 
that S28 phosphorylation is more prevalent in the rare H3.3 variant of histone 3 than 
S10 phosphorylation which is more heavily present in H3.1 and H3.2 variants, in these 
S28 phosphorylation is at much lower levels (Sun et al., 2007). Phosphorylation of H3 
has been shown to be affected by amount of DNA damage found within the cell as it 
passes through the cell cycle (see figure 1.3) especially through chemically induced DNA 
damage (Ozawa., 2008). Due to the specificity of H3 phosphorylation to mitotic events it 
proves a good biomarker for both cell cycle and mechanistic information (Bryce et al., 
2016) and highly specific antibodies for both S28 and S10 have been developed (Nowak 
et al., 2004) enabling assessment via flow cytometry platform. 
 
1.5 – Micronucleus End Point 
Within the pharmaceutical industry genetic toxicology plays a vital role in the safety stages 
of drug development. The regulatory guidelines require a minimum of two in vitro and one 
in vivo genotoxic assays to be negative before a compound can enter clinical trials (ICH., 
2011). One of the gold standard assays in the assessment of a compounds impact on DNA is 
the micronucleus (MN) assay (OECD., 2014; Fenech et al., 2003). Generation of MN can 
occur through induction of direct DNA damage (clastogenic chemical), resulting in 
chromosome break. MN can also be induced by damage to cellular machinery (aneugenic 
chemical) resulting in chromosome loss (Schmid., 1975). The failure of the chromosome 
fragment or whole chromosome to move to either one of the poles during mitosis results in 
nuclear DNA being left outside the main nucleus when the nuclear membrane reforms. This 
small additional nuclear body distinct from the main nucleus is a what we call a MN 






The frequency of MN induction induced by a chemical, as compared to that of control 
samples therefore assesses the genotoxic potential of a compound (OECD, 2014; Fenech et 
al., 2003). Currently, this assessment can be carried out in three main ways: Firstly, the 
manual scoring assay; Dosed cells are lysed, dropped onto a microscope slide, fixed and 
stained, MN are then counted manually under a light or fluorescent microscope.  Second, 
the Metafer™ system (MetaSystems™); Samples are prepared as in the manual assay but 
MN are counted automatically using a computer based imaging system. Third, MicroFlow™ 
assay; Cells are again lysed but are prepared in suspension before being run on a flow 
cytometer where front-scatter, side-scatter and fluorescence aids in the gating to assess the 
presence of MN (Verma et al., 2017; OECD, 2014; Fenech et al., 2003). Each of these 
methods for the assessment of MN induction, however, have their disadvantages. The 
manual assay, though accurate, is slow and labour intensive. The Metafer™ system although 
quicker, underscores MN due to program assessment parameters, therefore MN events 
often have to be double checked manually (Johnson et al., 2014). The MicroFlow™ method 
is quick, high-throughput and high-content but over-scores MN events due to lack of its 
ability to assess if the multiple MN or nuclei have occurred within one cell or many (Johnson 
et al., 2014). 
Figure 1.6:  Simple diagrammatic representation of MN induction. If the DNA damaging agent is 
a clastogen, MN formation will take route (a) this implies the compound has directly interacted 
with the DNA resulting in a chromosome break. If the agent is a aneugen, MN will form via 
route (b), this means the compound has affected the metaphase machinery i.e. the 
centrosomes themselves, the spindle fibres or even the kinetochore protein. Thus, resulting in 
a lack of attachment of the spindle at the centromere equalling whole chromosome loss. 
Chromosome break or loss from a daughter cell nucleus results in a MN formation as the 
aforementioned DNA segments are not pulled to one pole or the other and thus remain in the 
cytoplasm when the main nuclear envelope reforms and cytokinesis occurs. An additional 
nuclear membrane forms around the DNA fragment that has remained outside the main 
nucleus (MN is depicted in red).  
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Binucleate manual MN assessment, using the FlowSight® and ImageStream®X Mark II 
platform, has recently been validated by Verma et al., 2018 and has shown the platform to 
be a robust alternative to semi-automated microscopy and comparable to the gold standard 
manual scoring approach, with the addition of numerous advantages, including image 
collection and precision. Furthermore, use of image masking in binucleated MN has been 
shown by Rodriguez et al., 2018 to be a possibility. Mononucleated MN assessment in the 
imaging flow cytometry platform via chemical induction, whilst shown to be possible, has 
been brief and in no great detail with very limited published data. Whilst assessment of 
mono MN is not necessarily the first choice in the Genetic toxicology world it does present 
some benefits.  One major benefit is not adding the cytokinesis blocking chemical 
cytochalasin-B (cyto-B). Cyto-B works by inhibiting actin polymerase, allowing one nuclear 
division but preventing cell separation i.e., inhibits cell division (Fenech & Morley., 1985).  
Whilst this allows for easier phenotypic assessment of the cells and the likelihood that MN 
will be correctly identified the chemical adds additional stress to the cell and alters the true 
state of the cell cycle.  This means attempts to assess additional biomarkers such as ɣH2AX, 
P53 and H3 that are mediated by cell cycle and cell stresses would be skewed. Furthermore, 
any cell cycle effect of the genotoxic chemical being tested may be lost. As a result the 
micronucleus assessment using the ImageStream X Mark II in multiplex with the biomarkers 
ɣH2AX, P53 and pH3 will take place in mononucleated cells. Multiplexing the in vitro MN 
assay with mechanistic information obtained from well characterised histone biomarkers 
ɣH2AX and phosphorylated H3 (Audbert et al., 2010; Khoury et al., 2016; Bryce et al., 2016) 
would provide additional confidence in MN scoring, while also reducing the need for follow 
up MoA testing. 
1.6 – DNA Damaging Chemicals 
The complex relationship of cell cycle monitoring proteins such as P53 along with DNA 
superstructure epigenetic modifications and specific cell cycle phase DNA replication and 
condensation demonstrate the challenges posed when assessing a chemicals MoA. 
Expanding the tool box of available assays for elucidation of chemical MoA especially in vitro 
is therefore crucial to reducing animal usage, time and money during the drug development 
process. To develop such assays however, chemicals with known MoA need to be assessed 
to determine effectiveness of assays in identifying misleading positive chemicals. 
ECVAM (European Centre for the Validation of Alternative Methods) compounds are a set of 
64 compounds that are often used to aid the validation of new in vitro assays (Kirkland et 
al., 2008; Kirkland et al., 2016). The compounds cover three chemical groupings; True 
positives (Group 1): DNA interactive compounds that are known to cause mutation in vivo 
and in vitro. True Negatives (Group 2): Non-DNA interactive compounds that are negative in 
vivo and in vitro. Misleading positives (Group 3): Non-DNA interactive compounds that are 
negative in vivo but have been shown to induce chromosome damage at concentrations of 
high cytotoxicity and/or at high concentrations in vitro (Kirkland et al., 2008; Kirkland et al., 
2016). 
Six well defined genotoxic chemicals were chosen based on the varying Mode and 
Mechanisms of action to assess the platforms’ ability to distinguish between these different 
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chemicals and DNA damaging pathways. MMS, ARA-C and Etoposide work via a clastogenic 
Mode of Action and Carbendazim, Crizotinb, Vinblastine via a aneugenic Mode of Action. 
Whilst these chemicals may be grouped into either clastogenic or aneugenic Modes of 
Action, the mechanisms of these chemicals within the respective mode groupings differ. 
1.6.1 – Methyl Methane Sulfonate  
Methyl Methane Sulfonate (MMS) is a well characterised alkylating agent. MMS works 
by directly interacting with the DNA by alteration of the nucleotide bases guanine and 
adenine in the DNA structure. These physical changes to the DNA result in base 
mismatch and replication inhibition are most often repaired by base excision repair 
(BER) pathway and DNA alkyltransferases (Barreneck, 1990; Lindahl, 1999). Double 
strand breaks arise during BER when the replication fork encounter single strand breaks 
(Lord & Ashworth, 2012). Such types of DNA damage are referred to as being induced by 
a clastogenic Mode of Action.  
1.6.2 – Carbendazim 
Carbendazim is a antifungal compound that inhibits mitosis through potential 
interactions with tubulin and destabilisation of the microtubule spindle assembly 
(Hummelen et al., 1995). Carbendazim works primarily via a aneugenic Mode of Action.  
1.6.3 – Etoposide 
Extracted from mandrake root Etoposide is a Topoisomerase II inhibitor. Topoisomerase 
II acts by cutting both strands of the DNA to alleviate knots generated by the 
supercoiling of DNA structure (McClendon, 2007). Etoposide kills cells by stabilisation of 
cleavage complex which actively ‘chops up’ the genome induces permanent strand 
breakage leading to recombinant pathway DNA repair. These breaks can eventually 
overwhelm the cellular DDR pathways and result in cell death (Baldwin, 2005). 
1.6.4 – Crizotinib 
Crizotinib is a anti small lung cancer chemotherapy drug that works via Tyrosine Kinase 
inhibition more specifically its targeting of Anaplastic Lymphoma Kinase (ALK) and MET 
(MNNG HOS transforming gene) family (Megiorni et al., 2015; Zhang et al., 2018). 
Tyrosine Kinases are large protein families and aid in multiple cellular pathways 
including; activation of ATM, MDM2 regulation, Chromatin modulation DNA synthesis 
and repair such as non homologous end joining (NHEJ) as well as cell cycle G2/M arrest 
(Mahajan., 2015). 
1.6.5 – Vinblastine 
Vinblastine is a vinka alkaloid and works through a aneugenic MoA through the 
mechanism of binding to tubulin. This inhibition of microtubule formation and therefore 





1.6.6 – Cytosine β-Darabinofuranoside (ARA-C) 
Cytosine β-Darabinofuranoside also known as ARA-C or Cytarabine is a nucleoside 
analogue and whilst is can be found naturally in the cell and multiple food sources in 
higher concentrations it is used as a chemotherapeutic drug particularly looking at: 
acute non-lymphocytic leukaemia, acute lymphocytic leukaemia and blast phase of 
chronic myelocytic leukaemia (Momparler, 2013). When converted by cellular 
mechanisms ARA-C competes with the nucleotide Cytosine for incorporation into the 
DNA (Gerson et al., 2018). The altered sugar results in a ‘rigid’ DNA backbone that 
hinders structural movement affecting DNA replication the compound also inhibits DNA 
polymerase further reducing replication but also impacting DNA repair (Momparler, 
2013; Gerson et al., 2018).  
1.7 – TK6  Cells 
The TK6 human lymphoblastoid nearly diploid cell line was originally generated for use in a 
human lymphoblastoid forward mutation assay, similar to that of the MLA, based on the 
heterozygous nature of its thymidine kinase gene (TK+/-) (Skopek et al., 1981; Liber & Thilly, 
1982). A USA patent was originally filed for this assay in 1979 and granted in 1981. The 
parent cell line of TK6 is the Epstein Barr virus transformed cell line, WI-L2 (WIL2), derived 
from the spleen of a 5 year old male with hereditary spherocytosis free from evidence of 
malignancy (Levy et al., 1968). The first isolated subclone from the WIL2 cell line by Henry 
Hoppe IV at MIT was the HH4 cell line, these cells were then mutated using ICR191 
generating the heterozygous TK cell line H2BT more commonly known as TK6 cells (Skopek 
et al., 1978; Skopek et al., 1981; Liber & Thilly, 1982). Figure 1.7 demonstrates the 


















Whilst the TK6 cell line was originally intended for use in a thymidine kinase mutation assay, 
within genetic toxicology they are often used in a multitude of assays. The reasoning behind 
this is TK6 are a human cell line with a near diploid karyotype and active DDR system that 
are easy to grow with a doubling time of roughly 16-18hours. TK6 have two alleles of the 
wild type P53 gene meaning they are P53 proficient, and they also show low spontaneous 
chromosome and gene mutation frequencies however they are not metabolically active (Xia 
et al., 1995; Liber & Thilly, 1982; Jensen & Thilly, 1986). This wild type P53 activity is 
Figure 1.7:  TK6 cell line phylogeny. Three different cell line lineages were developed 
from the spontaneous immortalized lymphoblast culture WIL2 in 1968. Whilst the 
commercially available cell lines TK6, WIL2-S, and WIL2-NS stem from the same parent 
cell line they are now distinct cell lines with different genomic profiles. The original 
parent cell line as well as HH4 and WIL-2B are no longer available for acquisition (Kasai 
et al., 2020). 
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important in potential reduction of misleading positive results when using a in vitro testing 
system (Kirkland et al., 2007; Fowler et al., 2012). 
1.8 – Confocal Microscopy 
One of the major challenges compared to that of traditional flow cytometry is the 
maintenance of cell integrity during DNA staining and the penetration of any antibody and 
associated fluorophore through both the cell membrane and nuclear membrane. Use of the 
Zeiss 710 LSM confocal microscope has been invoked to confirm both maintenance of cell 
integrity and antibody penetration of the nucleus has occurred therefore any fluorescence 
of antibody fluorophore observed on AMNIS FlowSight® is not just surface nuclear binding. 
Zeiss 710 LSM confocal microscope is inverted meaning the Objective lens sits underneath 
the scanning stage and the Photon Multiplier Tube (PMT) detector sits on top of the 
microscope, see figure 1.8 (Zeiss., 2010). The objective lens (20X, 40X or 63X) is used to 
focus the lasers, 405/488/633/543/458/594nm, into the sample, the emitted fluorescence is 
then collected by the objected and directed to the PMT through the confocal aperture, also 





















The pinhole only allows fluorescence of a specific focal plane or ‘slice’ to pass to the PMT 
this results in a point by point assessment of fluorescent images in a scanning fashion. This 
Optical Axis 

















Figure 1.8: Overview of the confocal microscope LSM710 layout. Demonstrating scanning 
stage where sample slides are placed with objective lens closest to coverslip underneath the 
scanning stage, i.e. inverted. Oil immersion is only required for 40X and 63X magnification. 




means that not only can multicolour fluorescence be separated sufficiently to be assessed 
simultaneously, but movement of the sample along the Z axis using fine focus results in 
multiple slices that can be assessed and viewed as a 3D image (Zeiss., 2010). This therefore 
allows the assessment of the cellular and nuclear penetration of fluorescent probes in 
multiplex. The collected coloured fluorescent images are actually collected in levels of grey 
known as ‘bit depth’ and colour artificially added, the more levels of grey there are the more 
detailed your acquired image: 8 bit; 256 levels of grey. 12 bit (recommended for 
quantitative analysis); 4096 levels of grey (Zeiss., 2010) 
1.9 – Imaging Flow Cytometry 
1.9.1 – AMNIS FlowSight® & AMNIS ImageStream X Mark II 
Imaging Cytometry offers the speed, sensitivity and phenotyping abilities of flow 
cytometry, coupled to the detailed imagery and functional insights of microscopy. It 
therefore has high-throughput screening potential, with the added advantage that 
analysed cells do not need to be lysed. Figure 1.9 demonstrates the combination of 
FlowCytometry fluidics and microscopy components within the imaging cytometry 
platform. The FlowSight® and ImageStream®X MarkII (ISXII) have quantitative imaging 
sensitivity at 1 micron per pixel. This allows for determination of location and strength of 








MN analysis approaches that lyse cells can introduce artefacts that may mask or 
interfere with the micronucleus analysis. Each event/cell is photographed and images 
stored for validation; other types of cytology can also be documented (apoptosis, 
mitotic stage) and flow gating strategies can be refined with precision based on the 
available cell image (Amnis®., 2020). Furthermore, this platform allows for multiple 
endpoints to be combined in a unlysed cell system. Litron laboratories have recently 
shown the combination of labels for pH3, ɣH2AX, P53 and polyploidy to provide 
extensive MoA and dose response information in lysed cell samples via standard 
cytometry (Khoury et al., 2016; Bryce et al., 2016; Dertinger et al., 2019).  
 
Figure 1.9: Overview of sample uptake to image output on INSPIRE software of AMNIS 
ImageStream®X MarkII and FlowSight®. Fluidics: Sample is organised into a single cell stream and 
exposed to brightfield and laser light. Scattered, fluorescence and transmitted light is collected 
by the objective lens. Optics: Pixelated light is focused, and velocity tracked in relation to the cell 
flow speed before being split into multispectral bands by the spectral decomposition element 
(SDE) resulting in the collection of 6 different wavelengths concordant with channel by the 
Charged Coupled Detector (CCD) camera. The Imagestream X Mark II has 2 CCD cameras 12 
images per object can be collected, Camera 1 is channels 1-6 and camera 2 is 7-12. (Diagram 






1.9.2 – Workflow: Acquisition to analysis 
Both the FlowSight® and ISXII use the acquisition software INSPIRE™ and image data 
analysis software IDEAS®. Figure 1.10 demonstrates the workflow of data and file 
generation from INSPIRE™ and into IDEAS® software. The Raw Image File (.rif) contains 
the raw data obtained during experimental acquisition, these store all the raw 
fluorescence, channel, and pixel data along with the settings used on the instrument at 
collection. The .rif files cannot be altered.  
 
Compensated Image Files (.cif) are files automatically generated when .rif files are 
imported to the IDEAS® software regardless of presence of a compensation matrix a cif 
file is generated, this allows the generation of object identification and default mask 
generation. When no compensation matrix file (ctm) is selected the data that was 
collected at acquisition will be opened. When a ctm file is applied a pixel by pixel 
fluorescence compensation is performed ‘correcting the images’ removing fluorescence 
overlap, minimizing camera background and correcting for variability in flow speeds. 
Data Analysis File (.daf) is the IDEAS® file interface that allows analysis of the 
compensated image file, in other words this is the file format that opens in the IDEAS® 
software allowing direct interaction with the acquired cell images. This allows feature 
definitions, advanced masking options scatter and histogram generation, similar to that 
of conventional flow cytometry, display imagery and calculate response metrics. Daf files 
Figure 1.10: Schematic of file type workflow from the point of data acquisition 
on the imaging cytometer platform - Inspire software. Through to data analysis – 
IDEAS® software (Amnis®., 2015). 
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also allow generation of template (.ast) files. Template files save features, graphs and 
masks used that have been determined, by the user, to be optimal for the data analysis. 
Template files allow for batch processing of data in a consistent manner aiding removal 
of user bias. Compensation matrix (.ctm) files are generated during acquisition separate 
from experimental analysis files, they are generated using control positively stained and 
negatively stained populations with brightfield and side scatter turned off. These files 
contain no object data and is created to be applied to collected data sets where multiple 
fluorophores are present. 
 
1.9.3 – IDEAS® Software 
IDEAS® stands for Image Data Exploration and Analysis Software. This is the analysis 
software that allows assessment of Raw Image Files by converting them to CIF and DAF 
files. It is on the data analysis files that population selection and metric extraction is 




















Display settings allow 
adjustment for optimal 
fluorescence viewing and to 
display cannels of interest 
Brightfield image is the 
transmitted light 
microscope image. X20 
on the FlowSight and 
X40 IS XII. 
Composite images are overlays of each of 
the channel images on top of one another. 
His allows us to confirm spatial localisation 
of fluorescence  
Analysis work area 
Figure 1.11: Showing IDEAS software image analysis and work flow interface. Channel numbers 
can be renamed in relation to signal of interest being looked at. pH3, P53, gH2AX and Draq5 are 
in channels 2,3,7 and 11 respectively. Brightfield images are collected and displayed in channels 




1.10 – Summary 
A summary work flow of processing and results generation is provided in the flow chart 
schematic below (figure 1.12).  
 
 
1.11 – Aims 
This thesis intends to build on the work from these labs by designing a multiplex assay in 
whole cells that can simultaneously measure cell cycle MN, ɣH2AX pH3 and P53 response 
using the imaging flow cytometry platform, and I therefore plan to multiplex these with the 
micronucleus assay. 
Assess the feasibility of assessing ɣH2AX, P53, pH3 and MN response simultaneously in 
whole unlysed TK6 cells using the ImageStream platform. Optimise procedures to generate 
a automatically populated template using IDEAS® software that can be applied to multiple 
samples in a batch process system for consistent, minimally biased data providing a robust 
system for autofluorescence identification and implemented procedures to minimise AF 
effect. Assess if the multiplex system produces data that is in line with the current literature 
and dose response data for other platforms looking at MN, P53, pH3, and ɣH2AX responses 
of the model chemicals MMS and Carbendazim. Generate a novel approach for assessing 
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Figure 1.12: Flow chart of thesis overview. Focus on results chapters 
37 
 
identification of chemicals falling under the genotoxic headings: Aneugen, clastogen 









Chapter 2 – Materials & Methods 
2.1 – Materials 
2.1.2 – Equipment  
Equipment Supplier 
FlowSight® Luminex (Formerly Amnis®) 
ImageStream X Mark II® Luminex (Formerly Amnis®) 
Centrifuge tubes (15ml/50ml) Fisherbrand 
Centrifuges:  
                       BIOFUGE fiesco 
                       Centrifuge 5810R 
                       Centrifuge 






96 Well plate Fisher Brand 
CO2 Air-Jacketed Incubators NuaireTM 
CELLview™ slide (Multi Chamber cover slip) Greiner bio-one 
Cryovials® Elkay Laboratories 
Freezeable Gel Packs Various 
Fridge (4oC) Liebherr 
Freezer (-20oC) Proline 
Fume Hood Clean Air, Limited 
Heat Block Techne Di-Block 
Hotplate & Stirrer Jenway 
Ice machine Hoshizaki 
Carl Zeiss™ Immersol™ Immersion Oil Fisher Scientific 
Microcentrifuge tubes Eppendorf 
Microscopes: 
                          




Carl Zeiss Microscopy 
Olympus BX51 
Milli-Q Integral Water Purification System Millipore 
Multipurpose Container (20ml) Greiner bio-one 
Pipettes Gilson/ Eppendorf 
Pipette tips StarLAB 
Pipettors StarLAB/Fisherbrand 
Platform Shaker (InnovaTM  2100) New Brunswick Scientific 
Scales: 
             LA 120S 




Tissue Culture Flask (25cm2/75cm2/175cm2) Fisherbrand 
Tissue Culture Hood Scanlaf mars 
Ultra Low Temperature Freezer (-80OC) New Brunswick Scientific 
Vortex Fisons 
Water baths: 





The Belly Dancer® Hybridization water           
bath                                
Stovall Life Sciences Inc. 
Z1 Coulter Particle Counter Beckman Coulter Inc. 
 
2.1.2 – Reagents  
Reagents Supplier 
UltraComp eBeads™ Compensation Beads ThermoFisher Scientific 
Amnis® ImageStream SpeedBead 
calibration reagents 
ThermoFisher Scientific 
Cytochalasin B Merck 
Dimethyl sulfoxide (DMSO) Fisher Scientific 
Ethanol Fisher Scientific 
Heat Inactivated Horse serum Gibco® 
Phosphate saline buffer Gibco® 
Penicillin Streptomycin ThermoFisher Scientific 
BD FACS™ Lysing 
Solution 
BD Biosciences 
RPMI 1640 glutamax Gibco® 
 





Crizotinib  Sigma-Aldrich 
ARA-C Sigma-Aldrich 
 
2.1.3 – Antibodies and DNA stain  
BV421 Anti-H2AX (pS139)  
Clone  N1-431, Mouse BALB/c IgG1, κ 
BD Biosciences 
AF488 Anti-Histone H3-Phosphorylated 
(Ser28), Clone HTA28, Rat IgG2a, κ 
BioLegend 
PE anti-p53 Antibody, Clone DO-7, 
Mouse IgG2b 
BioLegend 
DRAQ5™ BD Biosciences 
 
2.1.8 Computer Programs  
Microsoft 3D paint 
Swansea University Mutait.org web package 
Graph Pad Prism 8, Version 8.4.3 (686) 
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Carl Zeiss Zen (2.3) Blue lite imaging software 
Carl Zeiss Zen (2.3) Black lite imaging software 
IDEAS® 6.2 software 
INSPIRE acquisition software  
ThermoFisher Fluorescence Spectra Viewer 
2.2 – Methods  
2.2.1 – Test Article Formulation  
Master stock solutions for each chemical were made fresh on the day of the experiment. 
DMSO (Cas. No. 67-68-5) was the solvent used to generate the dose concentrations and 
was therefore used as vehicle control. In instances where the chemical would not go 
into solution gentle warming and vortexing was used.  
Methyl Methanesulphonate (MMS), Cas no.: 66-27-3, Carbendazim, Cas no.: 10605-21-7, 
Crizotinib (Crztb) Cas no.: 877399-52-5, Etoposide (Etop) Cas no.: 33419-42-0, Cytosine 
β-Darabinofuranoside (ARA-C) Cas no.: 147-94-4 and Vinblastine (Vbstn) Cas no.: 143-67-
9 all supplied from Sigma-Aldrich.  
The working concentrations for MMS 0.00, 0.31, 0.63, 1.25, 2.50, 5.00 (µg/ml) and 
Carbendazim 0.00, 0.40, 0.60, 0.80, 1.20 and 1.60 (µg/ml) were selected based on the 
data produced by Verma et al., 2017.  
Working concentrations for the remaining chemicals were: Crizotinib, 0.00, 0.57, 1.31, 
2.25, 4.51 (µg/ml); Etoposide 0.00, 0.01, 0.03, 0.06, 0.13 (µg/ml); ARA-C 0.00, 0.01, 0.03, 
0.05, 0.21, 0.41 (µg/ml); Vinblastine, 0.0000, 0.0002, 0.0006, 0.0008, 0.0010, 0.0020 
(µg/ml). Concentrations were selected based on relative cell growth responses along 
with suggested concentrations found in the literature, Doherty et al., 2013, Kirkland, 
2010, Bryce et al., 2007, Cariou et al., 2012, and Dertinger et al., 2019.   
2.2.2 – Cell Culture and Growth Media 
Human, P53 competent, lymphoblastoid TK6 cells (Cat.No. 95111735, alternate 
collection no.: ATCC CRL 8015) were used in this study and obtained from European 
Collection of Cell Cultures (ECACC) Salisbury (Branda et al., 2001). 
RPMI 1640 (Gibco) culture media supplemented with 1% penicillin streptomycin (pen 
strep) and 10% heat inactivated horse serum (Gibco) was used for TK6 cell culture. Cells 
were incubated at 37˚C in a humidified atmosphere of 5% (v/v) CO2. TK6 cells doubled 
every 16-18hrs and once cells reached confluence sub-cultures were established. Each 
subculture did not exceed a confluence value of 1X106 cells/mL as per ECACC/ATCC 
recommendations. Cell culture passage number did not exceed passage 20 for 




2.2.2.1 – Treatment of Cell Cultures 
2x105 TK6 cells/mL were placed in a series of sterile vented tissue culture flasks 
(Fisher brand) and treated with either MMS, Carbendazim, Crizotinib, Etoposide, 
ARA-C or Vinblastine for a 1.5 cell cycle period with no recovery. Dose volume to cell 
culture did not exceed 1% i.e., 100ul of dose was added to 9.9mL of cell suspension. 
Any precipitation or colour change was noted upon chemical addition to cell culture 
flask. All incubation steps occurred at 37˚C, 5% (v/v) CO2± 0.5% in air. All 
experiments per chemical consisted of three replicates with the exception of ARA-C 
where two replicates were performed. Each replicate when performed on the same 
day were generated from cells of a different passage, when different chemicals were 
assessed on the same day the same cell passage was used.  
After the treatment period, cell counts were taken for each culture using a Beckman 
coulter counter. Cell cultures were then transferred to 15mL centrifuge tubes and 
were centrifuged at 200 xg for 8 minutes, supernatant was discarded, and the pellet 
re-suspended in 5mL pre-warmed RPMI HIHS culture media. Subsequently, the RPMI 
media was removed via centrifugation at 200 xg, the pellet was re-suspended and 
wash step repeated with 5mL Phosphate-Buffered Saline (PBS).  
The highest concentration tested is one that allows the maximum exposure up to 
2000 µg/mL or 10mM for freely soluble test articles, or the limit of solubility or 
toxicity, whichever is lower (OECD., 2014). 
If test article solubility in the test system is a limiting factor, the maximum 
concentration chosen for analysis will be the lowest concentration at which test 
article precipitation is observed by eye in treatment cultures at the end of the 
treatment period. If toxicity is a limiting factor, the maximum treatment 
concentration selected for analysis is that of relative cell growth at 30%. 
2.2.2.2 – Cell Counts 
Cells were counted automatically via Z1 Coulter Particle Counter. Cell counts were 
obtained by adding 100ul of cell suspensions to a beaker containing 10ml of isotone 
solution. The beaker was then placed on the counting platform of the Z1 coulter 
particle counter and the cell count per/ml was recorded. 
2.2.2.3 – Cytotoxicity 
Relative Cell Growth (RCG) was used to estimate cell death and cytotoxicity in 
treated samples. RCG was calculated as follows: 
                                      RCG =   No. of Cells/mL in treated cultures X 100 






2.2.3 – Cell Fixation and Staining 
Once the cell treatment period ended and cell wash steps performed to remove media 
containing the chemical dose, the cell pellet was resuspended in residual PBS and BD 
FACS Lyse was used to fix and permeabilise the cells. FACS Lyse solution is a proprietary 
buffered solution containing <15% formaldehyde and <50% diethylene glycol. BD FACS 
Lyse was diluted in a 1:10 ratio with distilled water (dH20) (1ml FACS Lyse:9mL dH2O). 
The solution was mixed thoroughly and 2mL of solution was added to each sample. 
Avoiding agitation after 12minute incubation time at room temperature the samples 
were spun on the centrifuge at 200xg for 5 minutes. Supernatant was discarded and the 
cell pellet gently resuspended in the remaining solution, PBS was added in excess (5mL) 
and samples returned to centrifuge for further 5 minutes, this wash step was repeated 
twice. Samples at this stage may be placed in the fridge and stained at a later date or 
stained immediately. Samples were stained with 300ul of antibody (AB) master mix for 
preliminary work and the optimal method. For preliminary work this consisted of BV421 
Anti- ɣH2AX AB and AF488 Anti- pH3 AB in PBS agitated at room temperature for a 
minimum of 60 minutes. For optimal work this consisted of BV421 Anti- ɣH2AX AB, 
AF488 Anti- pH3 Ab and PE Anti-P53 AB in PBS at room temperature for minimum of 60 
minutes and 100ul of DRAQ5™ diluted solution for minimum of 20 minutes. Further 
information on the antibody and DNA staining procedure can be found in section 2.2.3.1 
below. After the staining period ended samples were centrifuged and washed in 5mL 




















Figure 2.1: Demonstrating a generalised overview of the method followed in this thesis. 
Procedural steps were exactly the same prior to cell staining for both preliminary work and 
optimised work flow. Route A shows the preliminary work done on the FlowSight® and route B 
shows the optimal work flow. At point C analysis was either performed by manually imputing 
Eppendorf into the sample port or via 96 well plate sampling. Samples at point C may also be 






2.2.3.1 – Antibody Staining 
Regardless of ratio of antibody in PBS solution the antibody incubation of 
permeabilised and fixed cell samples is a minimum of 60 minutes at room 
temperature under agitation.  
For preliminary work (figure 2.1 route A) Immunofluorescence antibodies used were: 
Anti ɣH2AX Brilliant Violet 421 antibody (Cat. No. 564720) and Anti pH3 ser 28 
AlexaFluor 488 antibody (Cat. No. 641003) in multiplex. Antibodies were supplied by 
Beckton Dickinson and Biolegend respectively. These antibodies generated a master 
stock solution, in the ratio 3µl of pH3: 5µl of ɣH2AX: 292 µl of PBS 
For optimal workflow (figure 2.1 route B) Immunofluorescence antibodies used 
were: Anti ɣH2AX Brilliant Violet 421 antibody (Cat. No. 564720) supplied by Becton 
Dickinson Biosciences. Anti-phosphorylated Histone H3-ser28 AlexaFluor488 
antibody (Cat. No. 641003) and anti P53 PE antibody (Cat.No. 645805) were both 
obtained from BioLegend. These antibodies generated a master stock solution, in the 
ratio 3µl of H3: 5µl of ɣH2AX: 6µl of P53: 286µl of PBS. 300ul of master antibody 
solution was added to each resuspended cell pellet. Cells were stained in multiplex 
at room temperature under agitation for a minimum of 60 minutes. Excitation and 
emission spectra of each antibody and its associated fluorophore is summarised in 
table 2.1 below.  
Table 2.1: Summary of AB and associated fluorophores  
Biomarker 

















405 (Violet) 421 
Phosphorylated 
serine 28, H3 
AlexaFluor 
488 
488 (Blue) 525 
N-Terminal P53 PE 4881 (Blue) 574 
1Suboptimal excitation.  
2.2.3.2 – DNA Staining 
DNA staining only occurred in multiplex for route B in figure 2.1 due to the lack of 
lasers available on the FlowSight® and the inability for sufficient spectral separation.  
DRAQ5™ DNA stain (Cat. No. 564902 supplied from BD Biosciences, sub optimally 
excited by 488nm blue laser and optimally excited by 642nm red laser, was used to 
label nuclei and MN. 2ul DRAQ5™:98ul PBS was mixed, 100ul of the 1:49ratio stain 
solution added to each 300ul cell sample antibody solution making final staining 
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ratio of 1:199. Samples were counterstained with DRAQ5™ for a minimum of 20 
minutes. 
2.2.4 – Whole Cell Data Collection  
Whilst predominantly work was performed on the ImageStream platform once the 
staining and wash steps were completed the samples were also viable for analysis via 
confocal microscopy. Use of the Confocal LSM 710, AxioObserver was used as a 
qualitative tool for the assessment of antibody penetration of the cellular and nuclear 
membrane. No quantitative analysis was performed using the confocal microscope. The 
confocal acquisition and analysis steps are outlined in section 2.2.4.1.    
Samples that were analysed on the FlowSight® at Swansea University were either 
stained with antibody and processed immediately, stained placed in fridge protected 
from light and analysed no more than 48hrs later or stained up to 48hrs later followed 
by immediate analysis. The Flow sight acquisition and analysis steps can be found in 
section 2.2.4.2.1. 
Samples that were analysed on the ImageStream X Mark II® at the Core Flow Facility, 
Newcastle University were done so by myself or Andrew Filby. Samples were stained 
immediately placed on frozen gel pack and shipped via DHL overnight. Samples were 
either analysed on day of arrival or 24hrs later. From point of being picked up by DHL 
the samples were not analysed any later than 48hrs after being stained. The 
ImageStream X Mark II® acquisition and analysis steps can be found in section 2.2.4.2.2. 
2.2.4.1 – Confocal Microscopy 
2.2.4.1.1 – Slide Preparation 
Cells were processed as explained in section 2.2.3. No additional method steps 
were performed and a volume of 50ul was transferred to CELLview™ chamber 
slide from Greiner for analysis. Each one of the five samples were placed in a  
individual chamber of the chamber slide,  each were as follows; 1) 5.0 µg/mL 
MMS dosed TK6 cells stained with only BV421 anti-ɣH2AX AB, 2) 1.6 µg/mL 
Carbendazim dosed TK6 Cells stained with only AF488 anti-pH3, 3) 1.6 µg/mL 
Carbendazim dosed TK6 Cells stained with only PE anti-P53 AB, 4) Negative 
control TK6 Cells stained with only DRAQ5™, 5) DMSO dosed TK6 Cells unstained 
5) 1.6 ug/mL Carbendazim dosed TK6 Cells stained with all AB and DRAQ5™ stain. 
Please note no centrifugation or any other attempt to fix the cells to the 
coverslip glass was used. 
2.2.4.1.2 – ZEN Image Acquisition 
A compensation matrix file was generated using the same acquisition settings 
used for image collection using the individually stained and one unstained 
sample.  
Three fluorophores AF488, BV421, PE and one DNA stain DRAQ5™ were assessed 
using the 405, 488 and 633 excitation wavelengths across 4 signal channels. 
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These signal channels were split onto two different tracks BV421 and PE were on 
Track 1 and AF488 and DRAQ5™ were on track 2. Use of two different tracks in 
this way was used to minimise signal cross talk between the channels as the 
excitation spectra of AF488 and PE are close together (see figure 3.1) in section 
3.2.4. Image collection occurred using the Plan-Apochromat 63X/1.40 Oil DIC 
M27 objective, the pinhole was set to 51µm for both track 1 and track2, a 8 bit 
depth was selected. Light source balancing was performed for each sample 
exhibiting strongest signal for optimal intensity and gain settings. These same 
settings were used for the generation of a compensation file and collection of 
images.  
2.2.4.1.3 – ZEN Imaging Software 
Zen black and blue were used to assess images and perform pre-processing 
steps. The compensation file generated was applied to the Raw image file to 
allow linear unmixing to be performed. This step helped remove/minimise 
potential signal cross talk so signal observed could be trusted to be true signal in 
relation to the biomarker presence. Imaging software was then used to project 
the 3D image of Z stack generated files and available fluorescence pixel signal 
squeezed/expanded for optimal viewing of fluorescence signal. 
Images acquired for the confirmation of cell sample staining can be found in 
section 3.3.1. 
2.2.4.2 – Imaging Flow Cytometry 
Acquisition of samples as described in the following methods followed the 
recommended procedures stated in the Amnis® FlowSight® Imaging Flow Cytometer 
User Manual and INSPIRE™ ImageStream®X System Software User's Manual 
2.2.4.2.1 – AMNIS® FlowSight® 
Upon initiation of the FlowSight® and Inspire software click ‘StartUp’. This opens 
ASSIST. Once focus and fluidics stabilised (buttons greyed out became active) 
ASSIST prompts loading calibration beads onto the sample port of the 
FlowSight®. When the beads are running and appear central in the channel 
image viewing area and in focus all calibrations and tests are performed by 
clicking ‘Start all calibrations”. All calibration tests are passed when they turn 
green and the ASSIST window is closed. Calibrations were performed at least 
once before use and sample collection was only performed once all calibration 
tests were passed. 
Sample is loaded into the sample pump, a minimum of 50µl of sample is 
uploaded, and a new template or a saved template from previous experimental 
acquisition can be loaded. Each sample collection can be appropriately labelled 
and saved for export to IDEAS® analysis software.  
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Only chemicals Carbendazim and MMS were assessed on the FlowSight® for 
optimal staining and preliminary work. Carbendazim and MMS were selected for 
the well characterised nature, with clear MoA’s. This allowed me to assess the 
expected results against the response provided by my assay and adjust the 
methodology accordingly.  
2.2.4.2.2 – AMNIS® ImageStream®X Mark II 
Having switched on the ImageStream X Mark II® and launched inspire software, 
SpeedBead calibration beads are loaded onto the specific bead port. Unlike the 
FlowSight® the ISXII continually mixes and loads beads for more accurate velocity 
and image tracking. ‘StartUp’ is clicked, and beads are automatically loaded and 
focus, and fluidics are established. The option to run ASSIST immediately after 
fluidics and focus stabilisation was unticked to allow manual positioning of the 
core flow centre if required. Once focus and positioning of beads were confirmed 
‘Start All Calibrations and Tests’ was selected. When all calibration tests were 
passed the ASSIST progress light turns green. ASSIST window can then be closed. 
As with the FlowSight® only once all calibrations were passed was sample 
acquisition performed. 
Sample is loaded into the sample pump, a minimum of 50µl of sample is 
uploaded, and a new template or a saved template from previous experimental 
acquisition can be loaded. Each sample collection can be appropriately labelled 
and saved for export to IDEAS® analysis software.  
Replicates 1 and 2 of the chemicals MMS, Carbendazim and ARA-C were 
manually loaded onto the ISXII sample port and acquired. All other chemicals 
(Etoposide, Vinblastine and Crizotinib) were acquired using 96 well plate and 
autosampler procedure for unattended acquisitions.  
2.2.4.2.3 – INSPIRE™ 
INSPIRE™ is the acquisition software associated with the Amnis® imaging 
cytometer platform. Once samples are loaded on the imaging cytometer prior to 
sample image collection a template can be generated that best fits the 
experimental design and are explained below. Display settings of the Image 
gallery can be adjusted for optimal sample viewing to confirm populations being 
collected are single, in focus with exclusion of debris. This also allows a 
confirmation that the population of cells being collected are actually the 
population of interest.  For all sample collections a acquisition speed of low was 
selected to acquire samples with the highest sensitivity. The FlowSight® collected 
images at X20 magnification and IS XII collected images at X40 magnification.  
2.2.4.2.3.1 – Template Set up  
Cell sample acquisition using INSPIRE™ for FlowSight® and INSPIRE™ for 
ImageStream X Mark II® is the same process other than calibration beads are 
used alongside image acquisition on the ISXII for more accurate camera and 
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velocity tracking of cell samples. When acquiring samples collection is best 
for single and in focus cell population. The brightfield (microscope image) 
were plotted on a scatter graph aspect ratio plotted on the y axis and area of 
the cell plotted on the x axis. A gate was drawn around the single and round 
cell population based on cell density heat map, this population for TK6 cells 
usually sits between 1 and 0.6 of aspect ratio and above 70 but below 600 on 
the area axis, this allows debris to be excluded from sample collection.  This 
single cell population is then plotted on a histogram using gradient RMS to 
select cells that are most in focus a gate is then drawn across the histogram 
peak. Whilst this gate is usually based on the histogram peak the lowest gate 
value is never placed below 50 on the gradient RMS axis. Cells that are within 
this focussed gate are deemed to be sufficiently in focus for acquisition. This 
is the population of cells that will be used for laser balancing procedures and 
then collected.   
2.2.4.2.3.2 – Laser Balancing 
When dealing with samples that contain multiple fluorophores it is important 
to balance the different lasers you are using, especially if the fluorophores 
have excitation wavelengths that can be activated by the same laser. Whilst 
this won’t completely eliminate fluorescence spill over it will allow 
compensation matrices to be most effective at removing fluorescence that is 
not in the correct channel.  
Prior to cell image collection laser intensities need to be balanced for optimal 
fluorescence image collection. Based on the single in focus cell population 
selected a scatter graph with channel intensity plotted on the x axis and raw 






This was done for each channel of interest. Each channel that has cells with 
saturated pixel fluorescence need to be decreased in number to as low as 
possible, preferably zero, but not so low that signal separation is sacrificed, 
and that lower level signal is missed. This was done by starting the laser 
power off higher to induce saturation and then decrease laser power till 
saturated cells are minimal. This is repeated for each channel relative to the 
laser that excites them; AF488 is in channel 2, PE is in channel 3 both excited 
by laser 488nm. BV421 is present in channel 7 excited by laser 405nm. 
DRAQ5™ has a presence in channel 5 but is dominant in channel 11 is excited 
by laser 488nm and 642nm. If a laser is being used for more than one 
fluorophore it is important to have high enough fluorescence for one to be 
discernible from background autofluorescence but low enough so as not to 
induce large amounts of saturation. This is the case with AF488 and 
suboptimal excitation of PE with the 488nm laser. Once the laser values have 
then been set based on saturation, channel overlap is assessed, this is 
important when a fluorophore is either excited by more than one laser or has 
a distinct channel overlap. DRAQ5™ is excited sub-optimally by laser 488nm 
causing signal to be detected in channel 5 and optimally by 642nm for 
detection in channel 11. By plotting an intensity scatter graph of Ch5 (488nm 
blue laser) on y axis and Ch11 (642nm red laser) on x axis keeping laser 
intensities the same as determined by minimizing pixel saturation the 
balance of which channel the DRAQ5™ signal is most dominant in can be 
plotted, figure 2.3 is an example graph used during laser balancing for 
optimising signal to the correct ImageStream channel. 
Figure 2.2: Demonstrating example of intensity vs raw max pixel intensity on inspire 
software to aid laser power selection. 4096 is the maximum pixel intensity the system 
can read before the image becomes saturated. 






The orange line on figure 2.3 demonstrates an imagined line that passes 
through the origin of the graph if during laser balancing procedure the cell 
population signal for D5 sat above the line this would imply the DRAQ5™ 
signal was more dominant in channel 5 so the power of the 488nm laser 
would need to be decreased for the DRAQ5™ signal to become dominant in 
Ch11. This would also happen in the reverse, if the 642nm laser intensity was 
too low the signal would be dominant in channel 5 (cells above the line) and 
the intensity would need to be increased. This same process was performed 
for each of the main channels used (plotted on x axis) and compared against 
all other channels to confirm the dominant signal fell more below the origin 
line (in the correct channel) than above the line. This also minimalizes the risk 
of overcompensation when generating a compensation matrix.   
Once these steps were complete acquisition of cell images took place and a 
collection value of; 15,000-20,000 events were acquired on the FlowSight® 
and 30,000 events were collected for samples stained with the 4 
fluorophores on the ImageStream X Mark II®.  
The optimal laser settings for the FlowSight® for the dual marker stain was 
2mw for laser 488nm and 10mw for laser 405nm. The optimal laser settings 
All






















Figure 2.3: The graph was generated from collected compensated data as an example 
step. This being such means the Draq5 signal was optimal for the system. The cell 
population falls below the imagined orange line that passes through the graph’s 
origin. This means the laser was balanced with the 488nm laser so that the DRAQ5 
signal was dominantly picked up in the desired channel 11. 
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for the ISXMII four colour system were 120mw for laser 405nm, 90mw for 
laser 488nm and 80mw for laser 642nm. 
These laser settings for experimental acquisition were then used to generate 
the compensation matrix. 
2.2.4.2.3.3 – Compensation Matrix  
UltraComp eBeads™ Compensation Beads (Cas no:01-2222-41) from 
thermofisher scientific were used for compensation in relation to BV421, 
AF488 and PE signal. A cell stained sample containing true population 
(stained with D5) and a negative population not stained. Compensation files 
are then generated by either following the INSPIRE™ compensation wizard or 
performing manual collection. 
For both options side scatter laser and brightfield collection is turned off. All 
lasers that are used in the experiment are set at the same acquisition power 
as the experimental collection settings. One file is collected per fluorophore 
only the laser that is used to excite that specific fluorophore is turned on per 
file. The active fluorescence channel is selected and 500-1000 cells/beads 
that are classed as positive events are collected for each fluorophore. Signal 
that is then found in other channels i.e., not the active fluorescence channel 
is determined to be fluorescence overspill. Each compensation file can then 
be combined (if using the wizard this is done automatically) in IDEAS® 
software to generate a compensation matrix. All samples were collected with 
no compensation applied. 
2.2.5 – Whole Cell Image Assessment 
2.2.5.1 – IDEAS® 
Image Data Exploration and Analysis Software allows for the quantitative analysis of 
the Raw Image Files (rif.) collected on the FlowSight® and ISXII machines.  The 
following gives steps taken towards compensation matrix generation followed by a 
generalised method overview of template design and batch processing. In detail 
descriptions of the optimal template design can be found in in chapter 3, results 
section 1.  Additional information and in-depth explanations of the features used in 
the IDEAS® software can be found in the v6.2 User's Manual, Version 6.2. 
2.2.5.1.1 – Applied Compensation 
The removal of signal overspill from incorrect channels prevents signal from 
being miss identified as true signal and minimises compounding of true and false 
fluorescence to give a increase of biomarker signal that may not be there or be 
the difference between a positive and negative biomarker response. A visual 




Compensation files with no bright field and side scatter collected are uploaded to 
the IDEAS® 6.2 compensation wizard. All files for each fluorophore used in the 
experiments are uploaded to the compensation wizard. Active fluorescence 
channels that the experimental fluorescence signal is found in are selected. A 
coefficient table is then generated. The coefficient table shows all 12 channels. 
The compensation matrix coefficient table demonstrated in figure 2.5 display the 
Figure 2.4: Example of how compensation removes signal overspill from incorrect channels prevents signal 
from being miss identified. Histograms show effect on fluorescence overspill of AlexaFluor488 from Channel 2 
into PE Channel 3 with and without compensation matrix applied. A)  Shows the excitation and the normalised 
emission spectrum of AlexaFluor488 and PE to the 488nm laser. The band passes are also displayed giving 
demonstrating the wavelength (nm) covered for Channel 2 and Channel 3. The Area under the dashed red line 
(highlighted by arrow 1) highlights the overspill of the AF488 emission spectra into Ch03. B) Shows the 
accumulative effect of fluorescence overspill from Ch02 into Ch03. Without compensation to remove the 
overspill of fluorescence signal this increases the fluorescence intensity seen in CH03 by the IDEAS software 
resulting in a false intensity reading. C) Shows that with a compensation matrix applied the overlapping signal 
from AF488 has been removed from the PE signal in Ch03 leaving only true fluorescence intensity to be 













channel overlap of fluorescence signal. Values of 1 refer to the location of 100% 
signal i.e., Ch02 column, Ch02 Row is 1 so 100% of signal is in Ch02. All other 
values refer to the percentage of signal overspill from the active fluorescence 
channel into a neighbouring/suboptimal channel of collection i.e. active 
fluorescence channel 2 (fluorophore AF488) has a 1.3% signal overspill into 
channel 5. This means that 1.3% of AF488 signal that is not supposed to be in 
Ch05 will be removed. 
 
Best fit or mean selection may be used. Best fit tends to be used for cells that 
have varying intensities present but beads you could use mean as the variability 
is minimal. If values in the compensation matrix are red this implies the 
coefficient variations away from the line of best fit is more than 1% and the 
coefficient needs to be adjusted. This can be done by double clicking the 
concerning value, this will generate a coefficient graph, see label 2 in figure 2.5. 




Figure 2.5: Overview of compensation matrix generation using IDEAS® and following the steps in the 
compensation wizard. Compensation wizard allows you to select the active fluorescence channels for the 
experiment. The third step is assessing the generated coefficients based on the uploaded files and selected 
channels. Label 2 is an example of how coefficient accuracy can be assessed by clicking on values in the table. 
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passing through the origin, this implies the coefficient is accurate. If the cell 
population were skewed the population falling excessively above or below the 
line of best fit i.e., not a liner relationship the compensation matrix would not 
work correctly resulting in under or overcompensation. To clean up the sample 
population the coefficient graph can be added to the analysis area and a new 
positive population for that channel generated via drawing a new gate. A new 
coefficient can be generated based on the new population selected and the 
linearity of cell population confirmed. This checking of each coefficient was 
performed on each of the coefficient values regardless of a greater than 1% 
variation away from the line of best fit to confirm accurate coefficients and 
therefore matrix has been generated. This mainly helps reduce 
overcompensation which would result in the removal of true signal skewing any 
data generated.  
The compensation matrix can then be saved and applied to the raw data files 
prior to analysis and template based assessment. Per experimental run a new 
compensation matrix was generated and applied to the relevant files.  
2.2.5.1.2 – Template Design 
The IDEAS® 6.2 software can be used to generate a template that can then be 
used to batch process all experimental file with the same template. To generate 
a daf (data analysis file) the rif. (raw image file) is selected and at this stage 
either a new compensation matrix can be generated or a compensation matrix 
that has already been saved can be applied. Figure 2.6 shows the layout of 
IDEAS® software start up to generate a cif (Compensated image file) and daf file. 
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All templates were generated based on compensated fluorescence data.  There 
were two templates generated, one for preliminary data set and one for the 
optimal data set.  
For the preliminary data the template generated was simple and the parameters 
assessed were based on single and in focused cell population. pH3 signal and 
ɣH2AX signal intensity, the H3 positive signal cell population were excluded from 
ɣH2AX assessment. 
2.2.5.1.3 – Mask Development and Feature Use 
Masking is the process by which imaging software, in this case IDEAS® 6.2, 
identify pixels of interest. IDEAS® software uses default masks to based on 
available fluorescence signal, using the mask manager more specific masks can 
be generated based on the criteria that needs to be assessed. These user defined 
function masks can be generated using a limited number of functions that when 
combined create a set of rules/criteria that can then be used to assess different 
features based on size, shape, texture, comparison and location. These masks 
once defined can be combined using Boolean logic (AND, OR, NOT etc.) to add or 
subtract criteria to generate a new specific mask.  
Figure 2.6: Opening window start up for IDEAS® software for analysis of rif files. Cif and daf files 
are generated by applying the compensation matrix generated for the experiment and a template 
if available, the file name can be adjusted. If a analysis template is available it can be used to 
automatically populate the analysis area.  
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For the preliminary work performed on the FlowSight® imaging cytometer the 
default IDEAS® masks were used for ɣH2AX and pH3 analysis.  
For the optimal work flow and templates set up the following final masks were 
generated: Brightfield 1A, Brightfield 1B, Cytoplasm, Nuclear Mask 1, Nuclear Mask 2, 
Nuclear Mask 3, gH2AX mask, Nuclear gH2AX mask, pH3 Mask, Nuclear pH3 Mask, P53 
Mask, P53 Cytoplasmic Mask, P53 Nuclear mask and MN Complete Final Mask (CFM). 
The functions in various combinations used to generate these masks were 
morphology, adaptive erode, threshold, range, dilate, intensity, spot, watershed 
and level set. The masks and functions used are demonstrated in depth in section 
3.3.3. 
Features in the IDEAS® system are mathematical expressions that assess, within 
the image, quantitative and spatial information. These allow for the generation 
of histograms and scatter graphs in the analysis area for cell population 
responses to be assessed. The features used were: Aspect ratio and Area assess 
circularity and singularity respectively, contrast Gradient Root Mean Square 
(RMS) assesses in focus objects to generate the most appropriate cell population 
for biomarker and MN analysis. Intensity, Similarity, and spot count features 
were used to automatically populate and extract biomarker and MN data. Aspect 
ratio, area, Gradient RMS and Intensity were also used in preliminary work 
template analysis using the systems default masks. 
The finalised template generated can be saved as a ast file and used on all rif files 
in combination with the appropriate compensation matrix. This was done by 
selecting the batch data files option in the tools menu of the IDEAS® software. All 
the rif. files per chemical were grouped together in batches and given an 
appropriate name to be saved under. Once files were loaded either the 
preliminary or optimal template ast. file was selected and compensation matrix 
ctm. files were also applied. These batches were then run generating cif. and daf. 
Files for each individual sample data set and automatically saved.  Data tables 
were generated for each daf. File and the population response data was 
exported to excel for formatting, graph and table generation.  
The mask development and features used were based on the recommendations 
within the IDEAS® 6.2 user manual 2015, the publication Imaging Flow 
Cytometry: Methods and Protocols 2016 and literature Rodriguez et al., 2018, 
Verma et al., 2018, Filby et al., 2016, Patterson et al, 2015.  
2.2.6 – Data Assessment  
All tables and graphs were generated using Excel Microsoft. Unless otherwise stated 
data displayed in tables and plotted in graphs for biomarker and MN metrics are 
presented in raw response fold change that has been square-rooted to normalise 
responses. Cell cycle data is presented as raw response cell percentages.  
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Fold change cut offs were also applied to graphical data. These cut offs were applied in 
line with industry standards whereby fold change over a certain amount are considered 
a biologically relevant response. For pH3 this was 1.3 fold change increase and 0.7 fold 
change decrease as suggested by Khoury et al., 2016. For ɣH2AX fold change increase 
was 1.5 as per Smart et al., 2011. Whilst P53 is a popular marker for DNA damage 
assessment a fold change cut off can’t be easily identified from the literature. As P53 is 
induced by a DNA damage response, one could assume the fold change response is 
proportional to that of ɣH2AX biomarker response when assessing clastogens. It is 
therefore reasonable to suggest the same fold change cut off used for ɣH2AX may be 
used for P53 response. Whilst there is limited literature referring to a definitive industry 
standard of fold change for P53, the use of 1.5 fold change cut off is illuded to (Dertinger 
et al., 2019). 
As all raw fold change values were square rooted the fold change cut off values were 
also square rooted giving the square root cut off values of: 1.2 for ɣH2AX and P53 and 
1.1 for pH3 for increase in signal and 0.8 for decrease in signal. 
The MN response was considered positive based on a statistically significant response 
(P<0.05) compared to that of DMSO control (Johnson et al., 2014). Where statistical 
significance was not achieved the MN response was considered positive based on a 
greater than 2 fold increase compared to control (Takeiri et al., 2019; Shi et al, 2010). As 
data is displayed in square root fold change, the fold change cut off value for the MN 
response will be 1.4. A genotoxic response is considered positive when the mean 
response relative to control exceeds the fold change cut off or is statistically significant. 
Where both MN and biomarker response exceed fold change cut offs and/or are 
statistically significant a indication of MoA may be inferred (Bryce et al., 2017; Dertinger 
et al., 2019). 
2.2.6.1 - Statistical Analysis 
All data sets distributions were tested for homogeneity and normality using the 
Brown forsythe/Bartletts test and D’Agnostino-pearson omnibus (K2)/Shapiro Wilk 
test respectively. If datasets proved both normal and homogenous a one way 
ANOVA Dunnets test was performed to identify significance (p value<0.05) of data 
response. If data was found to be either not normal and or heterogenous the data 
was either Log or Square root transformed and distribution retested. In the event 
the transformed data failed distribution tests the non-parametric Dunns Kruskal 
Wallis test was performed on the raw response data. This procedure is as 
recommended by Johnson et al., 2014. Presence of statistical significance was used 
to identify the no- and the lowest- observed genotoxic effect levels (NOGEL, LOGEL). 
This procedure is as recommended by Johnson et al., 2014; Verma et al., 2018. All 
statistics were prepared using Mutait.org or Graph Pad statistical software. 
Note: The transformation of data for statistical analysis was log unless raw data 




Chapter 3 – Results 1: Assay and IDEAS® Template Optimisation 
3.1 – Introduction  
The ImageStream platform provides high content, high throughput, whole cell microscopic 
analysis. The system provides the speed of flowcytometry with the spatial localisation 
information that comes with image based analysis. The ImageStream® MN multiplex 
expansion (ISMN-me) assay allows for the assessment of the well defined biomarkers P53, 
ɣH2AX and pH3-S28 along with cell cycle and MN analysis using the nuclear stain DRAQ5™ in 
whole (not lysed) cells.  
Selection of the antibodies and DNA stain used in the development of the ISMN-me assay 
were based on a few factors.  
Work previously done at Swansea University within the In Vitro Toxicology Group (IVTG) and 
published by Verma et al demonstrated that DRAQ5™ both sub-optimally at 488nm and 
optimally at 642nm generated sufficient DNA staining and crispness to identify MN in 
binucleated cells. Using the IDEAS® software masking system, MN can be automatically 
identified when stained with DRAQ5™ (Rodriguez., 2018; Rodriguez et al., 2018). The far-red 
emission spectra of DRAQ5™ provides a distinct profile separate from the other 
fluorophores used in this multiplexed assay.  
The anti-ɣH2AX-Ser139 antibody has been used in numerous studies and publications, Bryce 
et al., 2016, Khoury et al., 2016, Smart et al., 2011, Cheung et al., 2015 and Wilson et al., 
2021 to name a few, it is a truly well defined biomarker associated with DNA damage 
directly in the form of strand breakage and of the DNA damage response pathway 
(Podhorecka et al., 2010). Selection of the ɣH2AX antibody conjugated to the BV421 
fluorophore was mainly chosen as it is excited by the 405nm laser which was available on 
the FlowSight® used at Swansea University for preliminary optimisation and work. 
Furthermore, BV421 signal is not as strong as the AF488 signal when excited by optimal 
lasers, as pH3 events are so much lower in frequency than the ɣH2AX response it was felt 
the pH3 detection sensitivity would benefit from having a more definitive fluorophore.  
In most instances the preferred antibody used in the literature for detection of Histone 3 
phosphorylation is Anti-pH3 Ser10. This antibody binds to H3 when phosphorylation at 
Serine 10 of the histone 3 tail occurs allowing for mitosis evaluation. However, H3 is 
normally phosphorylated at Ser10 in generic chromatin and is modulated by HMGN1 to aid 
gene expression and access of DNA damage repair proteins to DNA lesions (Huang et al., 
2006; Juan et al., 1998; Lim et al., 2004). This implies there is potential for the pH3 antibody 
to bind to these normally phosphorylated Ser 10 sites outside of mitosis, the Ser 10 
phosphorylation also occurs earlier in the cell cycle than mitosis being initiated throughout 
G2 phase (Hans & Dimitrov, 2001). As a result, the antibody selected for mitosis assessment 
as part of this multiplexing platform was Anti-pH3 Ser28. Phosphorylation of H3 at serine 28 
has only been observed at the end of G2/beginning prophase and end of anaphase/early 
telophase therefore this biomarker is more specific for mitosis response (Hans & Dimitrov., 
2001; Goto et al., 2002). The AlexaFluor488 Anti-pH3 Ser28 antibody was chosen for mitotic 
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assessment due to its strong signal when excited with the 488nm laser available on the 
FlowSight® at Swansea University.  
For the assessment of P53 the antibody selected was specific to N-terminal linear epitope aa 
20-25 of the P53 protein not any specific phosphorylation. Whilst use of the N-terminal P53 
antibody may be considered generic and not specific enough to confirm the true 
translocation of stabilised P53 to the nucleus. Not using a phosphor P53 antibody allows the 
overall assessment of P53 within the cell and the corresponding increases/decreases to all 
types of damage induced by the various chemicals being assessed. For instance, a P53 
antibody used that binds to phosphorylated serine 15 on the P53 protein is directly related 
to the damage induced by double strand breakage (Lavin & Geuven., 2006). Therefore, 
chemicals such as MMS that induce DNA breakages would have a corresponding increase of   
ɣH2AX response with pP53 Ser15 levels. However, when looking at a chemical that is not 
known for inducing strand breakage such as Carbendazim, there would be a lack of response 
in relation to   phosphorylated P53 on serine15. Thus, not using a phospo-P53 antibody 
allows for the detection of stabilized P53 molecules in relation to various types of DNA 
damage and assessment in combination with other biomarkers should aid in identifying 
chemical Mode of Action. The PE fluorophore conjugated P53 antibody was chosen as the 
PE emission spectra was distinct from the DRAQ5™, AF488 and BV421 emission spectra and 
the PE fluorophore is sub-optimally excited by the 488nm laser enabling staining 
optimisation on the FlowSight® and combination assessment in the optimal ImageStream X 
Mark II® system.    
Spectra for each of the conjugated antibodies and DNA stain, along with the associated 
channels on the IS XII and FlowSight® can be found in figure 3.1 below. Ch07 collects 
fluorescence emitted by BV421 associated with ɣH2AX. Ch02 collects fluorescence emitted 
by AF488 associated with pH3. Ch03 collects fluorescence emitted by the PE fluorophore 
associated with P53 and Ch11 collects the fluorescence associated with DRAQ5™ DNA stain.  
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This system provides the ability to compare these biomarker and MN responses directly to 
one another in the same cell. The system also allows us to confirm these relationships by 
looking at the associated generated cell brightfield image. Whilst this provides us with a vast 
pool of data, being able to sift through the large quantity of information poses a challenge, 
not only of identifying relevant data to analyse but also display and making sure the 
fluorescence associated with a specific biomarker is ‘true’. This chapter attempts to address 
these challenges through demonstrating the steps taken to: Use gating and masking 
strategies to minimise potential autofluorescence/of target binding assessment, generate a 
standardised template that can be used to display and extract metrics of interest whilst 
minimising bias when assessing cell populations of interest, automating cell image analysis. 
This was done by combining flow cytometry fluorescence analysis and microscopy methods.  
3.2 – Materials & Methods 
3.2.1 – Test Article Formulation 
Methyl Methanesulphonate (MMS), Cas no.: 66-27-3, and Carbendazim, Cas no.: 10605-
21-7 supplied from Sigma-Aldrich. The working concentrations for confirmation of 
antibody penetration and gating assessment are as follows, MMS 2.50, 5.00 (µg/ml) and 
Carbendazim 1.20, 1.60 (µg/ml) and vehicle control DMSO. 
Ch07 Ch02 Ch03 Ch11 
Figure 3.1: Emission spectra of each of the fluorophores conjugated to each of the antibodies and DNA 
stain present in the multiplex system. The band-passes demonstrate each of the channels the emission 
spectra associate with in both the IS XII and FlowSight®. The purple solid line represents the 405nm 
laser. The sky-blue solid line represents the 488nm laser and the Red solid line represent the 642 
lasers. Spectral histogram was generated from ThermoFisher spectral viewer, and the band passes 
applied for each channel were taken from Amnis® Spectral Imaging Channels and Corresponding 
Fluorophores table.  
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The working concentrations for the assessment of MN mask accuracy are: Crizotinib, 
4.51 (µg/ml); Etoposide, 0.13 (µg/ml); ARA-C, 0.05 (µg/ml) and Vinblastine, 0.0020 
(µg/ml). 
3.2.2 - Cell Culture and Growth Media  
Cell culture prepared as in section 2.2.2.  
3.2.3 – Treatment 
3.2.3.1 - Treatment Of Cell Cultures  
2x105 TK6 cells/mL were placed in a series of sterile vented tissue culture flasks 
(Fisher brand) and treated with MMS, Carbendazim, Crizotinib, Etoposide, ARA-C or 
Vinblastine for a 1.5-2 cell cycle period with no recovery. All incubation steps 
occurred at 37˚C, 5% (v/v) CO2± 0.5% in air. Cell cultures were washed at the end of 
the treatment period as per section 2.2.2.1. 
3.2.4 – Cell Fixation and Staining 
Cell samples having been sufficiently fixed and permeabilised by FACSLyse solution in a 
1:10 ratio with dH2O samples were stained with a maser antibody mix. The antibody 
master mix was made up fresh on the day of the experiment. The master mix consisted 
of anti ɣH2AX Brilliant Violet 421 antibody, anti pH3 ser 28 AlexaFluor 488 antibody, anti 
P53 PE antibody and PBS. DRAQ5™ DNA stain was added to each sample during antibody 
incubation. Refer to general material and methods in section 2 for full staining 
procedure.  
 
3.2.5 – Image Acquisition   
 
Stained samples were washed with PBS and transferred to appropriately labelled 
Eppendorf’s and subsequently acquired on the ImageStream®X MarkII imaging platform. 
Cell samples were also looked at on the Confocal LSM 710, AxioObserver microscope 
platform to confirm antibody nuclear penetration and specific binding.  Full acquisition 
details can be found in section 2.2.4.  
 
3.2.6 – Micronucleus Mask Accuracy   
To assess the effectiveness of the MN mask generated (see section 3.3.3.3) two metrics 
were assessed based on the MN populations of compounds, Crizotinib, Etoposide, 
Vinblastine and ARA-C.  
The first, percentage accuracy (%Accuracy); Of the cell population Identified by the MN 
mask as containing MN what percentage were true, this was confirmed by inspecting 
each saved cell image by eye. %Accuracy was calculated as follows: 
                          %Accuracy =       Total True MN identified by mask     X 100 




The second, percentage miss rate (%miss rate) required a defined cell population where 
the binned images could be assessed both by eye and using the MN mask. This 
population was selected by plotting healthy mononucleated cell population histogram 
using the Gradient RMS feature on the DNA content. A small gate termed DNA Focus 
was drawn to the right of the central peak (figure 3.2).  
 
 
The binned population taken forward provided cells with clear crisp nuclei staining, 
giving the MN mask the best chance of identifying all MN, whilst randomly selecting cells 
to help minimize technician population bias and still being representative of the whole 
cell population. The total number of cells assessed were 1000-1500.  
 
%Miss Rate was calculated as follows: 
 
                              %Miss Rate =   Total True MN identified by mask   X 100 
                                                        Total True MN identified manually 
 
 























Figure 3.2: Example of plotted histogram from a population of healthy 
cells containing only one nucleus. Gradient RMS plotted along the x axis 
assesses how in focus the DRAQ5 stained DNA is, 0 indicating the least in 
focus. The DNA Focus gate contains the binned population to be analysed 
for MN mask %Miss Rate.  
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3.3 – Results & Discussion  
Due to the optimisation nature of this chapter, the following results and discussion section 
is formatted in such a way to demonstrate the reasoning process behind the optimisation 
steps taken and generation of the IDEAS® template. This is in line with standard practise in 
the journals within the field of genetic toxicology. 
3.3.1 – Confirmation of Antibody Binding and DNA Counterstaining 
The confocal imagery in figure 3.3 below confirms that the antibody and DNA staining of 
permeabilised fixed cell samples sufficiently penetrated the cellular and nuclear 
membrane. The Z-Stack image also demonstrates that the antibodies have not just 
bound to the surface of the nucleus but have permeated through the depth of the 













Figure 3.3: 1.6µg/mL Carbendazim dosed TK6 cells demonstrating linear unmixed 4 colour, 
stained sample at x63 magnification acquired on confocal microscope. A) Shows the 
individual channels associated with BV421 gH2AX, PE P53, AF488 pH3 and DRAQ5 DNA 
stain. B) Shows a z-stack of the same region of cells as in A confirming the penetration of 
the antibodies throughout the nuclei.  
A)               ɣH2AX P53 
pH3 DRAQ5 
B)         Z-Stack: 3D projection 
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3.3.2 - Gating: Placement and Boundary Cut Offs  
Gate boundary cut offs have been a constant debate within the scientific community. 
From assessing population by eye to allowing software to automatically set gates, the 
process is a subjective art. Subjectivity is never ideal when it comes to scientific practice, 
so for the assessment of my data it was necessary  to generate a standardised method 
for generating gates and cut offs on my data. This was approached through the use of 
fixed unstained cells dosed with the solvent DMSO, MMS and Carbendazim, compared 
with DMSO, MMS and Carbendazim treated stained cells. The stains used were 
DRAQ5™, BV421, PE, AF488, appropriate compensation matrix was also applied to each 
of the assessed files prior to gate generation.  
Assessment of solvent treated and compound treated cells with no stain is a crucial step 
when it comes to assessing gate boundaries and establishing auto fluorescent cut offs. 
This is crucial during genetic toxicology assessments at combined autofluorescence with 
biomarker signal could be the difference between generating a misleading positive and 
true negative especially when it comes to borderline genotoxic chemicals.  
Trying to define finite gating cut-offs in a standardised manor is essential for compound 
analysis and has required definitive rules that can be applied to different chemicals 
especially if they exhibit more than ‘background’ autofluorescence of solvent treated 
cells. Populations of cells that were used for assessing the gating boundaries simply 
needed to meet the criteria of being single and in focus. 
3.3.2.1 - Cell Cycle Assessment Gates  
Cells cycle assessment gates were determined through initial assessment of pH3 
signal (a marker of mitosis) and multiplying the nuclear DNA peak (n=1) location by 
1.8-2. Gating of pH3 mitotic cells was plotted on DNA histogram of control sample 




The whole available cell sample population was then plotted on nuclear content 












Figure 3.4: Graph 1a Population of H3 positively stained cells plotted on nuclear content 
histogram graph. Nuclear content assessed by presence of DRAQ5 DNA stain. This peak was 




























The major cell cycle phases, G1, S and G2/M were then applied to graph 1c. Starting 
with the G1 gate generating graph 1d) then the G2 gate by applying a times 1.8-2 



















































Figure 3.5: Nuclear content graphs of entire available cell population.  Graph 1b demonstrates the entire 
cell sample population and the DNA content of those cells based on DRAQ5 DNA stain. The DRAQ5 channel 
AF (Auto Fluorescence) demonstrating the DNA content peaks are above background AF. The M gate from 



















Figure 3.6: DNA content graphs demonstrating G1 and G2 gate generation and use of region manager. Graph 1d) demonstrates the gated G1 peak, nuclear 
content n=1. The gate upper and lower cut offs were then multiplied independently by 1.8 and 2 to generate the G2 gate nuclear content n=2. (255454 – 384218 
x2 = 510908 – 768436.  255454 – 384218 x1.8 = 459817 – 691592).  An average of these two n=2 upper and lower bound gate cut offs was then taken. Generating 


























































The G2 and M phase gates were then combined due to their overlapping nature 
generating G2/M gate. S then filled the gap between G1 and G2/M gate as 
demonstrated by figure 3.7. 
Between sample sets for the same compound and dose there can be variation due to 
sample preparation differences, fluctuation in timings, ambient temperature 
variation, stain adherence to DNA, compound AF and cell orientation as the cell 
passes through the detector. This can be a potential problem when trying to 
generate a templated based approach to sample analysis using the IDEAS® software. 
However due to the presence of phosphorylated H3 as a mitotic marker I use this as 
a ‘anchor’ point on any DNA histogram and then position the other cell cycle gates 
based on the M gate position.  
This initial gating process was performed on the whole available sample i.e., included 
apoptotic/necrotic cells to try and avoid unconscious bias. The apoptotic and 
necrotic cell populations i.e., unhealthy cells were removed from the whole sample 
meaning the final cell population assessed were termed ‘Healthy’ based on nuclear 
content and brightfield contrast. Identification of this ‘Healthy’ population is 



























Figure 3.7: Demonstrating the final gate layout for cell cycle 
assessment based on DRAQ5 staining of nuclear content. 
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Despite consistent DRAQ5™ staining methodology with all things biological there is 
variability. Variability can be due to multiple factors: Environmental i.e. humidity, 
temperature; Technical; Variation between cells, cell cultures and replicates. These 
variations result in variability of DRAQ5™ staining meaning the G1, S and G2/M gate 
placement is the rate limiting step when it comes to template approach and batch 
processing of data sets because of subtle shifts of the DNA content histogram up and 
down the x axis. To counteract this effect the same method described in this section 
was used per dose per chemical. For each replicate of the same dose and chemical 
the same gate x co-ordinates for G1, S and G2/M were used.  Where a distinct G1 
peak was not present cells that were positive for pH3 staining were used to set the 
G2/M gate and then the S and G1 gates based on G2/M placement. 
3.3.2.2 - BV421 ɣH2AX Cut Offs  
To assess ɣH2AX response a step wise gating procedure was developed to help 
exclude any autofluorescence and determine a finite gating boundary cut off where 
background ɣH2AX levels are excluded from ɣH2AX metric generation and only 
ɣH2AX levels over a certain intensity are counted as being induced due to chemical 
related damage. Figure 3.8a and 3.8b shows the 12 steps taken to generate the 
lower gate and upper gate for ɣH2AX signal induction a stepwise description follows 
that relates to each graph within figure 3.8a and 22b.  
1- MMS unstained autofluorescence (AF) graph. Full AF peak gated to the point 
where histogram cell ‘bins’ reach less than 2 cells consistently. X co-ordinates: 
3210-32006. The lowest gate boundary needs to be higher than 32006, the 
highest point of AF.  
2- Unstained peak (UP) gating based on the centralisation of gates over the AF peak 
drawn by eye at three different positions on the histogram peak. X co-ordinates: 
1_MMS UP; 4917-21375, 2_MMS UP; 5168 – 19836; 3_MMS UP; 4678-23614 
3- Average of these three X coordinates was then taken to generate the 
Average_MMS unstained peak X coordinates:4921-21608 
4- MMS multiplexed (all biomarkers and DNA stain) cell sample. The stained distinct 
peak (SP) was assessed. The same process used as explained in step 2) i.e., 3 
gates drawn by eye. However, the lowest x point of the three does not drop 
below the 32006 x axis value as determined by step 1 by more than 10%. X 
coordinates: 1_MMS SP; 37170-108428; 2_MMS SP; 32850 – 117736; 3_MMS SP; 
29033 – 117736   
5- Average of the 3 gates in step 4 was taken, X coordinates; Average_MMS SP; 
33017-114633. The lowest x intercept is greater than the highest X point of the 
MMS AF peak 
6- Demonstrating the Average_MMS UP gate and Average_MMS SP gate. 
7- Working with the 10fold principle used as standard practice in flow cytometry. 
The x intercept coordinates of Average_MMS UP gate were multiplied by 10 




8- An average was then taken of these two gates from the two different methods 
(above AF and 10 fold) generating a Combined average MMS peak gate.  X 
coordinates: Combined Average;41113-165357.  
The combination of these two methods was used to provide a robust gate cut off 
with reduced subjectivity. The lowest X intercept 41113, will be the lowest gate cut 
off for ɣH2AX assessment and fulfils the requirements of: being greater than the 
highest MMS AF peak gate X intercept and does so by no more than 10%. This lowest 
gate will initially be referred to as; +BV421(gH2AX gate). 
9- Due to the nature of ɣH2AX the use of only one gate cannot be used to identify 
strand break induction due to DNA damage over that of a healthy cell system. 
This can be achieved by assessing the difference in intensity of; the solvent 
DMSO control stained sample BV421 peak and the MMS induced BV421 peak. 
Therefore, an average of 3 gates centralised of the solvent (DMSO) only stained 
sample peak was given: 1_DMSO SP: 29127-70422, 2_DMSO SP; 27662 – 72924, 
3_DMSO SP; 24734 – 82930. Average_DMSO SP; 27174-75425 
10- Accepting that the lowest X coordinate for the +BV421(ɣH2AX gate) is equal to 
the lowest X coordinate of the combined average MMS peak averaged with the 
lowest x co-ordinate of the Average_DMSO stained peak. Thus, the upper gate 
boundary of +BV421 (gH2AX) should be the higher X intercept of the 
Average_DMSO stained peak. This allows us to assume that the cells within this 
gate are healthy and are experiencing ‘normal’ ɣH2AX cell cycle responses and 
that anything greater than this X intercept could be considered critically 
damaged as a result of induced DNA Damage.  
11- MMS lowest gate intercept, 41113 combined with the highest Average_DMSO SP 
x axis intercept. This gives us +BV421 (ɣH2AX gate) lower and upper intercepts.  
12- Anything greater than 75425 x intercept can then be considered 
++BV421(ɣH2AX) and allow for the assessment of induced DNA damage based on 
compound interaction having taken into account any potential chemical AF. An 













































































































































Focussed Single Cells  
Average_MMS Stained Peak
Average_MMS Unstained Peak





































Figure 3.8b: Demonstrating steps 7-12 of the BV421 gating strategy 










































































































MMS BV421 AFmax UP





















Focussed Single Cells  
+BV421 (gH2AX gate)
++BV421 (gH2AX gate)
MMS BV421 AFmax UP




























Applying these gates (+BV421(gH2AX) and ++BV421(gH2AX)) to the solvent control, 
known clastogen at 2.5µg/mL MMS and known aneugen 1.2µg/mL Carbendazim 
provides a snapshot of ɣH2AX response percentages of the two gates and are 
displayed in table 3.1. This data was assessed on the entire available ɣH2AX signal 
without assessing cell cycle (i.e., initially ignoring the DNA stain) and not gating out 
apoptotic and mitotic cells. 
Table 3.1: Demonstrating the cell percentages that fall inside the boundaries of the 
+BV421(ɣH2AX) and ++BV421(ɣH2AX) gates for Carbendazim (Crbz), DMSO and MMS 
along with the fold change away from the solvent negative control 
 Crbz DMSO MMS 
Fold change                                                                                                                            
+BV421 (ɣH2AX) 15.2 25 27.1 
++ BV421 (ɣH2AX) 7.06 6.72 15.1 
Fold change                                                                   
 
At this stage although mitotic and apoptotic populations have not been excluded 
from the ɣH2AX assessment. This demonstrates a difference between known 
aneugen, clastogen and control that is consistent with the current literature. These 
numbers will now be refined through population narrowing that will exclude ɣH2AX 
events that are not due to DNA damage but are induced as a result of mitosis and 
cell death. 
3.3.2.3 - AF488 pH3 Cut Offs  
The fluorophore AF488 is a brightly fluorescent fluorophore that is excited using the 
488nm (blue laser). The emission spectrum in the ImageStream system is visualised 
in channel 2 of the 12 available channels. Initially Alexafluor488 fluorophore was 
chosen in association with the anti ɣH2AX antibody. However due to the available 
fluorophores that were commercially available with the antiH2AX antibody 
compared to Anti pH3 antibodies and the low levels of H3 signal available AF 488 
was considered more appropriate for picking up pH3 signal. The z stack from 
confocal microscope demonstrated in figure 3.9 Shows the antibody has bound the 
phosphorylated H3 proteins available in mitosis generating the distinctive fingers 
associated with the condensation of chromosomes in the nucleus.  
Whilst initial optimisation of the antibody (as with ɣH2AX antibody) was performed 
on the Amnis FlowSight® the now described gating strategy was used on data 
obtained on an Amnis® ImageStream X Mark II® at x40 magnification. This 
methodology was then followed and applied for data generated at x20 and x60 
























The AlexaFluor (AF) 488 conjugated H3 Antibody specifically binds to the Serine (S) 
28 residue when it has been phosphorylated. Due to the nature of Phosphorylated 
(p)H3 only occurring in late G2 and early mitosis phase of the cell cycle there is less 
subjectivity when compared to the transient nature of ɣH2AX when it comes to 
gating. This means the +ve pH3 gate simply needed to sit above/within 10% of the 
maximum autofluorescence of the cell sample. However, for consistency the 
methodology used to generate the ɣH2AX gates was applied to AF488 pH3 gate 
generation and adapted accordingly when needed. The population assessed was 
simply single in focus and circular, this helps to eliminate unconscious bias during the 
gating process.  
The following graphs show a step wise process of how the +ve pH3 gate was 
generated. For a unstained DMSO sample, collected with all lasers set for optimal 
fluorescence acquisition of a stained sample, AF488 fluorescence intensity was 
plotted on the x axis as a histogram (Figure 3.10).  A maximum unstained (US) peak 
gate for DMSO negative control was generated (Figure 3.10a) followed by averaging 
Figure 3.9: Z stack image taken on Zeiss confocal microscope x40 water lens 
objective. Demonstrates the penetration of the Anti H3 antibody throughout the 
entirety of the nucleus and not simply surface nuclear membrane binding.  
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the upper and lower x intercepts at three portions of the DMSO US histogram (Figure 
3.10b).  
 
The Average_DMSO Unstained Peak AF488 now termed Average_DMSO UP AF488 
was applied to acquired data for DMSO vehicle stained with the AF488 conjugated 
antibody. With AF488 intensity plotted along the X axis the histogram generated in 
figure 3.11 shows a primary peak that sits within the Average_DMSO UP AF488 gate 
(generated as per figure 3.10). This identifies cells that did not positively stain with 
the AF488 antibody despite its presence within the sample and that background 
autofluorescence in vehicle control samples is unaffected by antibody presence. The 
smaller secondary peak, zoomed in section of figure 3.11, are those cells positively 
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Figure 3.10: Unstained vehicle control autofluorescence peak for generation of an average 
autofluorescence unstained DMSO peak gate. a) Maximum DMSO autofluorescence gate. b) 






The next step was to assess this initial AF488 gate on a sample of data known to 
induce a positive response in pH3 and therefore increased fluorescence availability 
of AF488 signal. As such a unstained Crbz sample was looked at without 
compensation to assess background autofluorescence (AF), see figure 3.12. This 
showed a higher level of AF than that of the vehicle control as demonstrated by 
figure 3.12b. To confirm this shift in autofluorescence was appropriately accounted 
for the compensated file of the stained Crbz sample and AF peak was assessed, 
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Figure 3.11: Displayed histogram of AF488 stained DMSO sample. The true fluorescence peak was 


















Upon application of compensation matrix to stained Crbz sample the AF peak shifts down to the left and falls within the 
Average_DMSO UP AF488 gate. i.e., the main AF peak fell to vehicle control AF levels, see figure 3.12c below. As a result, an average of 
the unstained peak of Crbz was not strictly needed. However, due to the minimal presence of a secondary AF488 true stain peak 
average of the stained peak could not be generated so an average of the US crbz peak was still taken and therefore a 10fold gate for US 
Carbendazim was generated, figure 3.13. 
The following graphs in figures 3.13 – 3.14 demonstrate the 10 fold gate generation of estimated DMSO stained secondary peak and 10 
fold estimated Crbz stained secondary peak. The 10 fold DMSO gate and stained AF488 DMSO gate (as seen in figure 3.11) lower 
Figure 3.12: Display of Crbz unstained AF488 histogram peak. a) Shows the maximum AF of US Carbendazim following two cell bin rule. b) Demonstrates 
where the maximum AF DMSO gates from figure 3.10a and average DMSO UP gate from figure 3.10b sits on the unstained Carbendazim histogram. c) 
Showing the shift of the US Crbz peak to the stained Crbz peak 
Focussed Single Cells  






















Focussed Single Cells  
Crbz Unstained Peak AF488 AF
Average_ DMSO UP AF488






















Focussed Single Cells  
























Crbz peak Stained 
Crbz peak 
a) b) c) 
79 
 
boundary overlap, shown by yellow R9, were then averaged to demonstrate DMSO 10F + AF488 stained gate. The R10 region combines 














Focussed Single Cells  
Crbz UP AF488 AF
Average_ DMSO UP AF488
Average_DMSO UP AF488 10 fold






















Focussed Single Cells  
Crbz UP AF488 AF
Ave_DMSO AF488 10f
DMSO 10F+StainedAF488
DMSO Stained AF488 P






















Focussed Single Cells  
Crbz UP AF488 AF
Average_ DMSO UP AF488
Average_DMSO UP AF488 10 fold
DMSO Stained AF488 Peak























Focussed Single Cells  
Crbz UP AF488 AF
Average_ DMSO UP AF488






















Focussed Single Cells  
Crbz Unstained Peak AF488 AF
1_Crbz AF488 AF Peak
2_Crbz AF488 AF Peak
3_Crbz AF488 AF Peak






















Figure 3.13: Demonstrating a-e steps 
leading to +veAF 488 (H3 gate) generation. 
a) stained Crbz AF488 histogram with 
minimal secondary peak and the unstained 
DMSO average peak gate from figure 3.11. 
b) the generation of the average_Crbz 
unstained peak. c)UP DMSO AF488 gate is 
location is shifted 10 fold generating the an 
estimated gate for the secondary peak. d) 
The lower boundaries of DMSO UP AF488 
10 fold and SP AF488 were averaged to 
generate DMSO 10F +stained AF488 gate as 
seen in e). 

















The graphs in figure 3.15 show the +veAF488 (H3 gate) in histogram form and that 
there is some overlap with the maximum crbz AF demonstrated by the region R11. 
However, when this is plotted as a scatter graph the R11 AF overlap is diminished by 
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Figure 3.15: Combined +veAF488 is now referred to +veAF488 (H3 gate).  R11 showing the overlap 
between +veAF488 (H3 gate) and Carbendazim autofluorescence gate. 
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Figure 3.14: Demonstrating continued steps leading to +veAF 488 (H3 gate) generation. a) Showing 
the 10 fold increase of average unstained DMSO and Crbz peaks. b) R10 demonstrates the 
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Figure 3.16: Scatter graph of negative control DMSO demonstrating the gated 
populations of +ve Af488(H3) meaning positively stained for pH3 and -ve AF488 














Figure 3.17 demonstrates that (example in orange bubble) off target binding or AF 
falls outside of the gates based on the secondary characterisation of DNA stain and 
the cell population separating into the distinctive G1, S and G2/M phases of the cell 
cycle as described in section 3.3.2.1 above allowing by the definition of biology to be 
excluded as ‘True’ pH3 events due to them sitting in the G1 phase of the cell cycle. 
Though the gates are robust there are some examples of AF/ potential off target 
binding events occurring (example in green bubble of 3.17). To help make sure the 
data is normalised and what is being observed/detected is true pH3 events in the 
G2/M section of the cell cycle. Ideas software provides a feature termed similarity of 
morphology o help determine localisation of a stain/probe within the cell i.e., the 
likelihood of it being in the cytoplasm or the nucleus. It does this by creating a mask 
of the nucleus i.e., DNA stain and overlaying this with the biomarker of choice (in this 
case pH3) and then seeing how similar in location these pixels are two one another 
(figure 3.18). A value of 1 and above indicates the pH3 pixels are most similar to the 
nuclear stain i.e., are in the nucleus rather than the cytoplasm. Below zero means 
the signal is most likely in the cytoplasm so these are the pixels that are least similar 
to the nucleus. The values between 0 and 1 are intermediates this means that, most 
likely, due to the orientation of the cell as it passed through the camera on the 
ImageStream was partially in and out of focus, so a portion of the signal has fallen 
outside the focal plane the camera was trained on during collection. As a result, for 
anything that was above zero the H3 signal was determined to be sufficiently 
‘similar’ to the nucleus that the recorded result was not as a result of off target 
binding or AF. The use of this feature attempts to compensate for the lack of z 
stacking as available with confocal microscopy which provides the user with the 
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ability to definitively determine a probe/stain location. Though this feature does not 
provide definitive location of the biomarker it does lend confidence and allows for 
some assessment of the fluorescence spatially and not wholly relying on 






















Figure 3.17: Demonstrating top dose 
Carbendazim (1.6 µg/mL) scatter graph 
combined with image assessment for more 
accurate gating.  
Orange: Channel images falling outside the 
determined gates help exclude AF and or off 
target binding. 
Green: Demonstrating that off target 
binding/AF can still be present within +ve 
AF488 (H3) gate even though they are not 
‘true’ events. 
Stained Crbz 1_6 mg/mL
+ve AF488 (H3)













































Figure 3.18: Refining pH3 populations to exclude AF and or off target binding. The use of an additional feature within the IDEAS® software termed ‘Similarity’ generates a 
histogram of a chosen population and plots how similar pH3 presence pixel location is to DNA stain pixel location. 1) Shows an example where pH3 signal appears to be present 
in the cytoplasm. 2) An example of partial similarity of pixel location, termed intermediate. 3) Giving an example of a cell with H3 signal that is most ‘similar’ to that of the 
nuclear stain. 
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Unlike in other assays where pH3 has been looked at the mitotic phase was not 
boosted by any additional chemical incubation i.e., with Colcemid as performed in 
Bryce et al 2007 for the assessment of hypo and hyper diploid metaphase cells. This 
means in control samples H3% is ~1-2%, for a more complete view of the mitotic 
portion of the cell cycle especially with the important role of phosphorylation and 
dephosphorylation of serine residues, other than the phosphorylation of the 
Serine28 looked at here, would identify cells in the later stages of mitosis after H3 
S28 has been phosphorylated. This would not only provide a more comprehensive 
view of cells in the different phases of mitosis it would be interesting to see if 
chemical with different modes of action influence these different 
phosphorylation/acetylation etc events occurring during mitosis. 
3.3.2.4 - PE P53 Cut Offs  
The PE fluorophore is associated with an antibody that is specific for the N terminal 
of the P53 amino acid chain i.e., not the phosphorylated form of the tumour 
suppressing protein.  
Maintaining methodology for gate generation has been kept as consistent as 
possible. However due to the less than optimal excitation of PE using the 488nm 
laser the separation of the emission spectrum is not as distinct as BV421 ɣH2AX and 
AF488 pH3 emission spectrum. After the compensation matrix was applied, the cell 
population used was deemed single and in focus but no other criteria was used to 
maintain as much of the cell population as possible to provide the best 
autofluorescence profile of each sample. The population was plotted on a histogram 
graph based on the intensity of available pixels found in channel three i.e., the 
channel the emission spectrum of the fluorophore PE falls in. The X axis is therefore 
labelled as Intensity_MC_PE displayed in log scale. The unstained peaks were 
averaged and 10fold increase gates were generated as per the BV421 ɣH2AX gating 
method. However, as a result of the reduced peak separation, unlike with BV421 
ɣH2AX, only the Crbz stained peak was able to be averaged.  
Figure 3.19a below demonstrates the maximum autofluorescence (AF) available of 
unstained samples exposed to the same laser intensities as the stained samples. 
These unstained samples provide a base line unstained (US) AF peak. A maximum 
autofluorescence gate was generated through assessment of cell bins found within 
the histogram, once these ‘bin’ populations dropped below two cells this was 
determined as the upper and lower boundary of the gate. Three smaller gates 
covering the main curve of the US peak were centralised at the base middle and top 
of the peak and averaged. This was performed on both Carbendazim and vehicle 
control DMSO US peak. The process was not performed on the MMS US peak as the 
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Figure 3.19: P53 stepwise gating strategy 
a) Maximum UP autofluorescence PE gate b) Average 
UP AF gate generation c) Maximum US AF PE peak of 
Carbendazim sample d)Average PE AF  US peak gate 
generation e)Showing MMS unstained PE peak is 





The stained histogram peaks of PE is displayed in figure 3.20. below. These histograms demonstrate the lack of a distinctly separate PE 
peak with both MMS and DMSO stained samples. The highlighted red area on graph 34a) identifies an area of the PE MMS primary 
peak that lies outside the PE DMSO primary peak, this being said the region is not distinct enough to qualify as a secondary peak. 
















Figure 3.20: Demonstrates the stained PE peaks of negative vehicle DMSO and positive sample of the clastogen MMS and aneugen Carbendazim. The blue 
translucent peak is an overlay of the DMSO PE peak b) onto a) MMS stained peak and c) Carbendazim stained peak both in green. This demonstrates the lack of a 
distinct secondary peak in both a) and b) but a distinct secondary peak is present in c). The red drawn area on the MMS graph highlights the area that is outside 






























Having identified the average Carbendazim PE autofluorescence unstained peak (Ave_Crbz PE AF UP) in figure 3.19d) the lower and 
upper boundaries of the gate were multiplied by 10 to give the Carbendazim PE unstained peak 10 fold gate (Crbz PE UP 10F) as 
demonstrated in figure 3.21 graph a). The distinctive secondary peak of the stained Carbendazim sample was then averaged in a similar 
fashion as described for BV421 ɣH2AX making sure the lowest point was above the DMSO PE AFmax as demonstrated in figure 3.22.   
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a) b) c) 
Figure 3.21: Demonstrating PE stained peaks of Carbendazim sample and secondary peak gating. a) 10 fold increase of Ave_Crbz PE AF UP; lower X 
boundary and Upper X boundary generating Crbz PE UP 10F gate. b) The three gates 1_/2_/3_ Crbz PE SP (Stained Peak) upper and lower X 
boundaries were added together and averaged to generate Ave_Crbz PE SP. c) Crbz PE UP 10F from a) was added to Ave_Crbz PE SP from b) and 
averaged as per section 3.2.5.2 and was termed Combined Ave_Crbz PE peak. 
89 
 
The Combined Ave_Crbz PE P gate takes into account both the estimated fluorescence of the Crbz PE UP 10F and the true stained 
fluorescence peak Ave_Crbz PE SP. At this point the value of the upper x boundary of this gate is irrelevant and it is the generation of 
the intermediate gate boundary and the lower x intercept boundary. Previously with BV421 ɣH2AX intermediate gate boundary this 
was determined using an combined average of DMSO stained and 10 fold gates and the overlap of these gates.  As there is an absence 
of the distinct secondary peak for DMSO vehicle control PE stain the intermediate gate boundary was generated using and averaged of 
the lower X intercept of Combined Ave_ Crbz PE P gate and the upper X intercept of DMSO PE UP 10F gate as demonstrated by figure 
3.22 graphs a) through c). This generated the lowest x intercept of the gate termed ++PE(P53 gate) this x intercept also becomes the 
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Figure 3.22: Histogram demonstrating the generation of the ++PE (P53 gate). a) The upper and lower bound x intercepts of the Ave_DMSO PE AF UP gate 
multiplied by 10 gives the DMSO PE UP 10F gate as an estimation of the true fluorescence of PE. b) Intermediate graph demonstrating the DMSO PE UP 
10F gate and the Combined Ave_Crbz PE P gate. c) The dashes blue lines highlight the overlap between the Combined Ave and DMSO 10F gates. The lower 
x intercept of the former and upper x intercept of the latter were averaged to generate the lowest boundary of ++PE(P53 gate) . 
a) b) c) 
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To determine the lowest boundary of the +PE (P53 gate) in lou of having a secondary true fluorescence peak available for DMSO a value 
















3.3.2.5 – Gating Strategy Overview and Final Gating Boundaries 
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Figure 3.23: Demonstrating generation of lower boundary of +PE (P53 gate). a) Graph demonstrating the overlap of the Crbz PE AFmax UP and DMSO 10F 























 Average autofluorescence of unstained peak assessed 
 Gate multiplied by 10 generating 10fold gate of 
estimated fluorescence 
The unstained sample is important to help 
identify true fluorescence over background 
autofluorescence. This helps minimise scoring of 
false signal which can become important when 
chemicals are borderline positive/negative.  
Use of averaging allows for variability across 
samples.  
Using the 10 fold gate helps mitigate potential 
unconscious bias  
 Where a distinct secondary peak of positively stained 
cells available 
 Average of stained peak generated 
 Where applicable a combined average gate of true 
fluorescence stained peak and 10 fold estimated 
fluorescence is generated 
 Overlap of vehicle control and positive control gates 
are used to determine intermediate and lower gate 
boundaries 
Through combining vehicle control and positive 
control samples in generating the gates this 
allows for excluding as much background 
fluorescence as possible whilst still trying to 
include the lower/weaker available true 
fluorescence signal.   
 In the absence of a distinct secondary true fluorescence 
stained peak to identify the lowest gate boundary 
 10% lower than the AFmax upper boundary is used 
In the absence of a distinct secondary peak 10% 
of the upper x intercept of the AFmax provides a 
similar role as the combining of the vehicle 
control and positive control gates. i.e. Excluding 
as much background fluorescence as possible 
whilst still trying to include the lower/weaker 
available true fluorescence signal. 
Regardless of the lowest boundary cut off 
generation method, this boundary should be       
   10% higher than the upper boundary of the 
average unstained autofluorescence peak 
For the sake of robustness and to minimise inclusion of background fluorescence that 
may still be included using this gating method. When markers are known biologically to 
only be found in the nucleus use of similarity morphology feature is employed. This 
allows for removal of cells from the positively gated population where fluorescence is 
detected in the cytoplasm, the criteria of these cells is falls below zero. 
+ve AF488 (H3)  
Intermediate
No Similarity Positive Similarity
2-2 4310-1





















Flow Chart overview: Gating procedure  
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The above process demonstrates how for each parameter (pH3, ɣH2AX and P53) the 
gating boundary cut offs were determined. These X coordinates of +Bv421, ++BV421, 
+PE, ++PE and +veAf488 were applied to scatter graphs on the Y axis, the X axis 
coordinates were then chosen based on the DNA content histogram. These gates were 
then termed +Bv421 = gH2AX+, ++BV421 = gH2AX++, +PE = P53+, ++PE = P53++ and 
+veAf488 = pH3 +VE. The applied gates and their coordinates are shown in figure 3.24.  
 
The described gates were applied to all graphs that looked at biomarker fluorescence 
intensity, the gating boundaries maintained across all graphs and all chemicals that were 
tested using the ‘optimal’ ISMN multiplex expansion assay method obtained on the 
ImageStream® X Mark II. To generate the features displayed on the x and y axis’ in figure 
a series of defined masks and features for fluorescence analysis were used to set up a 
template based approach for chemical assessment. 
 
 
Figure 3.24: Finalised gating cut off points for the biomarkers pH3, P53 and ℽH2AX. a) pH3+VE 
(Green Gate) : Upper left (x) 4.2^5, (y) 5^6, upper right (x) 2.5^6, (y) 5^6, lower left (x) 4.2^5, (y) 
1^4, Lower right (x) 2.5^6, (y) 1^4. pH3+VE gated population was used to generate pH3 response 
data and to assess proportion of cells in mitosis phases. b) P53+ (Orange gate): Lower left (x) 1^5, 
(y) 1.14^4, Lower right (x) 3.19^6, (y) 1.14^4. Upper left (x)1^5 (y)2.56^4. Upper right (x)3.19^6 
(y)2.56^4. P53++ (Yellow gate) Lower left (x) 1^5, (y) 2.56^4. Lower right (x) 3.19^6, (y) 2.56^4. 
Upper left (x)1^5 (y)1^6. Upper right (x)3.19^6 (y)1^6. OVERALL P53 (Coral gate) uses the upper 
coordinates of P53++ and lower coordinates of P53+. The overall gate for P53 was used to 
generate the cell response results for P53. c) gH2AX+ (pink gate): Lower left (x) 1^5, (y) 3.41^4, 
Lower right (x) 2^6, (y) 3.41^4. Upper left (x)1^5 (y)7.54^4. Upper right (x)3.19^6 (y)7.54^4. 
gH2AX++ (Purple gate) Lower left (x)1^5 (y)7.54^4. Lower right (x)2^6 (y)7.54^4. Upper left (x)1^5 
(y)2.5^6. Upper right (x)2^6 (y)2.5^6. OVERALL gH2AX (Lilac gate) uses the upper coordinates of 
gH2AX++ and lower coordinates of gH2AX+. The population used to generate H2AX response was 
gH2AX++ gate. The population used to assess the H2AX response is the pH3 -VE cell population 
gated in light blue on graph a).  
a) b) c) 
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3.3.3 - Masks and Features 
The IDEAS® 6.2 software relies on a system of masking pixels and then measuring a series of 
morphology intensity shape and texture features within those masks to generate graphs to 
generate data not only based on fluorescence intensity but also spatial location. The masks 
that the system automatically applies to each of the 12 channels are generic but specific to 
any emission that falls within those channels. These masks can be refined to generate more 
accurate data sets relevant to the biology of the response being looked at whilst removing 
background from potential debris. The following describes the steps taken to generate 
specific masks for cytoplasm, nuclear DNA, ɣH2AX, pH3 and P53 signal based on the stain 
DRAQ5™ (signal collected in channel 11) Brilliant violet 421 (Signal collected in channel 7) 
Alexa Fluor488 (signal collected in channel 2) and PE (signal collected in channel 3). 
The two masks generated for nuclear and cytoplasmic assessment provide the basis for 
refining the biomarker populations by making the selection process for pixels assessed by 
the system more robust. This is done through the mask manager and ‘Defining mask 
function’ in the IDEAS® software. Once the mask input meets the criteria for your 
assessment, whether that be texture, shape, intensity, spot counting etc you can then layer 
the masks using Boolean logic i.e., ‘this AND this BUT NOT this’ ‘this Or this AND this’. 
System features can then be generated based on your designated masks to make your 
analysis more sensitive and specific.  
Masks can be complex or simple. When a biomarker such as ɣH2AX and pH3 are known only 
to be located in relation to nuclear DNA both masks can be as direct as ɣH2AX and DRAQ5™ 
but not Cytoplasm the same logic can also be used for pH3. These masks are basically saying 
that the fluorescence intensity of interest is that which is directly associated with the pixels 
of the DRAQ5™ stain. This helps reduce the potential for identifying off-target antibody 
binding and including it in the data analysis populations. The steps for how both these 
masks were generated, and the ensuing features used to help build the overall IDEAS® 
template are outlined below in figures 3.25 through to 3.43. 
 
3.3.3.1 - Cytoplasmic Mask and The Features That Use It 
New masks can be added in the Define Mask function and from these masks the rest of 
the data analysis features can be derived. The first mask to be refined is the brightfield 
mask. Criteria in this mask will then be used to separate out cell population that are 




Use of the morphology function includes pixels at the outer most edge of the image and 
is recommended by IDEAS® manual when shape is an important aspect to be taken into 
account. This combined with the adaptive erode function further taking shape into 
account removes pixels from the boundary of the morphology input. This refines the 
mask morphology to be more consistent with the brightfield image as shown in figure 
3.25 above. The more similar the brightfield mask to the actual shape of the cell image 
the more effective the ensuing features used in the IDEAS® template will be.  
Brightfield masks 1A and 1B use the same mask function inputs, figure 3.26. Separate 
masks are required when using multiple area and texture features for the same mask in 
an individual channel otherwise the system will not auto populate, and population 






















Aspect Ratio feature tells us how round an object is, and area tells us how large the 
object is i.e., the combination of the two features will give us a single cell reasonable 
round population. This is displayed in figure 3.27 below. Cells that are in the gated blue 
area are termed single cells and meet the criteria of having a aspect ratio of >~0.6 and 
brightfield area of >~70 but <~450 this is consistent with other ImageStream analysis 
settings in literature (Verma et al., 2018; Rodriguez et al., 2018; Filby et al., 2016). This 











Figure 3.26: Brightfield 1A (highlighted by red arrow) and Brightfield 1B (highlighted by green arrow) masks 




The next step to get to the working population for analysis is assessing image focus. The 
more focus the population the better the masks and features work. Using the same 
Brightfield 1A mask use of the gradient Root Mean Square (RMS) feature generates a 
histogram. A gate is then applied to the graph designating a single in focus cell 




























Figure 3.27: Example plot of the gating of single round cells with corresponding scatter point 





























The single in focus cell population was then used to determine health of cells being 
analysed this was done by generating a cytoplasmic mask and following the feature 
steps used in the apoptosis wizard. The cytoplasmic mask was generated by using the 
Figure 3.28: Generation of in focus cell population from single cell population. A) shows the feature 
selection to generate the ‘in focus histogram. B) Example of the focus histogram and corresponding 
images found in the selected ‘bin’. The higher the gradient RMS the more in focus the object image. 
Anything less than 50 was considered too out of focus for assessment. The highlighted red bins indicate 
the cell grouping the images displayed were taken from showing the differences between in focus and out 
of focus. 
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same mask functions as Brightfield 1A/B as described above combined with a nuclear 
mask using Boolean logic (Figure 3.29). Nuclear mask 2 that was used to generate this 
















Use of the Contrast feature with the cytoplasmic mask. This is a texture feature that 
assess sharpness quality. The higher the contrast the more likely the cell is to be 
unhealthy assessment of cytoplasmic contrast is a feature commonly used in manual 
microscopy to assess cell health. Further explanation of the generation of the healthy 
cell population will continue in the nuclear mask section below. Due to the nature of the 
P53 antibody being used for these experiments’ detection of stabilised P53 in the 
cytoplasm is possible. This is due as explained above to the antibody binding to the N 
terminal of P53 protein rather than in response to its phosphorylation. The cytoplasmic 




Figure 3.29: Demonstrates the specific cytoplasmic mask generated when the nuclear mask 





























Figure 3.30: Function use for P53 mask generation and P53 cytoplasmic mask generation. A) 
Morphology mask (identified by red arrow) was used to identify shape of P53 fluorescence and 
intensity (green arrows) was used to exclude potential background.  Use of the P53 pixel intensity 
histogram allowed the minimum pixel intensity to be selected. B) Using Boolean logic, the P53 






For P53 mask generation the morphology feature was used to assess the shape/spatial 
location of P53 this combined with intensity range of 45 – 4206 relative fluorescent 
units of pixel intensity generates the P53 mask based on shape and intensity. The lowest 
value of 45 was chosen as anything less than 30-40 pixel intensity units is not considered 
true fluorescence rather just background noise (Filby et al., 2016; Patterson et al., 2015). 
Using the P53 mask combined with the Cytoplasm mask the Cytoplasmic P53 mask is 
generated and can be used to assess P53 fluorescence in the cytoplasm. Whilst this 
feature has been applied in the template to assess cytoplasmic P53 compared to nuclear 
P53 giving the ability to assess P53 intensity ratios based on translocated vs 
untranslated this metric has not been assessed as part of this thesis. 
3.3.3.2 - Nuclear Mask, The Features That Use It and Refining Biomarker Signal  
Three different nuclear masks were used in the processing of the collected data sets. 
The masks were termed Nuclear Mask 1, Nuclear Mask 2 and Nuclear Mask 3, an 











3.3.3.2.1 - Nuclear Mask 1 
The first termed Nuclear Mask 1 was used to help identify the Healthy Cell 
population i.e., non-apoptotic/necrotic. This mask uses a 50% threshold feature that 
only allows the system to look at the top 50% of the highest intensity pixels. Whilst 
this is the same mask that is generated by IDEAS® software ‘Apoptosis Wizard’ this 
mask also includes a range feature that excludes nuclear bodies with less than 50 
pixels (12um) from being looked at, this was to try and prevent MN events being 
excluded from the healthy population as being identified as apoptotic (figure 3.32).  
 
M11 Nuclear Mask 1 Nuclear Mask 2 Nuclear Mask 3 
Figure 3.31: Same cell demonstrating the different nuclear masks used in template feature 
generation.  Captured in channel 11 the Draq5 nuclear stain of a single cell is displayed. Each 
column shows the exact same cell the differences being the criteria the system is looking at in 
various relationships of size shape and intensities, demonstrated as a blue overlay. M11 merely 
shows the generic default mask used to detect signal by the system. The mask differences 
between nuclear mask 1, 2 and 3 allow for different features to be assessed. Nuclear Mask 1 was 
used to help determine ‘Healthy’ cell population. Nuclear Mask 2 was the predominant mask 
used for cell cycle and similarity assessment as it best matches the generalised overall shape of 
the nuclear staining. Nuclear mask 3 was used to help identify potential binucleates for 




Combining nuclear area of the Nuclear 1 Mask with the cytoplasmic contrast feature 
as explained in section 3.3.3.1 Above allows the assessment of a healthy cell 
population as recommended by the IDEAS® manual and in experimental literature 
that healthy cells have a high nuclear area with pixels that meet the 50% threshold 
intensity and low cytoplasmic contrast (Rodriguez et al., 2018; Rodriguez., 2018;  
Filby et al., 2011; Filby et al.,2016). Figure 3.33 below shows the relative cell 
brightfield and corresponding DNA staining in relation to scatter points that either 
fall within the ‘Healthy Cells’ gate or outside it. Whilst it could be considered that a 
larger nuclear area above say 150 on the scale could be so dispersed that the 
nucleus has degraded and is dispersing, due to the large area of cellular nuclei when 









Figure 3.32: Nuclear mask 1 generation. a) Shows the 50% threshold mask that demonstrates the 
nuclear stain as being contrasting and only certain pixels meet the 50% highest intensity criteria. 
b)  Using a minimum area of 50pixels (equivalent to 12.5um) a area of staining that were it 
outside be counted as a MN is removed from the apoptotic assessment so healthy MN cells are 
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Figure 3.33: Example graph showing the Healthy Cells gate in red that will select cells to be taken forward to 
the next stage of DNA content assessment (optimal master population). A scatter point location at the main 
points outside of the gate show examples of the main type of cell that is able to be excluded as not healthy 
from the cell population.  
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Cells therefore that have a nuclear intensity (DRAQ5™ stained) area of greater than 
40 when looking at the top 50% of pixel intensity but a cytoplasmic contrast of less 
than 30 are gated as ‘Healthy Cells’. Without the use of additional viability stains or 
using a cleaved PARP indicator to identify apoptosis activation there cannot be a 
100% certainty that all apoptotic/necrotic cells are excluded from analysis, it does 
remove the most distinctly compromised cells.  
Nuclear mask 1 is also used in combination with a spot count and nuclear aspect 
ratio to assess mitosis stage of positive pH3 cells.  
3.3.3.2.2 - Nuclear Mask 2 
The second nuclear mask, the template attempts to match the morphology of the 

















The main feature used in combination with the mask is intensity for the master 
population of cells that will be assessed for MN, ɣH2AX P53 and pH3. DNA content 
cell cycle assessment (figure 3.7 in section 3.3.2), generation of the cytoplasm mask 
Figure 3.34: Nuclear mask 2 generation. Morphology function combined with range function allows for the shape of 
the nucleus to be mapped whist excluding smaller sized pixels that may also have DRAQ5 stain so only the main 
nucleus is looked at. Dilation of the mask proportionally expands the morphology input mask by 1 pixel allowing for 




as demonstrated in section 3.3.3.1, generation of ɣH2AX and pH3 masks (figure 
3.35A and 3.35B) and confirmation of biomarker location using the similarity feature 


























Figure 3.35: Demonstrating mask combination using Boolean logic and nuclear mask 2 to generate 
“True Nuclear” signal masks. A) ℽH2AX nuclear mask that all ℽH2AX metrics are generated from. B) pH3 
nuclear mask that all pH3 metrics are generated from C) P53 nuclear mask that P53 metrics are 
generated from. All masks use the functions: Morphology that matches the shape of the signal and 







Using boolean logic the nuclear mask 2 is combined with the gH2AX mask (gH2AX 
MASK And NUCLEAR MASK 2) this helps minimise assessment of cells that may have 
above average autofluorescence or off target binding. Figure 3.36 Shows the graphs 
used to assess the ɣH2AX populations. This process was the same for P53 and pH3 
signal, the differences being; the master population assessed was based on the 
entire DNA content profile so histogram gating step 4 as seen in figure 3.36 did not 
happen. P53 intensity was based on over all intensity assessed using just the P53 























Figure 3.36: Showing each graph used to generate the ɣH2AX response along with ɣH2AX response per each section 
of the cell cycle. gH2AX++ and gH2AX+ gate coordinates as developed in 3.2.5 applied on the Y axis, Nuclear gH2AX 
intensity. The x coordinates of each of the gates covered the DNA content range and were applied to the Nuclear 
intensity.  Unlike with pH3 and P53 populations, for the G2 assessment of H2AX cells stained positively with AF488 
pH3 were excluded from the assessment. 
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Passed just Bv421 ɣH2AX, AF488 pH3 and PE P53 assessment, these biomarkers 
were assessed in direct relationship with the portion of the cell cycle they each fell 
into. These ‘sub population’ gates, taken from the DNA content histogram, G1 S and 
G2M were plotted on a intensity graph for each of the biomarkers as demonstrated 
in figure 3.36 above. The same gating boundaries as: pH3 +VE, pH3-VE, gH2AX ++, 
gH2AX +, P53+ and P53++ as developed in section 3.3.2.5 were used and labelled 
accordingly. The G2 assessment of ɣH2AX was based on the population of cells that 
fell within the G2M gate boundary of the histogram that was negative for cells with 
H3 staining. 
The population of BV421 ɣH2AX ++, + and overall signal and AF488 pH3 were then 
further refined and confirmed using the similarity feature. The similarity feature in 
the IDEAS® software is usually used to assess the likelihood that a signal has been 
translocated into the nucleus or an overall move of a signal towards being 
translocated. This can be done by following the steps of the “Nuclear Localisation 
Wizard”.  The graph generated rates each of the pixels within the mask search 
criteria by assigning a + or – number to each pixel based on how similar pixels 
containing your signal of interest are in spatial location to your DNA stained pixel 
signal. The programme does this mathematically by plotting the log transformed 
pearsman coeffeicient correlation relationship of the DNA stain and signal (IDEAS® 
user manual 6.2, 2015). The system then places a gate of greater than or equal to +1 
on a graph and plots the available cell population as a histogram. Cells that are 
above +1 can be described as; there is a high probability that you are most likely to 
find the chosen signal in the nucleus rather than outside it i.e., in the cytoplasm. Any 
signal that is found to be less than zero i.e., negative are the cells that the signal is 
the least similar to the nucleus, the signal is in the cytoplasm. In terms of signal that 
is transient you can say that the majority of the cell population has signal that 
translocated to the nucleus. Whilst the similarity feature is mostly used to identify 
how translocated a signal into the nucleus is it can also be used to confirm that the 
signal of a biomarker is actually coming from the area of the cell its supposed to, 
therefore be able to assess any off-target binding or exclude autofluorescence in 
cells. This was the rationale behind its use, in combination with specific pH3 and 
ɣH2AX signal masks it will help reduce counting signal that is unrelated to true 
antibody binding. Demonstration of use of the similarity feature in the above 
described manner can be found in in the gating section 3.3.2 figure 3.18. 
Combination of the intermediate gate and positive similarity gate generates the 
population of ‘True nuclear pH3’ and ‘True Nuclear ɣH2AX’ these are the cell 
populations that were used to calculate the percentage cell response. 
As H3 phosphorylation on Ser28 only occurs in prophase metaphase and anaphase, 
the known features of these phases and microscopy assessment can be used to 
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identify cells in these various stages based on shape and pH3 presence. This is 

















































Figure 3.37: Graph demonstrating the separation of three phases of the mitosis cell cycle based on nuclear 
aspect ratio (how circular the DNA is) and spot count of nuclear bodies labelled Mitosis assessment that uses 
nuclear mask 1. An example image of the scatter points gated and their location in each of the mitosis phases is 
also highlighted. Population highlighted prophase is determined by its singular nucleus and relatively circular 
formation. Metaphase population is determined by it single nuclear content, the nuclear DNA being elongated 
as the chromosomes line up along the metaphase plate. Ana/meta orientation demonstrates the anaphase 
population based on the presence of two nuclei as the DNA content gets pulled towards opposite poles. The 
‘meta orientation’ portion of this gate title refers to the potential of the cells, that fall into this gate, of actually  
being metaphase and are only classed as anaphase due to the orientation the cell image was captured in. The 
graphing and gating strategy used here was based on work done by, Filby et al., 2011; Filby et al., 2016.  
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The final biomarker related graph looks directly at the relationship of the true 
nuclear ɣH2AX and the True Nuclear pH3 response. Whilst the biology of cells in 
mitosis has a phosphorylation of PH3 at the same time there is a global 
phosphorylation of ɣH2AX signal. As demonstrated in the optimised gating step 
above the H3+ve population can be excluded from ɣH2AX analysis so as to avoid 
classing a healthy ‘normal’ cell response as a result of DNA damage. Whilst this is 
important to take into account during analysis it is also reasonable to assume that 
cells exposed to a chemical that affects the mitotic phase of the cell cycle in some 
way would in turn affect the direct relationship of H3 and H2AX phosphorylation. 
This allows us to assess another parameter that could be a potentially useful 
clastogenic/aneugenic flag by looking at the percentage of cells that are positive for 
H3 but negative for ɣH2AX. This was simply done by plotting the nuclear ɣH2AX 
intensity against the nuclear H3 intensity and reusing the gating boundary cut offs 
determined in section 3.3.2.5. Example of the graph is shown in figure 3.38. 
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Figure 3.38: Demonstrating pH3 intensity plotted against ɣH2AX intensity as a scatter graph. Images 
show a ɣH2AX negative (abnormal) mitotic cell compared to a ɣH2AX positive (normal) mitotic cell. 
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3.3.3.2.3 - Nuclear Mask 3 
Nuclear mask three was used to determine mononucleated cells from binucleated 
cells through the use of the spot count feature. Nuclear mask 3 uses the input mask 
of nuclear mask 2 which assesses shape, the ‘watershed function (figure 3.39) is 
then applied which allows a mask to be divided into multiple components by 
removing a portion of the mask between areas of higher intensities. 
 
Based on this mask the spot count feature can be used, this counts the number of 
individual components generated by the mask and plots them as a histogram values 
cells that sit in the histogram bar at one indicate there is only one component, in this 
case nucleus, present. Figure 3.40 below demonstrates the feature being selected 
and the graph generated. The gate termed healthy mononucleates is the population 




Figure 3.39: Application of the watershed function to Nuclear mask 2 allows for separation of the 
nuclear mask into multiple components. Not weighting the intensity of the watershed function 
allows the system to input a break in the area with least signal this minimises function basing the 























3.3.3.3 - Micronucleus Mask and The Spot Count Feature 
MN mask 1 which can be summarised as simply as Cytoplasm And MN but Not Nucleus. 
For MN Mask 2 whilst follows the methodology of MN mask generation by Rodriguez et 
al the variations that have been allowed try to take into account the variable nature of 
what constitutes a “true” MN. For example, the Rodriguez mask focusses on events that 
are round, completely distinct from the nucleus generated from a very specific 
population set. However as per Fenech et al this does not account for all MN. MN may 
be touching the nucleus or may be kidney shaped and these may be excluded from the 
analysis due to population exclusion or the mask being too specific. A third MN mask 
was also generated with slight variations on size range of MN looked at and main 
--VE FOR pH3  
Healthy Mononucleates
31 2




















Figure 3.40: Showing use of the spot count feature to identify Mononucleated 
vs Bi-nucleated cells. The connectivity option circled in blue means the system 
only looks vertically and horizontally at the pixels next to the determined 
masked area of pixels to determine count.   
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nuclear shape to further account for variability in the populations. By combining all 
three masks and the cytoplasm presence addition the mask is trying to take into account 
variation of MN found in a cell population. A lack of refining the population that the spot 
count feature looks at based on this mask is trying to limit unconscious biasing of the 
data. The individual steps taken to generate the Complete Final MN mask are covered 
by table 3.2 and figure 3.41 and 3.42. 
To generate each different MN mask two main functions are used. The spot count 
function and range function. For the assessment of bright points such as MN stained 
with sufficient DRAQ5™ the spot feature selects bright spots by simply eroding the 
selected bright detail from the image and removing this background from the total 
fluorescence image leaving the mask to identify only the bright spots. This is controlled 
by adjusting the spot to background ratio, minimum and maximum area of the bright 
spots. The range function then further enables refinement of the bright spot criteria 
through filtering of area size and how round that area is. Table 3.2 displays the 
sequence of functions each of the three individual MN masks use 
Table 3.2: Summary of the functions used to generate the three MN masks that make up the 
Complete final MN mask 
 
The overall mask function combinations shows what the IDEAS® software reads to 
identify each different type of MN. In practice these sequences were divided up into 
stages and then each step was combined with the last, these steps can be seen in 




 Overall mask function combinations 
MN Mask 1 (Range(Spot(Threshold(M11, Draq5,90)Bright, 3,6,1)5-100, 0.4-1) 
AND NOT (Range(Dilate(LevelSet (M11, Draq5, Middle, 3) 1) 100-
5000, 0.2-1) 
MN Mask 2 Range ((Threshold (Spot (M11, Draq5, Bright 2,5,2) Draq5 88) AND 
NOT (Range (Level Set (M11, Draq5, middle, 5) 90 -5000, 0-1) 10-
80, 0.4-1) 
MN Mask 3 Range ((Threshold (Spot (M11, Draq5, Bright 2,6,2) Draq5 88) AND 
NOT (Dilate (Morphology (M11, Draq5) 1) 10-80, 0.4-1) 
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Combination of these masks using the term OR means the system will take each of the 
criteria into account when looking for MN spots. Collectively the mask will be looking for 
bright spots that meet the criteria of having an area of 1.25-25 microns and be 
reasonably round. Combining this with AND cytoplasm means as long as a portion of the 
bright spot is inside the cytoplasmic boundary but not within the larger nucleus it will be 
masked. This is why the variations of nuclear masks are also used to make these three 
different MN masks, the variations allow the system to look at MN that may be touching 
or that are distinct from the main nucleus. An overview of the complete final MN mask 













Figure 3.41: Demonstration of the basic principle of MN mask generated behind each of the three MN masks 
using IDEAS 6.2 software. a) Identification of DRAQ5 signal indicating nuclear content b) Removal of identified 
main nuclear pixels c) Remaining nuclear pixels above and below a specified size and roundness is classed as a 
MN.  
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Figure 3.42: Complete final MN mask spot count for MN metric generations. A) 
Demonstrating the overall rule for the final MN mask and the corresponding masks 
assessed. B) Complete final MN mask is used to generate the spot count feature and 





3.3.3.3.1 - Complete Final Micronucleus Mask Accuracy Rate 
Use of the IDEAS® mask in the IDEAS® software allows for the automation of MN 
assessment through use of the spot count feature, as explained in section 3.3.3.3 
above. Over 10,000 cells can be assessed based on the population of cells  being 
single, round, reasonably in focus, healthy DNA stained mononucleates with no pH3 
staining. Due to the limited combinations of masks through Boolean logic processing 
all the variations and nuances that could be picked up by an experienced technician 
may be missed by the system. To assess the accuracy of the used MN mask a 
population of roughly 1000 cells were looked at manually to assess if any MN were 
not identified by the system termed %Miss Rate, followed by assessment of 
%Accuracy (see section 3.2.6 for details).  
Based on the assessment of four top dose compounds known to induce MN the 
%Accuracy and %Miss rates are as follows:  
 Crizotinib showed 72% accuracy and 52% miss rate 
 Etoposide showed 57% accuracy 73% miss rate 
 Vinblastine showed 64% accuracy with a 3% miss rate.  
 ARA-C showed a 35%accuracy with 52%miss rate 
Whilst the numbers are highly variable and therefore not ideal, it does imply that 
different chemicals generate different MN types that the mask is better or worse at 
identifying. On average the complete final MN mask is 57% accurate with a 44-45% 
miss rate 
Based on the assumption that the system will consistently be ~57% accurate the 
dose response is relevant. The system will consistently miss the same types of MN 
within the population which ends up being balanced by the mask false identification 
rate. Use of the mask can be used to identify a general trend of MN fold change 
response of the assessed samples. It provides a quick overview snapshot of the 
potential MN within your sample whilst simultaneously providing a classic genotoxic 
endpoint that can be directly associated with DNA damage markers such as P53 and 
ɣH2AX levels. 
3.3.3.4 - Extracted Data Populations 
The population of cells that most of the analysis is based on is the healthy cells with 
DNA content of intensity greater than 1X105. The percentage cell response data that has 
been reported as square root fold change in sections 4 and 5 below was generated by 
the generic rule (cell count with marker of interest/total cell master population 
analysed) X100. The IDEAS® software uses a waterfall style system to calculate the 
percentage cell response i.e., the system takes the gated population of cells plotted on a 
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new graph as the master population which is then reported in a statistics table, see 
figure 3.43 below which can then be exported as a statistics report. 
 
Whilst these percentage calculations are calculated by the system and are able to be 
directly exported into excel, the master population to calculate the response of the 
signal is not necessarily the right population relevant for the analysis as a result the raw 
cell counts by the system for the relevant metric looked at were used to calculate the 
more accurate response using the correct master population cell count.  
 
Figure 3.43: Demonstrating the population plotted on the scatter graph is the cells that fall within the DNA content 
gate of the cell cycle histogram. In this instance the DNA content count is the master population and the pH3+ve 
population is a proportion of the DNA content cell population. 
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3.3.4 – Template overview  
Template generation allows for the batch processing of analysis files using the IDEAS® 
platform. This provides a easily extractable data set containing the specific feature 
assessment of: Single in focus, healthy cell population with corresponding cell cycle 
information. Fluorescence intensity assessment of ɣH2AX, P53 and pH3 with defined gating 
cut offs allows for the assessment of biomarker response in a un bias dose dependant 
manner allowing for elucidation of biologically relevant fold change responses whilst 
simultaneously excluding potential autofluorescence/camera background/off target binding 
skewing of results. The template as is, allows for direct comparison of cell cycle stage 
biomarker relationships and automatic acquisition of MN data, all achieved per cell. 
However, lack of a automated cell cycle analysis artificial intelligence feature for cell cycle 
assessment total user bias and subjectivity cannot be removed due to the need to 
interactively adjust cell cycle gates due to sample variability. Whilst the MN mask and spot 
count feature provides a trend of MN response as the systems miss rate and inaccuracy 
scoring are proportional the template identifies limits to the software. Due to the limited 
nature of Boolean logic masking combinations the IDEAS® system does not have the finesse 
or sensitivity to account for all potential variations of MN generated by the various DNA 
damaging chemicals (Rodrigues et al., 2018; Rodrigues et al., 2021).  
Whilst the template system is not perfect it provides a robust system for quick and efficient 
data extraction with minimal user interference creating relatively unbiased data to be used 















Chapter 4 – Results 2: Model Chemicals, Methyl Methanesulfonate and 
Carbendazim 
4.1 – Introduction   
Identification and scoring of MN using the ImageStream has been achieved by various labs 
specifically focussing on the bi-nucleated MN cytome assay (Verma et al., 2018; Rodriguez et 
al., 20; Wills et al., 2021) using DNA stains such as DAPI, Hoesht and DRAQ5™. However, dose 
response data has not been presented for the mononucleate assessment of MN nor has 
multiplexing of the biomarkers ɣH2AX, pH3, P53 using the FlowSight® or ImageStream X Mark 
II® (with the exception of Padalino et al., 2021 where data not used as part of this thesis was 
published).  Use of the Amnis® Imaging flow cytometry platform, FlowSight® and ImageStream 
X Mark II®, combines the high throughput acquisition of data, typical to flow cytometry, whilst 
using un-lysed cells allows for the high content information collection and archiving capabilities 
supplied by automated microscopy (Amnis®., 2015). This system also allows for increased 
confidence in flow cytometry gating and the development of imaging classifiers, through the 
availability of collecting cellular images, which subsequently can significantly improve scoring 
precision. The use of said images can be used to refine and validate gating approaches as well 
as support image scoring as discussed in chapter 3. 
This initial assessment looks at the feasibility of using the two imaging flow cytometry 
machines, FlowSight® and ImageStream X Mark II®, for detection of a dose response for the 
DNA damage markers ɣH2AX, pH3, P53 and MN. Usage in the first instance with the biomarkers 
ɣH2AX, pH3 compared to a second sample set of MN on the FlowSight® using mononucleated 
cells (without Cyto-B). In the second instance, also in mononucleated cells, a single sample set 
assessing dose response of ɣH2AX, pH3, P53 and MN on the ImageStream X Mark II®.  
Given the highly characterised nature of MMS and Carbendazim respective MoA’s (Kirkland et 
al., 2008; Kirkland et al., 2016; Sarrif et al., 1994; Van Hummelen et al., 1995) these two 
chemicals were used to initially assess the known expected responses of these chemicals in 
relation to ɣH2AX, pH3, P53 and MN response (Bryce et al., 2014; Khoury et al., 2016; Smart et 
al., 2011; Verma et al., 2017 ; Watters et al., 2009 ) versus the actual achieved responses of 
these biomarkers using the ImageStream platform.     
This chapter, using the model clastogen MMS and aneugen Carbendazim, demonstrates how 
the in vitro MN assay performed on the FlowSight®, can be directly compared with ɣH2AX and 
phosphorylated H3 combined assay, providing both assessment of chromosome damage and 
underlying MoA. Furthermore, this chapter shows the progression and feasibility of 






4.2 – Materials & Methods 
4.2.1 - Test Article Formulation 
Methyl methanesulphonate (MMS), Cas no.: 66-27-3, and Carbendazim, Cas no.: 10605-21-
7 supplied from Sigma-Aldrich. The working concentrations, MMS 0.00, 0.31, 0.63, 1.25, 
2.50, 5.00 (µg/mL) and Carbendazim 0.00, 0.40, 0.60, 0.80, 1.20 and 1.60 (µg/mL) were 
selected based on the data produced by Verma et al., 2017. Vehicle control was dimethyl 
sulfoxide (DMSO).  
4.2.2 - Cell Culture and Growth Media  
Refer to general material and methods section 2.2.2.  
4.2.3 - Treatment Of Cell Cultures  
TK6 at 2x105 cells/mL were placed in a series of sterile vented tissue culture flasks and 
treated with MMS or Carbendazim for a 1.5 cell cycle period with no recovery. All 
incubation steps occurred at 37˚C, 5% (v/v) CO2± 0.5% in air.  
4.2.4 - Preliminary  
 4.2.4.1 - Cell Processing 
Approximately 2x105 TK6 cells/mL were placed in a series of sterile vented tissue 
culture flasks (Fisher brand) and treated with MMS and Carbendazim for a 1.5 cell cycle 
period with no recovery. All incubation steps occurred at 37˚C, 5% (v/v) CO2± 0.5% in 
air.  
After the treatment period, cultures were centrifuged at 200 x g for 8 minutes, 
supernatant was discarded, and the pellet re-suspended in pre-warmed phosphate-
buffered saline (PBS). Subsequently, the PBS was removed via centrifugation at 200 x g 
and the pellet was re-suspended in BD FACS lysis solution enabling cell fixation and 
membrane permeabilization. Post fixation, cultures were centrifuged for 5 minutes at 
200 x g, supernatant discarded and subsequently stained either ɣH2AX, pH3, PBS AB 
solution or DRAQ5™ and agitated at room temperature for a minimum of 1 hour for the 
former and 20 minutes for the latter then washed with PBS. Stained cells were then 
transferred to appropriately labelled Eppendorfs and subsequently acquired on the 
FlowSight® imaging platform. 
4.2.4.2 - Antibody and DNA Staining 
Samples stained with only the antibody master mix will be referred to as experimental 
set 1 and samples counterstained with just DRAQ5™ will be referred to as experimental 
set 2.  
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Experimental set 1, 300µL of freshly made antibody master mix, containing 
Immunofluorescence antibodies anti ɣH2AX Brilliant Violet 421 antibody (Cat. No. 
564720) and Anti Histone pH3 AlexaFluor 488 antibody (Cat. No. 641003), was added to 
each sample and incubated under agitation protected from light at room temperature 
for a minimum of 60 minutes. 
Experimental set 2 stained with DRAQ5™ DNA was used to label nuclei and MN in a ratio 
of 1:99 of PBS due to DRAQ5™ suboptimal excitation on the FlowSight® using laser 
488nm. Samples were incubated for a minimum of 20 minutes.  
Additional information on the full staining procedure can be found in section 2. 
4.2.4.3 – Preliminary Data Acquisition FlowSight® 
Samples were analysed on an Amnis FlowSight® imaging flow cytometer using Amnis INSPIRE® 
software version 6.2 (Merck Millipore, Nottingham UK). Prior to experimental analysis, following 
the manufacturers instructions for appropriate Amnis FlowSight® set up and quality control 
procedures, all system calibrations performed and passed using Amnis® ImageStream 
SpeedBead calibration reagents (Cat. No. 400041). 75µL aliquots of cell suspension at a 
concentration of ~7x105 and no less than ~4x105 cells/mL were prepared in 1.5mL Eppendorf’s 
and loaded on the sample port. All samples were excited using 405nm and 488nm lasers. An 
INSPIRE® template was set up for in focus and single cellular event gating, using Aspect Ratio 
and Root Mean Square (RMS) features, to enable sample data acquisition, ensuring collected 
cells were sufficiently circular and in focus. Once established, data was acquired at a low 
velocity, resulting in 15,000 – 20,000 single cellular events being collected in approximately 45 
seconds, and subsequently automatically saved for each experimental replicate. Experimental 
set 1 acquisition of images for ɣH2AX and pH3 combined assay assessment occurred in: Channel 
1, bright field; channel 2 and 7 fluorescence. Acquisition of images for experimental set 2 of 
mononucleated MN events, stained with DRAQ5™ DNA stain occurred in: Channel 1, bright 
field and channel 5 fluorescence. 
Once data has been collected for all samples, the acquired raw image files (.RIF ) data files were 
analysed using IDEAS® v 6.2 software, compensation matrix and template applied and 
subsequent, .CIF (compensated image files) and .DAF (Data Analysis Files) were generated.  
4.2.4.4 - INSPIRE® Compensation File Acquisition 
 Compensation sample files were acquired using the INSPIRE® acquisition compensation 
wizard. Acquisition of correct compensation samples was performed without the 
presence of brightfield or side scatter, but both 488nm and 405nm lasers were utilised 
at the same intensity value as used during the experimental setup. 500-1000 cells were 
acquired for MMS (5.0 µg/mL) dosed TK6 cells stained with the anti-ɣH2AX antibody 
BV421, and Carbendazim (1.6 µg/mL) TK6 cells stained with the anti-pH3 antibody 
AlexaFlour 488. 50µL of each stained sample was combined with 50 µL of unstained 
untreated cells. Acquired files formed compensation matrices in AMNIS IDEAS® 6.2 
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software. Compensation file acquisition was not required for DNA stained only set 2 
samples. 
4.2.4.5 - Amnis IDEAS® v6.2 Template 
Data analysis was conducted using Amnis IDEAS® software version 6.2 (Merck Millipore, 
Nottingham, UK). Prior to signal assessment RIF files were converted to compensated 
image files (CIF) and data analysis files (DAF).  
For the assessment of BV421 ɣH2AX and AF 488 H3 signal of experimental set 1, an 
additional gate was included for analysis to exclude cells that were considered 
saturated, using the Raw Max Pixel function to exclude cells with saturation pixel count 
of >1 and raw max pixel function of 4095≤ (Amnis 2015). Composite images of combined 
bright field, BV421 ɣH2AX and AF488 H3 were generated to visually confirm signal was 
within the cytoplasmic boundary and assess the viability of the cells. The single, in-
focused unsaturated cells were then used to assess ɣH2AX and H3 presence. 
Fluorescence signal positivity was determined through the use of visual assessment of 
cell images allowing the extraction of positive and negative populations with regard to 
H3 and γH2AX signal intensity by comparison of control samples and top dose of 
aneugenic/clastogenic compound, thus a subsequent gate was established. Once these 
parameters were established the CIF files were batch processed via the use of an IDEAS® 
template. A total of 15000 cells were assessed to obtain the ɣH2AX and phosphorylated 
H3 dose response. For full details on template and gate generation steps see general 
methods and section 3.3.2 respectively. 
For the preliminary assessment of mononucleated MN cells using experimental set 2, an 
overlay of DRAQ5™/Bright field (Composite) images was created in IDEAS® by combining 
images of DRAQ5™ (nuclear stain) stained nuclei/MN collected with bright field images 
of cells (Verma et al, 2018). The composite images were manually assessed to classify 
cells based on their morphology as mono’s, bi and tri nucleates with and without 
micronuclei present (Verma et al, 2018). MN scoring within the mononucleated cells 
was carried out by adopting the criteria designed for slide based scoring (Fenech et al., 
2003). Therefore, the MN that were DRAQ5™ positively labelled were accepted for 
scoring were, circular/oval, 1/3-1/16 the size of the main nuclei and resided within the 
cytoplasmic boundary (Verma et al, 2018). A total of 6000 mononucleated cells were 
assessed per dose to obtain the MN dose response. Please note no mask for automated 
MN assessment was used for this data nor was cell cycle data generated.  
4.2.4.6 - Statistical Analysis 
Preliminary data experimental set 1, distributions were tested for homogeneity and 
normality using the Brown forsythe/Bartletts test and D’Agnostino-pearson omnibus 
(K2)/Shapiro-Wilk test respectively. If datasets proved both normal and homogenous a 
one way ANOVA Dunnett’s test was performed to identify significance (p value<0.05) of 
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data response. If data did not pass these trend tests the data was either Log or square 
rout transformed and distribution retested. In the event the transformed data failed 
distribution tests the non-parametric 1 sided Dunns Kruskal Wallis test was performed 
on the raw response data. Presence of statistical significance was used to identify the 
no- and the lowest- observed genotoxic effect levels (NOGEL, LOGEL). This procedure is 
as recommended by Johnson et al., 2014; Verma et al., 2018.  
For preliminary data experimental set 2 no statistical analysis was performed as 
experimental repeats were n=1.  
4.2.4.7 - Positive Response Criteria 
With regards to histone signal, here a >1.5 fold increase over that of control values, for 
either histone signal, to be classed as a biologically relevant positive result as per 
industry standards (Smart et al., 2011). A positive decrease was defined as a <0.7 
change, in respect to control values, based on criteria proposed by Khoury et al., 2016. A 
result was considered equivocal if the fold change was equal to either, exactly a 1.5 
increase or 0.7 decrease. Values that fall <1.5 fold but >0.7 fold are considered negative. 
Based on available literature such as Smart et al., 2011, Bryce et al., 2016, Khoury et al., 
2016 with regards to industry defined fold change cut offs for ɣH2ax and pH3 is a 1.3-1.5 
fold increase and a 0.7 fold decrease as being biologically relevant. A positive response 
criterion for the preliminary MN response was considered to be a greater than 2 fold 
change induction compared to control (Takeiri et al., 2019; Shi et al., 2010).  
For the preliminary data set the data was not transformed and is reported in normal 
fold change. 
4.2.5 - Optimised  
4.2.5.1 - Antibody and DNA Staining 
Immunofluorescence antibodies used were: Anti ɣH2AX Brilliant Violet 421 antibody 
(Cat. No. 564720) supplied by Becton Dickinson Biosciences. Anti-Histone pH3 
AlexaFluor488 antibody (Cat. No. 641003) and anti P53 PE antibody (Cat.No. 645805) 
were both obtained from Biolegend. These antibodies generated a mass stock solution, 
in the ratio 3µl of pH3: 5µl of ɣH2AX: 6µl of P53, with 286µl of PBS. Cells were stained in 
multiplex at room temperature under agitation for a minimum of 60 minutes.  
DRAQ5™ DNA (Cat. No. 564902 supplied from BD Biosciences) was used to label nuclei 
and MN in a ratio of 1:199 of PBS. Samples were incubation time for DRAQ5™ was a 
minimum of 20 minutes.  
4.2.5.2 - Optimised Cell Processing 
After the treatment period, cultures were centrifuged at 200 x g for 8 minutes, 
supernatant was discarded, and the pellet re-suspended in pre-warmed phosphate-
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buffered saline (PBS). Subsequently, the PBS was removed via centrifugation at 200 x g 
and the pellet was re-suspended in BD FACS lysis solution enabling cell fixation and 
membrane permeabilization. Post fixation, cultures were centrifuged for 5 minutes at 
200 x g. Supernatant discarded and subsequently stained with ɣH2AX, pH3 and P53 
antibody solution and agitated at room temperature for a minimum of 1 hour followed 
by the addition of DRAQ5™ nuclear stain for a minimum of 20 minutes then washed 
with PBS. Stained cells were then transferred to appropriately labelled Eppendorfs and 
shipped on ice via DHL to: Newcastle Flow Cytometry Core Facility (FCCF), William Leech 
Building (2nd floor Room M2.099), Newcastle University, NE1 7RU, for subsequently 
acquisition on the ImageStream X Mark II® imaging platform.  
4.2.5.3 – Optimised Data Acquisition ImageStream X Mark II® 
Samples were analysed on a Amnis® ImageStream X Mark II® imaging flow cytometer 
using Amnis INSPIRE® software version 6.2 (Merck Millipore, Nottingham UK). Prior to 
experimental analysis, following the manufacturer’s instructions for appropriate 
ImageStream X Mark II® set up and quality control procedures, all system calibrations 
performed and passed using ImageStream X Mark II® SpeedBead calibration reagents 
(Cat. No. 400041). 100µL aliquots of cell suspension at a concentration of ~7x105 and no 
less than ~4x105 cells/mL were prepared in 1.5mL Eppendorf’s for shipment upon arrival 
at the FCCF facility, samples either remained in the Eppendorf’s or were transferred to a 
96 well plate and loaded on the sample port. All samples were excited using 405nm, 
488nm 642nm lasers at 120mw, 90mw, 80mw respectively. Laser 785nm was used for 
side scatter at laser power 5mw. An INSPIRE® template was set up for in focus and 
single cellular event gating, using Aspect Ratio and Root Mean Square (RMS) features, 
ensuring collected cells were sufficiently circular and in focus. Once established, data 
was acquired at a low velocity 66.0(mm/sec), resulting in 15,000 – 30,000 single cellular 
events being collected in approximately 45 seconds, and subsequently automatically 
saved for each experimental replicate. Acquisition of images for ɣH2AX pH3, P53 and 
DRAQ5™ assessment occurred in: Channel 1, bright field; channel 2, 3, 7 and 11 
fluorescence; Channel 6 side scatter. Whilst these channels were of main interest data 
was acquired for all 12 channels.  
Once data has been collected for all samples, the acquired raw image files (.RIF ) data 
files were analysed using IDEAS® v 6.2 software, compensation matrix and template 
applied and subsequent, .CIF (compensated image files) and .DAF (Data Analysis Files) 
were generated.  
4.2.5.3.1 - Acquisition Error 
Due to an acquisition error and laser malfunction experimental repeats 1 and 2 for 
both Carbendazim and MMS had no side scatter laser and a reduced 405nm (BV421 
ɣH2AX excitation laser) laser power of 20mw. To account for this, the optimal gate 
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positioning discussed in section 3.3.2 for template analysis, was shifted down by a 
factor of 6, proportional to the laser power reduction. Historical data (not shown) of 
vehicle control response, 1.2 µg/mL Carbendazim and 2.5 µg/mL MMS using optimal 
power settings as described in section 4.2.5.3, were used to confirm the suboptimal 
BV421 collection and adjusted gating parameters were reasonable adjustments to 
confirm response consistencies despite acquisition error. Laser powers for 488nm 
and 642nm were 100 and 90mw respectively. As these laser powers were only 10% 
different from optimal acquisition setting the pH3+ve gates and P53 gate was not 
adjusted. Experimental repeats 3 for both chemicals had the laser powers as 
described in section 4.2.5.3.   
4.2.5.4 - INSPIRE® Compensation File Acquisition 
Compensation sample files were acquired using the INSPIRE® acquisition compensation 
wizard or manually using Compensation beads (Cat.No.01-2222-41) from Thermofisher 
Scientific.  Acquisition of correct compensation samples was performed without the 
presence of brightfield or side scatter but both 488nm 405nm and 642nm lasers were 
utilised at the same intensity value as used during the experimental setup. Acquired files 
formed compensation matrices in AMNIS IDEAS® 6.2 software. Two separates 
compensation matrices were generated for optimal and acquisition error settings. 
4.2.5.5 - Amnis IDEAS® v6.2 Template 
Data analysis was conducted using Amnis IDEAS® software version 6.2 (Merck Millipore, 
Nottingham, UK). Prior to signal assessment RIF files were converted to compensated 
image files (CIF) and data analysis files (DAF).  
Of the initial RAW cell population collected using brightfield and nuclear parameters 
single in focus healthy cell population was determined as laid out in section 3.3.3.2. DNA 
content was then plotted on a histogram, and cells with nuclear intensity greater than 
1X105 was the final population used for MN, ɣH2AX, P53 and pH3 assessment.  
Using the brightfield channel and DRAQ5™ DNA stain for the assessment of 
mononucleated MN cells, the cell population was determined my using nuclear mask 3 
to distinguish mononucleated cells from cells with multiple nuclei using the spot count 
feature. This mononucleated population of cells was then used to generate MN data. 
The designed mask termed Complete final micronucleus mask in combination with spot 
count feature was used to automatically score the MN response (See section 3.3.3.3 for 
in-depth description nuclear and MN masking criteria). The automated MN scoring 
within the mononucleated cells was carried out by attempting to include the criteria 
designed for slide based scoring (Fenech et al., 2003) in the MN mask. Therefore, the 
MN that were DRAQ5™ positively labelled were accepted for scoring were, circular/oval, 
1/3-1/16 the size of the main nuclei and resided within the cytoplasmic boundary. A 
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minimum of 5000 mononucleated cells were assessed per dose, per replicate to obtain 
the MN dose response. 
For the assessment of BV421 ɣH2AX, AF 488 pH3 and PE P53 fluorescence signal 
positivity was determined through pixel intensity through the use of stained vs 
unstained populations, signal separation on scatter graphs and specific signal masking 
based on nuclear/cytoplasmic localization. Gates were then applied to scatter graphs to 
extract positively stained cell populations for each of the three biomarkers (see section 
3 for boundary cut-offs and mask development). To assess the specific biomarker 
response per stage of the cell cycle the same gate cut offs were used as the overall 
population assessment of each of the biomarkers but the populations used were taken 
from the cell cycle gates placed on the DNA content graph. Once these parameters were 
established the CIF files were batch processed via the use of an IDEAS® template.  
  
4.2.5.6 – Optimal Data Set Positive Response Criteria 
For the optimal data set the fold change responses and statistical analysis were as 
described in 2.2.6 data assessment section of general methods.  
 
4.3 – Preliminary Results 
4.3.1 – Preliminary Dual Biomarker and MN Assessment   
The results from the well characterised chemicals, MMS (clastogen) and Carbendazim 
(aneugen), show a distinct pattern with regards to ɣH2AX and phosphorylated H3 (pH3) 
signal. Examples of the images obtained during data processing can be seen presented in 
figure 4.1.  
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As figure 4.2A, presented in fold change, demonstrates, all concentrations of MMS lead to 
statistically significant (p <0.05) increases in a dose dependant manner of ɣH2AX signal. 
Doses 1.25µg/mL to 5.0 µg/mL have a fold change >1.5 fold change. Demonstrating a 
positive response. The H3 signal decreased dose dependently, a NOGEL was determined to 
be 2.5µg/mL with a statistically significant decrease of signal at 5.0µg/mL with a <0.7 fold 
change. The MN scored using FlowsSight® in mononucleated TK6 cells, following exposure 
to MMS, data shows a dose dependant increase (See figure 4.2B). This is consistent with the 
dose dependant response generated by ɣH2AX along with previous microscopy based 
analyses (Verma et al., 2017). 
Figure 4.1: Demonstrating images obtained on Amnis FlowSight® at 20x magnification of sample 
dual stained with pH3 and ɣH2AX AB. Brightfield light microscope image. Composite is an overlay of 
brightfield and all fluorescent image channels. Row 1 – 3 shows negative control cellls. Row 1 shows 
images with no AB binding. Row 2 demonstrates cell at beginning of mitosis. Row 3 shows cell in 
telophase of mitosis. Row 4 images shows 1.2ɥg/mL Carbendazim dosed cells, with reduction in 
ɣH2AX. Row 5 images show 2.5ɥg/mL MMS dosed cells with ɣH2AX signal. 


































Preliminary Mononucleated fold change MN response of  
MMS dosed TK6 cells (n=1) 
 
Figure 4.2: Demonstrating biomarker response of set 1 compared to the independent DRAQ5 stained MN response of set 2 spanning similar dose ranges of 
MMS using the Amnis FlowSight®. Graphs include Relative Cell Growth (RCG) % of treated TK6 cells. A)  Induction of ɣH2AX and pH3 dual marker response to 
MMS a known clastogen. The red line shows the 1.5 fold change and orange line shows the 0.7 fold change industry standards. B) MN fold change response 




As demonstrated in Figure 4.3A, presented in fold change, exposure to Carbendazim results in an increase of phosphorylated H3 
signal and corresponding decrease in ɣH2AX signal.  
Preliminary Mononucleated fold change MN response of 
Carbendazim dosed TK6 cells (n=1) 
Figure 4.3: Demonstrating biomarker response of set 1 compared to the independent DRAQ5 stained MN response of set 2 spanning similar dose ranges of 
Carbendazim using the Amnis FlowSight®. Graphs include Relative Cell Growth (RCG) % of treated TK6 cells. A)  Induction of ɣH2AX and pH3 dual marker 
response to Carbendazim a known aneugen. The red line shows the 1.5 fold change and orange line shows the 0.7 fold change industry standards. B) MN fold 




The pH3 NOGEL was determined to be 0.6µg/mL with a statistically significant increase 
(p<0.05) from 0.8µg/mL. Phosphorylated H3 signal for 0.6µg/mL is considered positive, even 
though not statistically significant, via a >1.5 fold increase with respect to control values as 
per industry standard. The NOGEL for ɣH2AX is at 0.4 µg/mL with statistically significant 
decrease of ɣH2AX from 0.6 µg/mL to the top dose tested. A ɣH2AX positive fold decrease 
of <0.7was observed at the 0.6 µg/mL dose, however, was not sustained resulting in the 0.8 
µg/mL through to 1.6 µg/mL doses being considered as an equivocal decrease. The MN 
scored with mononucleated TK6 cells using the FlowSight® platform for Carbendazim, 
shows a dose dependant increase of MN events (See figure 4.3B) consistent with the dose 
dependant response generated by phosphorylated H3. 
4.4 – Optimal Results  
4.4.1 – Optimised Multiplex System: ɣH2AX, pH3, P53 MN and Cell Cycle Analysis 
In depth assessment of ɣH2AX, P53 & pH3 biomarkers in direct relation to each stage of the 
cell cycle of the chemicals MMS and Carbendazim. Due to the acquisition error of MMS and 
Carbendazim the data should be considered preliminary.   
4.4.1.1 – MMS: Optimal Staining Sub Optimal Laser Settings (Preliminary Response 
Data) 
Methyl Methane Sulfonate is a well defined genotoxic chemical, its Mode of Action 
falling under clastogenicity. The following results demonstrate the fold induction of the 
biomarkers ɣH2AX, P53 and pH3 compared to that of the DMSO vehicle control as well 
as cell cycle assessment relationships.  
Figure 4.4 shows a significant increase of ɣH2AX from the 1.25 µg/mL dose onwards 
compared to control which also rises above the industry fold change standard for a 
biologically relevant result. There is a significant increase at all MMS doses for P53 
response the response rising above the determined cut off from 1.2 µg/mL onwards. 
MN response also increases with dose and does so proportionally with ɣH2AX and P53 






ºVehicle control DMSO  
ªAquisition error n=2        
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 4.4: Combination graph showing the square root of raw fold change values of the 
biomarker responses for ɣH2AX, pH3, P53 and the Micronucleus (MN) genotoxic endpoint in 
response to MMS doses. RCG shows the % growth of cell cultures, RCG response decreases in a 
dose dependant manner. The dashed lines are the fold change cut offs for the biomarkers pH3, 
P53 and ɣH2AX. ɣH2AX response rises above the fold change cut off from 1.25 µg/mL onward 
and is also statistically significant the same doses. P53 increases with ɣH2AX in a dose 
dependant manner and is significant from 0.63 µg/mL onwards. MN gradually increases across 
all doses but only shows a significant response at 5.00 µg/mL. pH3 response initially increases 
but then from the peak at 0.63 µg/mL the response decreases until dropping below the fold 
change decrease cut off at 5.00 µg/mL. No doses for pH3 were significant. There was no dose 
that was not significant for all biomarkers. ɣH2AX NGEL was 0.63 µg/mL and MN NOGEL was 
2.50 µg/mL.   
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With the inclusion of the DNA staining, whilst this allows for MN assessment it also 
allows for cell cycle analysis. Figure 4.5 below demonstrates the percentage of cells 
found in each portion of the cell cycle. The figure shows that as MMS concentration 
increases the G1 population decreases and the G2 population increases whilst the 
synthesis stage decreases initially before increasing. This cell cycle response is 
consistent with the literature (Bryce et al., 2017). When looking at this data in 
combination with other factors additional patterns begin to emerge. Table 4.1 shows 




ºVehicle control DMSO 
ªAquisition error n=2        
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 4.5: Graph showing percentage of cells found in each portion of the cell cycle in relation to 
MMS concentration. Statistically significant decrease of cells in G1 phase compared to control was at 
1.25 µg/mL and onwards though all doses showed a trend decrease. S phase remained stable across 
all doses though there is a slight s phase decrease from control at 0.63 and 1.25 µg/mL.  G2/M cell 




As the system response occurs all within the same cell the platform allows additional 
relationship assessment passed that of overall dose response per biomarker. Tables 4.1a 
and 4.1b contain the fold responses for the assessment of each biomarker in relation to 
each stage of the cell cycle ±1 standard deviation is displayed, values that are 
highlighted green have shown a decrease in signal and values highlighted red a increase.  
Statistical significance is indicated with a Asterix.
132 
 
Table 4.1a: Fold change average of biomarkers ɣH2AX and P53 in direct relation to the phase of the cell cycle the cell population is in 
±1SD for MMS doses. 
 



















0.00 º 1.00 0.52 1.00 0.10 1.00 0.48 1.00 0.11 1.00 0.25 1.00 0.19 1.00 0.03 1.00 0.09 1.00 0.43 1.00 0.40 
0.63 1.29 0.23 1.16 0.08 1.27 0.25 1.64* 0.08 1.13 0.19 1.62* 0.28 0.98 0.06 1.05 0.20 1.42 0.43 0.96 0.40 
1.25 ª 2.10* 0.69 1.47* 0.33 2.03* 0.81 2.22* 0.24 1.67 0.71 2.20* 0.82 0.98 0.05 1.04 0.15 1.36 0.57 1.29 1.09 
2.5 ª 2.57* 0.82 1.81* 0.39 1.99* 0.74 2.83* 0.27 1.37 0.45 2.42* 0.82 1.03 0.02 0.87 0.13 1.61 0.78 1.45 0.94 
5.00 3.80* 1.78 2.49* 0.30 2.89 1.72 3.08* 0.91 1.29 0.58 2.24* 0.67 0.95 0.03 1.15 0.09 1.72 1.35 2.71 2.16 
ºVehicle control DMSO 
n=3    ªAcquisition error n=2       *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
Trend decrease        Trend Increase 
 
 
Table 4.1b: Fold change average of the ratio of Prophase, Metaphase and Anaphase cells populations when compared to control for 
MMS doses 
 
 Mitosis stage fold change ratio 
MMS 
(µg/mL) 
Prophase:Ananaphase+Metaphase Metaphase:Prophase Anaphase:Prophase 
0.00 º 1.00 1.00 1.00 
0.63 0.94 1.07 1.20 
1.25 ª 0.85 1.19 1.13 
2.5 ª 0.99 0.96 1.11 
5.00 0.85 1.20 1.08 
ºVehicle control DMSO 




The above data has been displayed as a set of scatter graphs for visual assessment of 




When comparing figure 4.4 displayed results of the individual biomarkers to cell cycle 
analysis of the biomarkers, increases in the biomarker response for both ɣH2AX and P53 
ºVehicle control DMSO        ªAcquisition error n=2        
 
Figure 4.6: Line scatter graph visually displaying data in table 4.1a illustrating relationship of each 
biomarker and cell cycle stage for MMS dose. The abnormal mitosis label refers to H3+ve H2AX-ve cell 
fluorescence. Primary Y axis shows the P53 response data. Secondary Y axis plots ɣH2AX and pH3 cell 
cycle signals and relationship the axis was log scaled. Statistical significance of each response can be 
found in table 4.1a.  
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is observed for all doses. The data trend does show that the ɣH2AX response is highest 
in G1 phase and lowest in G2 phase whilst P53 response is highest in S phase followed 
by G2/M phase. This corresponds to the increase of cells in anaphase implying a mitotic 
arrest of some description which is also confirmed by the increase of abnormal mitotic 
cells that are positive for pH3 but negative for ɣH2AX response. Whilst cell mitosis ratios 
as displayed in table 4.1b and figure 4.7 show a limited change in the overall cells in 





ºVehicle control DMSO      ªAquisition error n=2        
  
Figure 4.7: Line scatter graph displaying the ratio of average fold change responses for MMS 
concentrations (data in table 4.1b). Allowing assessment of proportional changes of the different phases of 
mitosis to one another. Primary Y axis shows the changes compared to vehicle control of the individual 
metaphase prophase change, and anaphase prophase change. Secondary Y axis plots the overall prophase 
response to anaphase and metaphase combined. No statistical analysis was performed, a qualitative trend 
only was looked at. There was a plateau trend of prophase population to the combined 




4.4.1.2 - Carbendazim: Optimal Staining Sub Optimal Laser Settings (Preliminary 
Response Data) 
Carbendazim response data for individual biomarkers, their fold change and statistical 
evaluation are shown in figure 4.8. Followed by cell cycle response in figure 4.9. The 
response for ɣH2AX is reasonably stable when compared to control, however, there 
does appear to be an equivocal fold change decrease of ɣH2AX response at 0.6 µg/mL 
and 0.8 µg/mL for Carbendazim perhaps even showing a slight decrease, this is to be 
expected as Carbendazim does not induce strand breakage. pH3 signal increases and 
rises above the pH3 fold cut off value from 0.6 µg/mL onwards and is statistically 
significant for P53 at the same doses. The highest fold change induction of MN occurred 





The cell cycle was also able to be assessed and displayed below in figure 4.9. The graph 
demonstrates that whilst the percentage of cells increases in G1 with dose S percentage 
decreases and G2/M phase remains reasonably stable when compared to the control 
cell cycle profile. G1 and G2/M responses are not statistically significant at any dose. S 
phase responses are significant at all Carbendazim doses.  
ºVehicle control DMSO 
 ªAquisition error n=2         *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 4.8: Combination graph showing the square root of raw fold change values of the biomarker 
responses for ɣH2AX, pH3, P53 and the Micronucleus (MN) genotoxic endpoint in response to 
Carbendazim doses. RCG shows the % growth decrease of cell cultures as Carbendazim concentrations 
increase. The dashed lines are the fold change cut offs for the biomarkers pH3, P53 and ɣH2AX. This 
highlights a equivocal response for ɣH2AX decrease at 0.60 and 0.80 µg/mL.  The doses that are 
statistically significant are indicated with Asterix. The only dose demonstrating NOGEL for all 
biomarkers is 0.40 µg/mL. The NOGEL for the MN response is at 0.80 µg/mL. 
137 
 
As with MMS having this cell cycle data directly related to biomarker response could 
prove beneficial in identifying additional trends that lend themselves towards classifying 
chemicals. The tables 4.2a and 4.2b show these additional end point metrics and 
statistically significant responses are indicated with a asterix. These tables were then 
plotted graphically see figure 4.10 and 4.11 below. 
 
 
ºVehicle control DMSO 
 ªAquisition error n=2         *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 4.9: Graph showing percentage of cells found in each portion of the cell cycle in relation to 
Carbendazim concentration. Statistically significant decrease of cells in S phase was seen from 0.4 
µg/mL onwards. Whilst not significant there was a trend increase of cells present in G1, the decrease 
toward vehicle control at 1.60 µg/mL is most likely due to increase in cell death as suggested by the 
RCG plot in figure 4.8. G2/M population remained relatively stable. Response was seen at doses 1.25 
µg/mL onwards for G1 and G2/M at all doses. No significant change for S at any dose was observed. 
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Table 4.2a: Fold change average of biomarkers ɣH2AX and P53 in direct relation to the phase of the cell cycle the cell population is in 
±1SD for Carbendazim doses 























0.00º 1.00 0.44 1.00 0.06 1.00 0.22 1.00 0.12 1.00 0.05 1.00 0.05 1.00 0.01 1.00 0.03 1.00 0.71 1.00 0.87 
0.40ª 1.17 0.37 2.62** 0.99 1.13 0.25 2.54 0.83 1.14 0.24 2.19 0.82 0.98 0.04 1.04 0.11 1.37 0.42 0.56 0.42 
0.60ª 0.92 0.51 4.15** 1.65 0.99 0.18 3.93 1.35 1.05 0.06 3.81* 1.50 0.97 0.02 1.10 0.07 0.97 0.20 1.01 0.61 
0.80ª 0.66 0.13 4.43** 1.14 0.89 0.12 4.18** 0.89 1.02 0.14 4.05* 1.16 0.95* 0.06 1.15* 0.19 1.06 0.04 2.52 2.00 
1.20ª 0.94 0.29 5.19** 0.52 1.32 0.39 5.23** 0.52 1.21 0.17 5.26** 0.81 0.92* 0.04 1.23* 0.12 1.25 0.22 2.30 1.43 
1.60 1.15 0.20 5.89** 0.13 1.55 0.15 6.04** 0.56 1.32 0.18 6.02** 0.09 0.91* 0.04 1.26* 0.12 1.17 0.09 2.51 1.68 
ºVehicle control DMSO 
n=3           ªAquisition error n=2         *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
Trend decrease        Trend Increase 
 
 Mitosis stage fold change ratio 
Crbz 
(µg/mL) 
Prophase:(Ananaphase+Metaphase) Metaphase:Prophase Anaphase:Prophase 
0.00º 1.00 1.00 1.00 
0.40ª 0.93 1.06 1.63 
0.60ª 0.89 1.14 1.18 
0.80ª 0.88 1.24 1.31 
1.20ª 0.75 1.36 1.53 
1.60 0.73 1.39 1.46 
ºVehicle control DMSO 




The ɣH2AX response especially in G1 population decreases and at 0.80µg/mL passed the 
0.8 fold change cut off. From 0.80 µg/mL dose onwards levels of ɣH2AX in G1, S and G2 
started to increase. The P53 response in relation to the cell cycle is interesting, here P53 
at all doses in each of the stages of the cell cycle increase over that of control, all 
responses being greater than the 1.2 fold change cut off and being significant from 0.40 
µg/mL in G1, 0.08 µg/mL in S and 0.06 µg/mL at G2/M. P53 G1 levels are slightly higher 
than the S and the G2M phases until 1.6 µg/mL where the signal starts to drop below 
the S and G2M response. From 0.8 µg/mL to the top dose both anaphase and 
metaphase increases being a greater than the 1.2 fold change cut off. When assessing 
ºVehicle control DMSO 
 ªAquisition error n=2          
 
Figure 4.10: Line scatter graph visually displaying data in table 4.2a illustrating relationship of each 
biomarker and cell cycle stage for Carbendazim doses. Primary Y axis shows the P53 response data. 
Secondary Y axis plots ɣH2AX and pH3 cell cycle signals and relationship on a logged scale. Statistical 
significance of each response can be found in table 4.2a.  
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The ratio of prophase to metaphase and anaphase population decreases as crbz dose 
increases this is mirrored by a corresponding increase in the anaphase to prophase.  
 
ºVehicle control DMSO 
 ªAquisition error n=2          
 
Figure 4.11: Line scatter graph displaying the ratio of average fold change responses for Carbendazim 
concentrations (data in table 4.2b). Allowing assessment of proportional changes of the different phases of 
mitosis to one another. Primary Y axis shows the changes compared to vehicle control of the individual 
metaphase prophase change, and anaphase prophase change. Secondary Y axis plots the overall prophase 
response to anaphase and metaphase combined. No statistical analysis was performed, a qualitative trend 
only was looked at. There was an overall trend decrease of prophase population to the combined 
anaphase/metaphase population whilst there was a simultaneous increase of metaphase to prophase and 
anaphase to prophase cell populations. These occurred in a dose dependant manner. 
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4.5 – Discussion  
4.5.1 – Preliminary Data Set: Dual Biomarker and MN Assessment 
This preliminary data comparing response of the biomarkers ɣH2AX and pH3 for MoA 
assessment against separately stained DRAQ5™ cells for MN assessment allows for a initial 
proof of principle assessment. From the data increases in micronucleus dose responses can 
be observed, alongside their corresponding respective responses with the MoA markers 
ɣH2AX and pH3. The data appears to demonstrate the typical responses indicative of MMS 
acting via a clastogenic MoA and Carbendazim acting through an aneugenic MoA.  
For MMS there was a dose dependent increase of ɣH2AX and MN at the same doses where 
pH3 signal decreasing. The relevant increase in ɣH2AX reflects an increase of cells with DNA 
strand breaks, at the same concentration as MN, along with there being a decrease of cells 
in mitosis as demonstrated by the reduction in pH3 signal. From the results generated, 
MMS appears to cause MN through chromosome breaks, and this is displayed without the 
need for kinetochore labelling. By contrast the aneugen Carbendazim had the reverse 
ɣH2AX, pH3 profile at the same concentrations as an increase in MN. The decrease in strand 
breaks observed, could be linked with mitotic arrest, and the increase in pH3 is in line with 
the response of known aneugens, particularly when happening at the same concentrations 
as the increase in MN. This suggests that MN are generated through aneuploidy dominant 
mechanism.  
Use of this dual staining approach on the Amnis® Imaging flow cytometry platform allows 
for specific image analysis of individual cells, combining the assessment of signal intensity 
(both ɣH2AX and pH3) per cell and cellular morphology offers additional Mode of Action 
information alongside the MN assay.  
ɣH2AX and pH3 use on the flow cytometry platform have become increasingly popular and 
the combination of ɣH2AX and pH3 signal results on the Amnis FlowSight® has proven 
consistent with current literature (Bryce et al, 2016; Khoury et al, 2016). Combined use of 
ɣH2AX and pH3 signal in a single sample provides a reduction in experimental variability 
when compared to separate sample analysis. This process also reduces time of sample 
preparation, number of samples needing to be assessed and amount of compound required 
for analysis. 
4.5.2 – Optimal Staining Preliminary Data Set 
The biomarker response for MMS is consistent with the expected biology as P53 is a DNA 
damage marker and its increase in line with ɣH2AX increase shows a double check system 
that confirms the DNA damage response alongside MN induction. Whilst there is an initial 
increase of pH3 response, above the fold change cut off, at 0.63µg/mL compared to control 
and the 1.25µg/mL dose is still higher than vehicle control, the pH3 biomarker shows a 
decreasing trend as the MMS dose increases from 0.63µg/mL. Whilst there is no statistically 
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significant increase or decrease when compared to that of control, the initial increases of 
pH3 does rise above the fold change cut off at 0.63 µg/mL and 1.25 µg/mL and then at 5.0 
µg/mL does fall below the 0.8 cut off value. This could suggest that MMS at lower doses 
may have a dual MoA. Similar observations have been made in the literature (Bryce et al., 
2017; Krishner et al., 1992). The large standard deviation bars for the MN response is to be 
expected due to the variability of MN automated counting as explained in section 3.3.3.3 
The accuracy rate of the system is only 57% with a miss rate of around 45%, for chemicals 
that induce the smaller MN such as MMS due to the largely clastogenic nature of the 
chemicals MoA the system simply isn’t sensitive enough to identify these smaller events 
especially in the Mono MN assay where the nucleus takes up more of the cell cytoplasm 
offering more places for the MN to ‘hide’ behind the nucleus or blend with it depending on 
cell orientation when passing by the camera. Assessment of the cell cycle alongside the 
biomarker responses demonstrates a cascade type of event i.e., a increase of ɣH2AX in G1 
leads to an upregulation of P53 resulting in a increase of DNA damage response pathway 
leading to DSB being fixed during S phase. As a result, ɣH2AX response decreases during S 
phase resulting in the loss of statistically significant responses at G2. A limited decrease of 
P53 at G2M demonstrates DNA damage is still present after S phase.  
Delving further into the cell cycle relationship of fold increases in each stage of the cell 
cycle, with the highest P53 response being in the S phase followed closely by G2M phase 
and the highest response being in G1 for ɣH2AX. These responses for ɣH2AX are to be 
expected as it is a transient DNA damage repair signal, this means when the cell cycle 
passes through its check points more damaged is detected by the cell and so there is a 
corresponding increase of ɣH2AX signal as the cell recruits damage repair proteins. Whilst 
overall there wasn’t really a change in pH3 levels there was an increase of anaphase cells 
and when assessing pH3 response for each prophase, anaphase and metaphase there was a 
ratio decrease of cells in prophase when compared to the combined metaphase and 
anaphase population and a ratio increase of anaphase cells. The metaphase ratio did not 
change. 
The chemical Carbendazim works through a aneugenic MoA via microtubule destabilisation 
(Hummelen et al., 1995). A statistically significant response for pH3 induction was found at 
all doses with the exception of 0.40 µg/mL an indication of aneugenicity (Muehlbauer & 
Schuler, 2005) The strongest P53 response is in line with the MN response increase, and 
whilst this is the same for MMS the fold change P53 for MMS did not exceed 3 fold 
induction. This is to be expected as loss of chromosomes is a more damaging effect on the 
cell than strand breakages. The higher MN response picked out by the system could also be 
as a result of the aneugenic MoA, as the MN present in the cell will be of the larger variety 
therefore stained easier and less able to hide behind the nucleus as is probably the case 
with MMS above. The MN response is again proportional to the DNA damage P53 signal 
response and the increase of cells arresting in mitosis. Whilst there is a increase of cells with 
pH3 you would expect a corresponding increase of G2M cell population rather than G1. 
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However, all this means is that whilst the percentage population in G2/M has not changed a 
greater proportion of those cells have arrested in mitosis therefore leading to the increase 
in pH3 signal. These cells once they eventually pass into G1 a higher proportion will be 
abnormal resulting in cells that cannot pass the G1, S check point. This therefore explains 
the decrease in S phase population, as cells are halting at G1 but healthy synthesised cells 
continue on into G2/M. The increase of ɣH2AX at the different phases of the cell cycle at the 
higher dose concentrations is most likely due to apoptotic pathway induction which results 
in the global phosphorylation of ɣH2AX (Moeglin et al., 2019; de Feraudy et al., 2010). 
The P53 cell cycle signal response is line with the cell cycle assessment graph and suggests 
the most active phase for DNA damage and cell cycle control is actually S phase relative to 
G1 and G2M when you compare the small cell population.  As explained above the lack of 
ɣH2AX presence in abnormal mitotic pH3 positively stained cells could be a indicator of 
clastogenicity vs aneugenisity and as the graph displays there is a large fold change in the 
abnormal mitotic (ɣH2AX -ve H3+ve) response from 0.6 µg/mL onwards. This combined with 
the individual assessment of prophase, metaphase and anaphase and the ratio responses to 
one another based on the pH3 response implies the cell cycle is stalling specifically at 
metaphase/anaphase stages of mitosis, as Carbendazim is suspected to affect spindle 
stability this affect is reasonable to assume. This proportion trend and over all cell cycle 
biomarker responses is consistent/similar with another aneugenic spindle poison assessed, 
Vinblastine (See section 5 below). 
There is a overall trend increase of P53 for both the Carbendazim and MMS data set along 
with a mirrored response of MN induction. The increase of biomarker the biomarker signals 
pH3 and ɣH2AX respectively for Carbendazim and MMS, are indicative of aneugenic and 
clastogenic MoA’s. These responses are consistent with that found in the literature (Bryce 
et al., 2007, Audbert et al., 2010) 
 
4.5.3 – Disparity Between FlowSight® and ImageStream X Mark II® 
The above data of the 3 marker and MN genotoxic endpoint combined system shows a 
trend that consistent with the preliminary development stage data response in section 4.3 
above. However, there are some discrepancies for instance the pH3 response in the multi-
marker system does not give as definitive a trend decrease from control level for MMS and 
as large a increase for Carbendazim. This could be due to a few reasons; 1) As the data was 
collected at different magnifications on separate machines the plane of focus for spectrum 






This limitation of the imaging flow system explains why at a lower magnification the pixels 
available have a higher overall fluorescence intensity causing some saturation even at lower 
laser powers and optimal staining compared to the higher power settings at the x40 
magnification. This means some of the lower intensity pH3 stained cells in the control 
samples may have been missed by the higher magnification system. Due to this lower end 
of the population being missed the overall proportional change of the pH3 signal could have 
been affected.  
Whilst there are some discrepancies between the data collected on the FlowSight® and 
ImageStream X Mark II® the overall trend that ɣH2AX increases for MMS and pH3 increases 
for Carbendazim whilst the alternate marker plateaus/ does the opposite remains. 
Furthermore, the data is in line with expected clastogenic aneugenic MoA already reported 












Movement in and 





Cone of detection 
Figure 4.12: Demonstrates the variation in spectrum detection between X20 FlowSight® machine and X40 ISXII. 
A) Shows that at lower magnification the detector has a greater field of view to both collect more of the 
spectrum emitted by the fluorophore and has more tolerance for object movement in the focal plane. B) At a 
higher magnification the cone of detection becomes narrower this means the system has a lower tolerance for 
movement out of the central plane of focus and less of the available excitation spectrum is detected. 
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2010). This also demonstrates that a multiplex system that assesses the biomarker P53 
ɣH2AX, pH3 and MN can be achieved simultaneously in the same cell sample without lysing 
the cells meaning spatial location information is maintained and can be used for further in 
depth data analysis and mining.  
Despite suboptimal laser excitation of the biomarker’s identification of MMS as a clastogen 
and Carbendazim as a aneugen was possible at the 24hr time point. Furthermore, additional 
cell cycle relationship information was obtained suggesting most likely location of cell cycle 
arrests and what biomarkers are most prevalent when. Whilst this type of data individually 
is not necessarily new, assessment in single sample of whole unlysed cells allowing for 
direct relationship analysis in a high content fashion using the imaging cytometer platform 
is. This along with the flexibility of including additional mechanistic markers, shows that this 
















Chapter 5 – Results 3: ImageStream Micronucleus Expansion (ISMN-me) 
assay: Optimal Staining and Laser Acquisition For The Chemicals ARA-C, 
Vinblastine, Etoposide and Crizotinib.  
5.1 - Introduction 
As established in section 4.1, the use of ɣH2AX, pH3, P53 and DRAQ5™ in a multiplexing system 
in TK6 cells is possible and the responses in the model chemicals MMS and Carbendazim are 
consistent with that in the literature. Figure 5.1 shows the type of images acquired using the 
multiplex platform that available for analysis.  
Figure 5.1: Images obtained at x40 magnification on Amnis ImageStream X mark II® demonstrating the combined 
platform. This allows the assessment of ɣH2AX, pH3, P53 and MN generation simultaneously. Rows 1,2 and 4 show 
vehicle control biomarker examples. Row 2 shows P53 activation in potentially in response to cell cycle control. 
Row 4 shows a healthy biomarker response in metaphase. Row 3 demonstrates a typical ɣH2AX response in 




Assessment of additional chemicals of known classification, mode and mechanism of action is 
required to further assess this multiplexing platform ability to identify chemicals of varying 
MoA. 
Whilst genotoxic chemicals can be broadly divided into Clastogens and Aneugens as the 
predominant MoA, the underlying mechanisms are often varied. Taken from the list of ECVAM 
recommended chemicals for assessment of new in vitro genetic toxicology assays, Kirkland et 
al. 2016, the additional chemicals assessed under 24 hour exposure at varying concentrations 
were, the Aneugens: Crizotinib, which is a tyrosine kinase inhibitor and Vinblastine which binds 
to tubulin inhibiting microtubule formation (Sahu et al., 2013; Kong et al., 2018; Alder et al., 
1991. The Clastogens: Etoposide is a topoisomerase II inhibitor and Cytosine Arabinoside (ARA-
C) which is a nucleoside analogue that inhibits DNA synthesis (Kirkland et al., 2008; Fenech et 
al., 1994). These chemicals were selected as alternate platforms have assessed them using the 
biomarkers ɣH2AX, pH3, P53 either individually or in some form of combination (Dertinger et 
al., 2019; Watters et al, 2009; Cheung et al, 2015; Khoury et al, 2016). Further to this, as each 
chemical has a different MoA and underlying mechanism the platforms ability to correctly 
identify MoA and potential variations in biomarker responses can be investigated.  
This ImageStream MN multiplex expansion assay, termed ISMN-me assay, initially assesses the 
traditional response of these DNA damage markers in fold change using both gating and 
microscopy strategies. Through immunohistological staining with antibodies the following are 
identified; pH3 providing metaphase cell frequency as a aneugenic flag (Muehlbauer & Schuler, 
2005), ɣH2AX identifying clastogenicity based on fluorescence shift within nuclei (Smart et al., 
2011) and P53 stabilisation as a signal for DNA damage induction (Sun et al., 2013; Bernacki et 
al., 2016). Counterstaining the DNA with DRAQ5™ allows for the identification of the MN 
genotoxic endpoint and cell cycle assessment based on the change of cell population 
percentage in G1, S and G2/M relative to vehicle control (Fenech et al., 2011; Parry & Parry 
2006; Avlasevich et al., 2011).  
This chapter focuses on the ability of ISMN-me to identify dose responses of the DNA damage 
biomarkers ɣH2AX, pH3, P53 and MN endpoint in fixed permeabilised P53 proficient TK6 cells 
using ImageStream X Mark II® leading to MoA identification. Given the intact nature of the cells, 
maintaining the integrity of the cytoplasmic membrane, the platform also investigates cell cycle 
response relationships for each of the biomarkers, identification of mitotically abnormal cells, 
as well as biomarker presence within MN. Thus, providing scope for identification of underlying 






5.2 – Materials & Methods 
5.2.1 - Test Article Formulation 
Master stock solutions for each chemical were made fresh on the day of the experiment. 
DMSO (Cas. No. 67-68-5) was the solvent used to generate the dose concentrations and was 
therefore used as vehicle control. In instances where the chemical would not go into 
solution gentle warming and vortexing was used.  
Methyl Methanesulphonate (MMS), Cas no.: 66-27-3, Carbendazim, Cas no.: 10605-21-7, 
Crizotinib (Crztb) Cas no.: 877399-52-5, Etoposide (Etop) Cas no.: 33419-42-0, Cytosine β-
Darabinofuranoside (ARA-C) Cas no.: 147-94-4 and Vinblastine (Vbstn) Cas no.: 143-67-9 all 
supplied from Sigma-Aldrich.  
Working concentrations for the remaining chemicals were: Crizotinib, 0.00, 0.57, 1.31, 2.25, 
4.51 (µg/ml); Etoposide 0.00, 0.01, 0.03, 0.06, 0.13 (µg/ml); ARA-C 0.00, 0.01, 0.03, 0.05, 
0.21, 0.41 (µg/ml); Vinblastine, 0.0000, 0.0002, 0.0006, 0.0008, 0.0010, 0.0020 (µg/ml).  
To confirm test validity positive controls of MMS and Crbz were used as confirmation of 
true system activity and response for P53, ɣH2AX and pH3 was ran alongside each of the 
test article experimental repeats. MMS positive control doses were 2.50 or 5.00 (µg/ml) and 
Carbendazim positive control doses were 1.20 or 1.60 (µg/ml). Whilst this data was not 
shown a statistically significant response was obtained when compared to vehicle control 
relevant to the MoA. 
5.2.2 - Cell Culture and Growth Media  
Refer to general methods section 2.2.2.  
5.2.3 - Treatment Of Cell Cultures  
TK6 cells were cultured at 2x105 cells/mL and treated with Crztb, Etop, ARA-C or Vbstn for 
1.5-2 cell cycles alongside concurrent positive controls. All incubation steps occurred at 
37˚C, 5% (v/v) CO2± 0.5% in air. Please refer to section 2.2.2.1 for further detail.  
5.2.4 – ISMN-me Antibody and DNA staining 
Antibody master mix was prepared fresh on the day of experiment, 300ul of the antibody 
master mix was added to each sample and protected from light. After the initial incubation 
period 100ul of DRAQ5™ was added to each sample for continued incubation. Full details of 
the staining procedure please see section 2.2.3 of general methods.  
5.2.5 – ISMN-me Cell Processing 
After the treatment period, cultures were washed then fixed and permeabilised by FACS 
Lyse. Post fixation samples stained and incubated under agitation whilst protected from 
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light. Please see section 2.2.3 for full fixation and staining procedures with focus on route B 
of figure 10 highlighting the optimal workflow.  
At the end of the incubation period  cells were then transferred to appropriately labelled 
Eppendorf’s and shipped on ice via DHL to: Newcastle Flow Cytometry Core Facility (FCCF), 
William Leech Building (2nd floor Room M2.099), Newcastle University, NE1 7RU, for 
subsequently acquisition on the ImageStream X Mark II® imaging platform.  
5.2.5.1 - ImageStream Flow Cytometry: ImageStream X Mark II® 
Samples were analysed on a Amnis® ImageStream X Mark II® imaging flow cytometer 
using Amnis® INSPIRE™ software version 6.2 (Merck Millipore, Nottingham UK). Prior to 
experimental analysis, following the manufacturers instructions for appropriate 
ImageStream X Mark II® set up and quality control procedures, all system calibrations 
performed and passed using Amnis® ImageStream SpeedBead calibration reagents (Cat. 
No. 400041). 100µL aliquots of cell suspension at a concentration of ~7x105 and no less 
than ~4x105 cells/mL were prepared in 1.5mL Eppendorf’s for shipment upon arrival at 
the FCCF facility samples were transferred to a 96 well plate and loaded on the sample 
port. All samples were excited using 405nm, 488nm 642nm lasers at 120mw, 90mw, 
80mw respectively. Laser 785nm was used for side scatter at laser power 5mw. 
INSPIRE® instrument software acquired cell data  at a low velocity 66.0(mm/sec), 
resulting in 15,000 – 30,000 single cellular events being collected in approximately 45 
seconds, and subsequently automatically saved for each experimental replicate. 
Acquisition of images for pH3, P53, ɣH2AX and DRAQ5™ assessment occurred in: 
Channel 2, 3, 7 and 11 fluorescence respectively; Channel 1, bright field; Channel 6 side 
scatter. Whilst these channels were of main interest data was acquired for all 12 
channels. Additional detail on INSPIRE® template set up and image acquisition, including laser 
balancing can be found in section 2.2.4.2.2 and 2.2.4.2.3.  
Once data has been collected for all samples, the acquired raw image files (.RIF ) data 
files were analysed using IDEAS® v 6.2 software, compensation matrix and template 
applied and subsequent, .CIF (compensated image files) and .DAF (Data Analysis Files) 
were generated.  
5.2.5.2 - INSPIRE™ Compensation File Acquisition 
Compensation sample files were acquired using the INSPIRE® acquisition compensation 
wizard or manually using Compensation beads.  Acquisition of correct compensation 
samples was performed without the presence of brightfield or side scatter. Lasers 
488nm 405nm and 642nm were utilised at the same intensity value as used during the 
experimental setup. Acquired files formed compensation matrices in AMNIS IDEAS® 6.2 




5.2.5.3 - Amnis IDEAS® v 6.2 Template 
Data analysis was conducted using Amnis IDEAS® software version 6.2 (Merck Millipore, 
Nottingham, UK). Prior to signal assessment RIF files were converted to compensated 
image files (CIF) and data analysis files (DAF).  
Of the initial RAW cell population collected using brightfield and nuclear parameters 
single in focus healthy cell population was determined as laid out in section 3 DNA 
content was then plotted on a histogram, and cells with nuclear intensity greater than 
1X105 was the final population used for MN, ɣH2AX, P53 and pH3 assessment.  
Using the brightfield channel and DRAQ5™ DNA stain for the assessment of 
mononucleated MN cells, the cell population was determined my using nuclear mask 3 
to distinguish mononucleated cells from cells with multiple nuclei using the spot count 
feature. This mononucleated population of cells was then used to generate MN data. 
The designed mask termed Complete final micronucleus mask in combination with spot 
count feature was used to automatically score the MN response (See section 3.3.3.3 for 
in depth description nuclear and MN masking criteria).  The automated MN scoring 
within the mononucleated cells was carried out by attempting to include the criteria 
designed for slide based scoring (Fenech et al., 2003) in the MN mask. Therefore, the 
MN that were DRAQ5™ positively labelled were accepted for scoring were, circular/oval, 
1/3-1/16 the size of the main nuclei and resided within the cytoplasmic boundary. A 
minimum of 5000 mononucleated cells were assessed per dose, per replicate to obtain 
the MN dose response. 
For the assessment of BV421, ɣH2AX, AF 488 pH3and PE P53 fluorescence signal 
positivity was determined through pixel intensity via stained vs unstained populations 
assessment, signal separation on scatter graphs and specific signal masking based on 
nuclear/cytoplasmic localization. Gates were then applied to scatter graphs to extract 
positively stained cell populations for each of the three biomarkers (see section 3 for 
boundary cut-offs and mask development). To assess the specific biomarker response 
per stage of the cell cycle the same gate cut offs were used as the overall population 
assessment of each of the biomarkers but the populations used were taken from the cell 
cycle gates placed on the DNA content graph. Once these parameters were established 
the CIF files were batch processed via the use of an IDEAS® template, generation 
described in section 3 results.  
5.2.5.4 - MN Containing Biomarker Signal 
Whilst not assessed automatically using the optimised IDEAS® template of the true MN 
population (confirmed manually) a brief look into presence of either P53 and or ɣH2AX 
signal is present in distinct MN. This was performed by assessing the P53, ɣH2AX and 
DRAQ5™ DNA stain channels along with composite overlay of signal images and 
brightfield. The criteria here was simple, visually do the MN have: DRAQ5 and ɣH2AX 
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signal; DRAQ5™ and P53; DRAQ5™ with both P53 and ɣH2AX; DRAQ5™ only. This was 
performed as preliminary assessment as to whether the high content nature combined 
with imagery allows for assessment of rare cellular events providing additional MoA 
information.  
5.2.5.5 – Data Assessment 
Positive response criteria of fold change values and statistical analysis were as described 
in 2.2.6 data assessment section of general methods.  
 
5.3 – Results: ISMN-me Assay Chemical Assessment  
 5.3.1 - Etoposide 
Etoposide inhibits topoisomerase II and primarily impacts the S and G2 phases of the cell 
cycle. Ligation of cleaved DNA is inhibited and therefore there is an increase of single and 
double strand breakage. Figure 5.2 displays the biomarker response and RCG data for 
Etoposide.   
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There is an increase in ɣH2AX response but the induction does not exceed the 1.2 fold 
change cut off nor is it statistically significant The NOGEL for P53 was at 0.01 µg/mL with 
statistical significance and exceeding of the fold change cut off occurring from 0.03 
onwards. There is a corresponding increase of MN response, the MN NOGEL being 0.03 
µg/mL and being significant from 0.06µg/mL, this is consistent with the expected DNA 
damage response. There is a steady decrease of pH3 response but statistical significance 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.2: Combination graph showing the square root of raw fold change values of the biomarker 
responses for ɣH2AX, pH3, P53 and the Micronucleus (MN) genotoxic endpoint in response to 
Etoposide doses. RCG shows the % growth decrease of cell cultures as Etoposide concentrations 
increase. The dashed lines are the fold change cut offs for the biomarkers pH3, P53 and ɣH2AX. This 
highlights the relatively stable pH3 and ɣH2AX response though there is a slight trend decrease and 
increase respectively. ɣH2AX does not on average exceed the fold change cut off and no responses are 
significant. pH3 shows a statistically significant decrease at 0.24µg/mL and falls below the fold change 
cut off. The doses that are statistically significant are indicated with a Asterix. The only dose 




and dropping below the 0.8 fold change cut off only occurs at the top Etoposide does, 
0.24µg/mL.  
The cell cycle response data for 24 hour Etoposide exposure is displayed in figure 5.3 below. 
There is a slight decrease of cells in G1 and S from 0.03 onwards and this is proportional to a 
G2/M increase. All phases of the cell cycle show a statistically significant response at the 
highest concentration of Etoposide, G1 and S decreasing where G2/M increases relative to 
control.  The decrease in S phase population percentage relative to control is statistically 
significant from 0.13µg/mL. Table 5.1a and 5.1b show the additional biomarker metrics of 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.3: Graph showing percentage of cells found in each portion of the cell cycle in relation to 
Etoposide concentration. Statistically significant decrease of cells in S phase was seen at 0.13 and 0.24 
µg/mL over all S phase showing a decreasing trend in relation to dose. A decrease in G1 was observed 
with significance at 0.24 µg/mL. A steady increase in G2/M population occurred with dose significance 
occurring at 0.24 µg/mL. 
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Etoposide response in relation to the cell cycle, this data is also displayed graphically in 
figures 5.4 and 5.5 respectively.  
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Table 5.1a: Fold change average of biomarkers ɣH2AX and P53 in direct relation to the phase of the cell cycle the cell population is in 
±1SD for Etoposide 























0.00 º 1.00 0.08 1.00 0.09 1.00 0.19 1.00 0.21 1.00 0.17 1.00 0.13 1.00 0.04 1.00 0.25 1.00 0.23 1.00 0.00 
0.01 1.05 0.21 1.12 0.08 0.97 0.16 1.05 0.15 0.95 0.08 1.19 0.05 0.98 0.01 1.12 0.17 1.28 0.54 1.05 0.08 
0.03 1.24 0.18 1.44 0.10 1.22 0.28 1.34 0.17 1.07 0.20 1.48* 0.11 1.00 0.01 1.01 0.07 0.99 0.24 1.00 0.00 
0.06 1.18 0.10 1.76* 0.08 1.21 0.18 1.73 0.24 1.04 0.13 1.93** 0.13 0.97 0.01 1.21 0.22 1.28 0.70 1.04 0.07 
0.13 1.29 0.05 2.20** 0.10 1.25 0.17 2.03* 0.41 0.95 0.06 2.53** 0.19 0.98 0.02 1.14 0.20 1.16 0.18 1.06 0.10 
0.24 1.03 0.10 2.19** 0.26 1.26 0.18 2.66** 0.12 0.93 0.07 2.95** 0.27 0.97 0.02 1.19 0.22 1.27 0.39 1.06 0.11 
ºVehicle control DMSO 
n=3           *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
Trend decrease        Trend Increase 
 
 Mitosis stage fold change ratio 
Etop 
(µg/mL) 
Prophase:Ananaphase+Metaphase Metaphase:Prophase Anaphase:Prophase 
0.00 º 1.00 1.00 1.00 
0.01 0.85 1.08 1.27 
0.03 0.99 0.98 1.06 
0.06 0.78 1.18 1.16 
0.13 0.83 1.09 1.13 
0.24 0.79 1.15 1.21 
ºVehicle control DMSO 










ºVehicle control DMSO 
 
Figure 5.4: Line scatter graph visually displaying data in table 5a illustrating relationship of each 
biomarker and cell cycle stage for Etoposide. Primary Y axis shows the P53 response data. Secondary 
Y axis plots ɣH2AX and pH3 cell cycle signals and relationship.  Statistical significance of each response 




Whilst overall levels of ɣH2AX only increase slightly not reaching fold cut off, or presenting 
significance there are cell cycle response differences, G1 and S phase ɣH2AX signal both 
increase from 0.03 to 0.13 µg/mL at which point the G1 ɣH2AX then decreases. At 0.24 
µg/mL the S phase ɣH2AX increases relative to the decrease of the S phase cell cycle 
population. The ratios of prophase metaphase and anaphase remain relatively stable 
compared to control. There is a slight increase of metaphase and anaphase cells but 
prophase cells remain at a control level. The pH3 positive ɣH2AX negative cells i.e., 
abnormal mitotic there is no change. The greatest P53 response is at G2/M which is 
consistent with cell cycle response and suggested G2 effect on the cell cycle, G1 and S phase 
ºVehicle control DMSO 
  
Figure 5.5: Line scatter graph displaying the ratio of average fold change responses (data in table 5.1b) for 
Etoposide concentrations. Allowing assessment of proportional changes of the different phases of mitosis 
to one another.  Primary Y axis shows the changes compared to vehicle control of the individual 
metaphase prophase change, and anaphase prophase change. Secondary Y axis plots the overall prophase 
response to anaphase and metaphase combined. No statistical analysis was performed, a qualitative trend 
only was looked at. There was a very slight trend decrease of prophase population to the combined 
anaphase/metaphase population whilst there was a equivalently gentle increase of metaphase to 
prophase and anaphase to prophase cell populations. These occurred in a dose dependant manner. 
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P53 levels rise at a consistent rate and are similar in response. However, until 0.24 µg/mL 
P53 is slightly higher in G1 than S.  
Table 5.2 shows MN that were found to have detectible biomarker fluorescence within 
them. 
Table 5.2: Etoposide 0.24µg/mL - Biomarker presence or absence in true MN microscope 
images obtained on ISXII  
Stain present in MN Total count % MN Cells 
DRAQ5™ only  90 80.4 
DRAQ5™ and P53 1 0.9 
DRAQ5™ and ɣH2AX 18 16.1 
DRAQ5™  P53 and ɣH2AX 3 2.7 
n=1, 112 true MN  
Table 5.2 looked at a total of 112 true MN events and shows presence of biomarker signal 
within the MN. 80% of detectible MN had no additional biomarker presence. Even though 
the overall ɣH2AX signal is not as impactful as would be expected proportionally there are 
more MN with ɣH2AX signal than P53. To assess the statistical significance of this additional 
data analysis would be required on the other Etoposide replicates and doses. 
5.3.2 - Crizotinib 
Crizotnib is a tyrosene kinase inhibitor and more specifically Anaplastic Lymphoma Kinase 
(ALK) inhibitor. ALK is a major contributor to the DNA damage repair pathway in cells and 
therefore has a downstream effect on many important regulatory proteins (Gandhi & 
Janne., 2012). Crizotinib mainly affects P53 response which is demonstrated in figure 5.6 
showing that from 2.25 µg/mL the P53 fold change not only rises above the fold change cut 
off but is also statistically significant. MN response also increases above control levels 
starting at 2.25 µg/mL which is the same point at which P53 levels pass the fold change cut 
off. Along with ɣH2AX, pH3 stays at control levels however at the top dose the pH3 
response does begin to increase.    
159 
 
Figure 5.7 displays the cell cycle data of cell cycle stage population percentages. At the 
lower doses of Crizotinib incubation the cell population percentages are relatively similar. 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.6: Combination graph showing the square root of raw fold change values of the biomarker 
responses for ɣH2AX, pH3, P53 and the Micronucleus (MN) genotoxic endpoint in response to Crizotinib 
doses. RCG shows the % growth of cell cultures, RCG response stays relatively stable until the top two 
responses where it drops off. This suggests a more finite dose range between 2.25 and 4.51 µg/mL is 
required. The dashed lines are the fold change cut off’s for the biomarkers pH3, P53 and ɣH2AX. This 
highlights the relatively stable pH3 and ɣH2AX response, pH3 begins to increase ate 2.25 µg/mL and 
though not significant the pH3 signal passes the pH3 fold change threshold at 4.51 µg/mL. ɣH2AX does 
not on average exceed the fold change cut off and no responses are significant. P53 and MN NOGEL is 
at 1.31 and 2.25 µg/mL respectively. The doses that are statistically significant are indicated with a 
astrix. The only dose demonstrating NOGEL for all biomarkers is 1.31 µg/mL.  
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There is a increase of the G1 population that reaches statistical significance at 2.25 µg/mL 
and a significant decrease in S phase at the same dose. At the top dose there is a significant 
decrease of G1 and S phase population and increase of G2/M population relative to control.   
 
Tables 5.3a and 5.3b look into the cell cycle relationship of the biomarkers. Data displayed 
in these tables include significance and ±1SD. These data were then plotted on scatter 
graphs for visual assessment, figures 5.8 and 5.9. 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.7: Graph showing percentage of cells found in each portion of the cell cycle in relation to 
Etoposide concentration. Statistically significant decrease of cells in S phase was seen at 2.25 and 4.51 
µg/mL over all S phase showing a decreasing trend in relation to dose. A statistically significant 
increase in G1 was seen at 2.25 followed be a statistically significant decrease at 4.51 µg/mL decrease 
in G1 was observed with significance at 0.24 µg/mL. The reverse is true for G2/M demonstrating a 
trend to decrease but there being a significant increase at the top dose.  
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Table 5.3a: Fold change average of biomarkers ɣH2AX and P53 in direct relation to the phase of the cell cycle the cell population is in 
±1SD for Crizotinib 
 
Table 5.3b: Fold change average of the ratio of Prophase, Metaphase and Anaphase cells populations when compared to control for 
Crizotinib  
 Mitosis stage fold change ratio 
Crztib 
(µg/mL) 
Prophase:Ananaphase+Metaphase Metaphase:Prophase Anaphase:Prophase 
0.00 º 1.00 1.00 1.00 
0.57 1.07 1.04 0.84 
1.31 0.89 1.17 1.07 
2.25 1.00 1.10 0.93 
4.51 1.12 1.02 0.69 
ºVehicle control DMSO 
n=3           ªAquisition error n=2         Trend decrease        Trend Increase 
 
 



















0.00 º 1.00 0.08 1.00 0.17 1.00 0.05 1.00 0.25 1.00 0.09 1.00 0.35 1.00 0.02 1.00 0.14 1.00 0.35 1.00 0.00 
0.57 1.21 0.28 0.94 0.16 1.09 0.24 0.97 0.08 1.04 0.18 1.10 0.33 1.00 0.05 1.00 0.26 0.67 0.67 1.11 0.09 
1.31 1.25 0.16 1.03 0.15 1.13 0.19 1.07 0.18 1.09 0.13 1.28 0.49 0.99 0.04 1.14 0.19 0.90 0.67 1.00 0.00 
2.25 1.32 0.55 1.96* 0.45 1.18 0.57 2.01* 0.38 1.22 0.42 2.16* 0.85 0.97 0.02 1.07 0.30 1.00 0.35 1.09 0.09 
4.51 0.82 0.13 3.67** 0.85 0.82 0.08 3.91* 1.26 0.87 0.13 5.29** 2.62 0.99 0.03 1.04 0.36 0.77 0.18 1.09 0.14 
ºVehicle control DMSO 
n=3           *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
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Figure 5.8: Line scatter graph visually displaying data in table 5.3a illustrating relationship of each 
biomarker and cell cycle stage for Crizotinib. Primary Y axis shows the P53 response data. Secondary 
Y axis plots ɣH2AX and pH3 cell cycle signals and relationship. Statistical significance of each response 




Figure 5.8 displaying data from table 5.3a shows a dose response increase for S and G2 
ɣH2AX along with metaphase pH3 from control levels until 2.25 µg/mL where the response 
drops off. Whilst there is a limited overall ɣH2AX response, assessment when breaking the 
response down into cell cycle reveals there is a fold change induction that is equivocal at 
0.57 and 1.31 ug/ml whilst being above the fold change cut off at 2.25 µg/mL for G1 ɣH2AX. 
Anaphase pH3 fold change levels are lower than control at all doses. Figure 5.9 
demonstrates that there is little to no change in the ratio of metaphase to prophase or 
prophase to metaphase and anaphase but there is a decrease in the ratio of Anaphase to 
prophase cells when compared to control.  
ºVehicle control DMSO 
  
Figure 5.9: Line scatter graph displaying the ratio of average fold change responses (data in table 5.3b) for 
Crizotinib. Allowing assessment of proportional changes of the different phases of mitosis to one another. 
Primary Y axis shows the changes compared to vehicle control of the individual metaphase prophase 
change, and anaphase prophase change. Secondary Y axis plots the overall prophase response to anaphase 
and metaphase combined. No statistical analysis was performed, a qualitative trend only was looked at. 
There was a very slight trend decrease of prophase population to the combined anaphase/metaphase 
population before increasing at 1.31 µg/mL. There was a equivalently gentle increase of metaphase to 
prophase and anaphase to prophase cell populations followed by decrease at the same does.  
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Table 5.4 looked at a total of 496 true MN events and shows presence of biomarker signal 
within the MN.  
Table 5.4: Crizotinib 4.51µg/mL - Biomarker presence or absence in true MN microscope 
images obtained on ISXII  
N=1     True MN total=496 
MN containing both ɣH2AX and P53 signal were rare at 0.2%, 10% of MN were found to 
have ɣH2AX signal. Unlike Etoposide there is a greater percentage of cells with just DRAQ5™ 
stain and more MN with just P53.  
5.3.3 - Vinblastine 
Vinblastine Sulfate is a compound used in chemotherapy and is an alkaloid isolated from 
the Vinca Rosea also known as the periwinkle plant. This compound has a aneugenic Mode 
of Action disrupting microtubule formation resulting in cell cycle arrest at the M Phase 
(Gerson et al., 2018). Due to the well characterized nature of this chemical, it is 
recommended on the ECVAM list of chemicals to assess assays ability to differentiate Mode 
of Action and assess misleading positive rates (Kirkland et al., 2006; Kirkland et al., 2016). 
The following figure 5.10 shows the dose response induction of the biomarkers ɣH2AX, pH3 
and P53 along with the automated acquisition MN data plotted as a square root fold change 
when compared to the control response. RCG did not reach cytotoxic levels assessed here 
even at 0.0020µg/mL 
Stain present in MN Total count % MN Cells 
DRAQ5™ only  435 87.7 
DRAQ5™ and P53 9 1.8 
DRAQ5™ and ɣH2AX 51 10.3 





ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.10: Combination graph showing the square root of raw fold change values of the biomarker 
responses for ɣH2AX, pH3, P53 and the Micronucleus (MN) genotoxic endpoint in response to 
Vinblastine doses. RCG shows the % growth of cell cultures, RCG response decreases in a dose 
dependant manner. The dashed lines are the fold change cut off for the biomarkers pH3, P53 and 
ɣH2AX. ɣH2AX response drops below fold change decrease from 0.0006 to 0.0010 µg/mL before 
increasing to vehicle control levels at 0.0020. ɣH2AX response was significant at 0.0006and 0.0008 
µg/mL. P53 was significant at all doses, increasing in a dose dependant manner being above the fold 
change cut off. pH3 response increased from 0.0006 µg/mL onwards and was both greater than the 
fold change cut off and significant at theses doses. At the same doses as pH3 MN response also 
increased and was significant. There was not a NOGEL doses where all biomarkers were not significant. 
The NOGEL dose for pH3 ɣH2AX and MN was 0.0002 µg/mL.  
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Figure 5.11 below demonstrates the percentage of cells in each portion of the cell cycle and 
the ensuing effect of Vinblastine on the cells cycle of TK6 cells. The general trend of the cell 
cycle phases demonstrated in figure 5.11 are a gradual increase of G1 cell population, a 
decrease of S phase cells and a consistent G2/M phase response until the top dose of 
0.0002 µg/mL. Cell cycle response significance are shown with asterix in figure 5.11.  
 
` 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.11: Graph showing percentage of cells found in each portion of the cell cycle in relation to 
Vinblastine concentration. Statistically significant decrease of cells in S phase compared to control 
was at all doses. From 0.0010 S phase began to increase but was still lower than control S. G2/M cell 
populations decreases until 0.0006 µg/mL demonstrating a statistically significant decrease, from this 
point onwards G2/M increased and was significant at 0.0020 µg/mL. G1 response increased and then 
decreased at the same doses S and G2/M populations decreased then increased. 0.0006 to 0.001 had 
a significant G1 increase, the top dose then had a significant decrease.  
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The decrease of ɣH2AX was statistically significant at doses 0.0006 and 0.0008 µg/mL, these 
same doses and  0.001 µg/mL have a fold decrease of ≤0.8 fold change cut off.  Increase of 
pH3 signal from 0.0006 µg/mL dose onwards exceeding the fold change cut off of 1.1 and 
showing statistically significant from the same. The P53 marker demonstrates significance at 
all doses and the increase is proportional with increase pH3 expression and MN generation. 
Statistical significance is seen for the MN response at al doses with the exception of 0.0002 
µg/mL. 
Based on the availability of data a more in-depth look into these biomarker responses in 
relation to one another has been assessed. Tables 5.5a and 5.5b display the fold change 
data of the individual biomarkers in direct relation to a stage of the cell cycle.  Tables 5.5a 
and 5.5b are graphically visualized in figure 5.12 and 5.13 below.
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Table 5.5a: Fold change average of biomarkers ɣH2AX and P53 in direct relation to the phase of the cell cycle the cell population is in 
±1SD for Vinblastine 
 



















0.0000 º 1.00 0.36 1.00 0.04 1.00 0.36 1.00 0.04 1.00 0.15 1.00 0.07 1.00 0.05 1.00 0.23 1.00 0.07 1.00 1.00 
0.0002 1.01 0.43 2.16** 0.09 1.13 0.52 2.10* 0.06 1.05 0.24 2.21** 0.07 0.99 0.03 1.05 0.13 1.19 0.23 1.00 1.00 
0.0006 0.55* 0.23 4.98** 0.22 1.00 0.38 4.63** 0.09 0.95 0.15 5.57** 0.32 0.97 0.02 1.17 0.18 1.06 0.12 4.55 0.79 
0.0008 0.60* 0.25 5.05** 0.27 1.17 0.60 4.65** 0.09 0.91 0.12 5.62** 0.39 1.01 0.02 1.02 0.10 0.68* 0.09 7.93* 2.85 
0.0010 0.72 0.22 5.24** 0.16 1.14 0.28 4.82** 0.19 0.96 0.07 5.85** 0.46 1.05 0.03 0.87 0.16 0.54* 0.03 8.18* 3.13 
0.0020 1.84* 0.69 5.01** 0.14 1.07 0.50 4.83** 0.24 0.77 0.14 5.67** 0.46 1.12* 0.05 0.26* 0.10 0.21* 0.21 3.79 1.35 
ºVehicle control DMSO 
n=3           *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
Trend decrease        Trend Increase 
 
Table 5.5b: Fold change average of the ratio of Prophase metaphase and anaphase cells populations when compared to control for 
Vinblastine 
 Mitosis stage fold change ratio 
Vinbstn 
(µg/mL) 
Prophase:Ananaphase+Metaphase Metaphase:Prophase Anaphase:Prophase 
0.0000 º 1.00 1.00 1.00 
0.0002 0.91 1.04 1.18 
0.0006 0.84 1.15 1.09 
0.0008 1.05 0.99 0.69 
0.0010 1.26 0.79 0.51 
0.0020 5.63 0.22 0.17 
ºVehicle control DMSO 




Whilst the overall response of ɣH2AX decreases slightly as shown in figure 5.10 above, 
further assessment of the biomarker in direct relationship to each stage of the cell cycle was 
attempted. At G1, ɣH2AX biomarker decreases significantly from 0.0006 to 0.0010 µg/mL 
however, there is a statistically significant increase relative to control at 0.0020 µg/mL dose. 
There was a increase of fold change of ɣH2AX at the S phase portion of the cell cycle but 
this response was not statistically significant. The G2 population of cells demonstrate a 
slight trend decrease in ɣH2AX signal and the greatest decrease being at the top dose. This 
fold decrease at 0.0002 µg/ml falling below 0.8 fold change cut off. Cells that are pH3 
positive but have reduced ɣH2AX are termed H3+ve ɣH2AX -ve in table 5.5a and Abnormal 
mitosis in figure 5.12. There is a overall trend increase compared to control from 
0.0006µg/mL onwards, with statistically significant change of this relationship at 0.0008 and 
0.0010µg/mL.  
P53 Demonstrates the most obvious response for a mitotic arrest inducing compound. 
Being statistically significant at all cell cycle phases and dose concentrations. Figure 5.12 
shows that the overall nuclear P53 levels in G2/M phase cells has a greater fold change over 
that of control compared to the G1 phase which in turn has a greater fold change over that 




With the exception of the 0.0020 µg/mL Vinblastine concentration where there is a statistically 
significant increase of cells in prophase, there is no other increase in prophase, metaphase or 
anaphase population at any of the doses. In metaphase and anaphase, however, there are 
statistically significant decreases in populations. 0.0008 and 0.0010 µg/mL showed a statistically 
significant decrease of the anaphase population and at 0.0020 µg/mL both anaphase and 
metaphase presented a decrease in population that was statistically significant. The ratios of 
these phases of mitosis can be compared with one another and is displayed graphically in figure 
5.13. 
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Figure 5.12: Line scatter graph visually displaying data in table 5.5a, illustrating relationship of each 
biomarker and cell cycle stage for Vinblastine dose concentrations. Primary Y axis shows the P53 
response data. Secondary Y axis plots ɣH2AX and pH3 cell cycle signals and relationship the axis was 





There is an initial fold change increase of the metaphase:prophase and anaphase:prophase 
ratios at 0.0002 and 0.0006 µg/mL relative to control and a corresponding decrease of the 
prophase: combined anaphase and metaphase ratio. However, from 0.0008 µg/mL onwards 
the relationships flip and prophase: combined anaphase and metaphase ratio increase. 
None of these responses were statistically significant.  
For the top dose Vinblastine the additional metric for true MN and presence or absence of 
either ɣH2AX and or P53 biomarker in the MN can be found in table 5.6.  
 
ºVehicle control DMSO 
  
Figure 5.13: Line scatter graph displaying the ratio of average fold change responses (data in table 5.5b) for 
Vinblastine. Allowing assessment of proportional changes of the different phases of mitosis to one 
another. Primary Y axis shows the changes compared to vehicle control of the individual metaphase 
prophase change, and anaphase prophase change. Secondary Y axis plots the overall prophase response to 
anaphase and metaphase combined. No statistical analysis was performed, a qualitative trend only was 
looked at. There was a plateau trend of prophase population to the combined anaphase/metaphase 
population before increasing at 0.0010µg/mL onwards. There was a decrease of metaphase to prophase 
and anaphase to prophase cell populations. Metaphase:Prophase was lower initially than 
Anaphase:Prophase at 0.0002 µg/mL at all other doses the trend was higher but still decreasing.  
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Table 5.6: Vinblastine 0.002ug/mL - Biomarker presence or absence in true MN microscope 
images obtained on ISXII  
Stain present in MN Total count % MN Cells 
DRAQ5™ only  44 33.1 
DRAQ5™ and P53 66 49.6 
DRAQ5™ and ɣH2AX 11 8.3 
DRAQ5™  P53 and ɣH2AX 12 9.0 
n=1        Total MN 133 
In contrast to Etoposide and Crizotinib there is a large percentage of assessed MN with P53 
signal more so than DRAQ5™ only. D5 only MN% decreased compared to Etoposide and 
Crizotinib. An increase in MN with both P53 and ɣH2AX could indicate cells about to enter 
apoptosis.  
5.3.4 - ARA-C 
ARA-C specifically affects the synthesis phase of the cell cycle as it acts as a nucleoside 
analogue i.e., it becomes incorporated into the DNA rather than the correct pyrimidine.  
Figure 5.14 shows the biomarker responses for ARA-C. Doses 0.01 through to 0.05 µg/mL 
had a RCG percentage of 78 – 46.1% respectively, this is in line with regulatory guidelines 
that biologically relevant responses have a RCG value of above 30%. The doses 0.21 and 
0.41 µg/mL had RCG values of 26.1 and 28.9%. In terms of genetic toxicology assessment, it 
is considered that RCG values of less than 30% any genetic toxicological response is more 
likely to be as a result of cytotoxicity rather than genotoxicity. When assessing the following 
data this potential for a cytotoxicity response should be remembered however in lieu of 
intermediate doses between 0.05 and 0.21 µg/mL the metrics for 0.21 and 0.41 µg/mL are 




The increase of ɣH2AX at all doses and is above the fold change cut off, being statistically 
significant from 0.05 µg/mL is consistent with the chemical’s MoA. A decrease of pH3 
happens at each dose being significant from 0.03 µg/mL dropping below the cut off fold 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.14: Combination graph showing the square root of raw fold change values of the biomarker 
responses for ɣH2AX, pH3, P53 and the Micronucleus (MN) genotoxic endpoint in response to ARA-C 
doses. RCG shows the % growth of cell cultures, RCG response drops with increasing ARA-C dose, after 
the white dashed line the RCG has fallen below 30% as a result only one repeat at the doses 0.21 and 
0.41 µg/mL were assessed. This suggests a more finite dose range between 0.05 and 0.21 µg/mL is 
required. The horizontal dashed lines are the fold change cut offs for the biomarkers pH3, P53 and 
ɣH2AX. Statistical significance of 0.21 and 0.41 µg/mL were not performed due to there only being one 
experimental repeat. pH3 from 0.03 onward drops below the decrease fold change cut off and is 
significant at 0.03 and 0.05 µg/mL. ɣH2AX exceed the fold change cut off from 0.01 to 0.05 µg/mL only 
0.05 was significant. P53 response was significant at both 0.03 and 0.05 increasing with ɣH2AX and MN 
response. The only dose demonstrating NOGEL for all biomarkers is 0.01µg/mL.  
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change decrease value. Fold change for P53 surpasses the suggested cut off and is 
significant at 0.03 µg/mL. MN increases as dose increases however no response is 
significant, this could be due to the large SD value at 0.03 µg/mL and 0.05 µg/mL doses.  
Figure 5.15 below demonstrates the effect of ARA-C on the cell cycle. G1 population 
decreases with dose and G2/M population increases whilst S phase stays stable up to 0.05 
ug/mL. A statistically significant decrease in G1 and a statistically significant increase in 
G2/M are observed at 0.05 µg/mL.   
 
ºVehicle control DMSO 
 *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
 
Figure 5.15: Graph showing percentage of cells found in each portion of the cell cycle in relation to 
ARA-C concentration. As the ARA-C concentration increases the G1, S and G2 stages of the cell cycle 
shift. G1 decreases at all doses including 0.21 and 0.41 µg/mL and is significant at 0.05. Number of S 
phase cells remain stable up to 0.05ug/mL after this the S phase population increases dramatically. 
G2/M phase demonstrates the reverse of S phase increasing initially, being significant at 0.05, before 
decreasing drastically at 0.21 and 0.41 µg/mL doses. The white line indicates the doses where the RCG 





Tables 5.7a and 5.7b below show the data for direct cell cycle assessment with biomarker 
response and statistical significance is demonstrated with an Asterix. Data for 5.7a is also 





Table 5.7a: Fold change average of biomarkers ɣH2AX and P53 in direct relation to the phase of the cell cycle the cell population is in 
±1SD for ARA-C 






































































































0.21¯ 1.58  1.10  1.15  1.05  0.96  1.36  1.01  0.92  0.00  2.95  
0.41¯ 2.04  1.36  1.38  1.31  1.10  1.52  0.99  1.06  0.00  0.00  
ºVehicle control DMSO 
n=2           ¯n=1         *Significant response p value < 0.05*           ** Highly Significant Response p value<0.0001 
Trend decrease        Trend Increase 
 
 Mitosis stage fold change ratio 
ARA-C 
(µg/mL) 
Prophase:Ananaphase+Metaphase Metaphase:Prophase Anaphase:Prophase 
0.00 º 1.00 1.00 1.00 
0.01 0.62 1.48 1.24 
0.03 0.56 1.65 1.17 
0.05 0.60 1.58 1.04 
0.21¯ 0.00 0.00 0.00 
0.41¯ 0.00 0.00 0.00 
ºVehicle control DMSO 






The ɣH2AX response is seen most in the G1 portion of the cell cycle being statistically 
significant at all doses as seen in table 5.7a. Though no doses were significant for S 
pahse ɣH2AX response, there was a trend increase greater than fold change cut off at all 
doses. Levels of ɣH2AX increase slightly at the G2 portion of the cell cycle compared to 
control, this could be due to DSB repair. Whilst pH3 overal has decreased reultining in no 
change of cells in prophase, a increase of cells in metaphase generating a statistically 
significant response at doses 0.03 and 0.05 µg/mL and decrease of cells in annaphase. 
Whilst cells in healthy mitosis decreases, cells that have managed to enter mitosis 
display abnormal mitotic profile by being positive for pH3 signal but negative for ɣH2AX 
signal have increased. At all doses ARA-C seems to have the most impact on P53 at the 
G2/M phase of the cell cycle . G1 has the next highest P53 activation followed lastly by S 
phase of the cell cycle. Doses being significant at 0.03 and 0.05µg/mL. Figure 5.17 
ºVehicle control DMSO 
 
Figure 5.16: Line scatter graph visually displaying data in table 5.7a illustrating relationship of each 
biomarker and cell cycle stage for ARA-C. Primary Y axis shows the P53 response data. Secondary Y 
axis plots ɣH2AX and pH3 cell cycle signals and relationship, the axis scale is logged. Statistical 
significance of each response can be found in table 5.7a. 
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further demonstrates assessment of Metaphase anaphase and prophase relationship 
response to ARA-C.  
There is a decrease of prophase: combined anaphase and metaphase ratio and a 
increase of metahase:prophase ratio, there is not much change of the 
anaphase:prophase ratio this is expected due to the decrease of cell phosphorylated H3 
in mitosis.  
 
 
Table 5.8 looks at biomarker signal presence within the MN. 
ºVehicle control DMSO 
  
Figure 5.17: Line scatter graph displaying the ratio of average fold change responses (data in table 5.7b) for 
ARA-C. Allowing assessment of proportional changes of the different phases of mitosis to one another.  
Primary Y axis shows the changes compared to vehicle control of the individual metaphase prophase 
change, and anaphase prophase change. Secondary Y axis plots the overall prophase response to anaphase 
and metaphase combined. No statistical analysis was performed, a qualitative trend only was looked at. 
There was a trend decrease of prophase population to the combined anaphase/metaphase population 
before starting to increase at 0.05 µg/mL. There was an increase of metaphase to prophase at all doses 
and anaphase to prophase cell populations followed a slight increase both starting to decrease at 
0.05µg/mL. 0.21 and 0.41 µg/mL doses are not shown due to a lack of anaphase response as shown in 
table 5.7b.  
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Table 5.8: ARA-C 0.05ug/mL - Biomarker presence or absence in true MN microscope 
images obtained on ISXII 
N=1    Mn total= 586 
Presence of MN with P53 signal are minimal which is consistent with the overall low 
response of P53 biomarker levels. There is a 3% portion of the MN have ɣH2AX 1.5% 
that has P53 and 0.2% that have both biomarkers. These responses are relatively low 
when compared to the other chemicals and their biomarker MN assessment most of the 
MN present contained no biomarker signal.  
5.4 – Discussion 
5.4.1 – Etoposide  
Etoposide is a topoisomerase II inhibitor, it stabilizes the cleavage topoisomerase II-DNA 
complex which prevents the sealing of the DNA  backbone leading to DSBs (Caldecott et 
al., 1990).  
Though there is a slight increase of ɣH2AX the response is not necessarily consistent 
with the expected larger increase suggested by the initial understanding of the 
mechanism. Especially as the P53 response indicating DNA damage presence is so strong 
and is statistically significant from 0.03µg/mL onwards. However, this is consistent with 
results in the literature, Tamamori-Adaci et al., 2018 in the P53 competent H295R cells 
ɣH2AX response was not detected prior to 72hrs of treatment. The cell cycle responses 
of ɣH2AX do demonstrate differences (see table 5.1a) the decrease of G1 ɣH2AX signal is 
likely related to the G1 population decrease. The increase of ɣH2AX at 0.24 µg/mL S 
phase suggests the beginnings of senescence of S phase checkpoint in relation to ɣH2AX 
response  
Whilst the ɣH2AX response is not necessarily as drastic as expected the decrease of pH3 
is consistent with compound effect. Cells are not exiting the G2/M phase of the cell 
cycle, but cells are continuing to exit the G1 and S phases. The decrease of pH3 
population combined with the S/G2 arrest at the 24hr time point is consistent with 
current literature (Ando et al., 2014). P53 response is the best DNA damage indicator at 
the 24hr time point looked at for Etoposide along with MN response. At 0.24µg/mL, like 
ɣH2AX, the P53 at S phase increases over that of G1 which again suggests the cell cycle 
induced affect at higher doses is important and consistent with the biology. 
Stain present in MN Total count % MN Cells 
DRAQ5™ only  556 94.9 
DRAQ5™ and P53 9 1.5 
DRAQ5™ and ɣH2AX 20 3.4 
DRAQ5™  P53 and ɣH2AX 1 0.2 
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It has been suggested that topoisomerase II inhibiter induced DSB’s are marked for 
repair by the NHEJ pathway as a result, cells containing a DNA repair system, as is the 
case with TK6’s, would confir a threshold level at which this repair system would 
become overwhelmed (Smart et al., 2008; Mao et al., 2001; Malik et al., 2006). This 
therefore suggests that at the 24 hour time point chosen combined with the rapid 
continual repair nature of NHEJ along with the dose concentrations selected results in 
any initial ɣH2AX response based on immediate DSB’s generated on initial introduction 
of Etoposide would be repaired resulting in the dissipation of the ɣH2AX signal as seen 
here. It is therefore reasonable to suggest that to truly assess the Etoposide MoA in this 
system a more finite dose range exceeding 0.5 µg/mL at the 24 hour time point to 
overwhelm the system tolerance for Etoposide exceeding the DNA damage threshold 
should be assessed alongside similar doses at a 3-4 hour exposure time point (Smart et 
al., 2008; Lynch et al., 2003; Kirkland et al., 2010; Wilson et al., 2021). 
5.4.2 – Cizotinib  
Crizotinib inhibits ALK but stabilises the P53 protein resulting in cell cycle arrests (Lev et 
al., 2018). This cell cycle profile and increase of G2/M cell population at the top dose is 
consistent with literature (Megiorni et al., 2015). 
 Crizotinib on its own does not sufficiently induce double strand breakage to further 
signal P53 response to induce an apoptotic outcome for the cancer cell, rather it induces 
cell cycle arrest that could potentially be recovered from, this is why Crizotinib cancer 
therapies are usually combinatorial (Lev et al., 2017). This lack of DSB induction is 
identified here through lack of ɣH2AX response above that of control levels, this is 
consistent with aneugenic MoA and with current literature (Dertinger et al., 2019). The 
increase of G1 ɣH2AX is more likely due to the chemical simply inducing stress on the 
cells and the lack of G1 P53 response at these lower levels of Crizotinib where ɣH2AX 
has these fold increases implies this is generic background stress response rather than 
actual induced DNA damage. P53 response is significant at G1, S and G2/M at the same 
doses 2.25 and 4.51µg/mL.  
The lack of pH3 induction that is usually a sign of aneugenicity could be as a result of off 
target effects on aurora kinases that are used in the phosphorylation of H3 (Kong et al., 
2018; Dertinger et al., 2019; Crosio et al., 2002). When assessing the prophase, 
metaphase, anaphase relationships, pH3 being of less than control levels, when there is 
no reduction over all in the collective pH3 population, may be a suggestion of slight 
mitotic arrest at the metaphase portion of the cell cycle. Whilst more in depth analysis 
would need to be taken, it is a interesting trend to take note of. This suggestion is 
further backed up by an increase of multinucleated cells (bi, tri and tetra nucleated) 
examples of which are demonstrated below in figure 5.18 suggesting potential for a non-
disjunction event and or blocking of cytokinesis. This observation was also noted and 




The limited response of ɣH2AX response variation along with P53 increases confirm 
Crizotinibs tyrosine kinase inhibition potentially having an effect on the ɣH2AX response 
pathway whilst re-affirming Crizotinibs stabilisation of the P53 anti tumour molecule.  
The lack of activity at the lower doses of Crizotinib, <2.25µg/mL showed no significant 
changes of biomarker response (figure 5.5) or cell cycle response (figure 5.6) suggests 
that between the dose concentrations of 2.25 and 4.51 µg/mL a more refined set of 
interval concentrations should be used to truly elucidate the biomarker and MN dose 
response. This being said the profile generated by the platform of no ɣH2AX and pH3 
dose response whilst being statistically significant for P53 and MN response as seen in 
figure 5.6 and polyploidisation is consistent with recently reported results (Dertinger et 
al., 2019).  
Vinblastine – 5.4.3 
Vinblastine binds to tubulin inhibiting mitotic spindle assembly. Based on the data above 
the dose response of Vinblastine recorded is consistent with that in the literature of a 
aneugenic profile (Smart et al., 2020; Dertinger et al., 2019). The response by ɣH2AX for 
the system is consistent with the expected hypothesis that there would be no or limited 
increase in ɣH2AX signal detected. The slight increase back to control levels of ɣH2AX at 
the top dose could be indicative of an increase in cells signalling entry into apoptosis. 
This is consistent with Carbendazim data suggesting a lack of ɣH2AX increase can be 
linked to a aneugenic MoA (Bryce et al., 2016; Audbert et al., 2016). Increase of pH3 
signal is now well classified in the literature with being consistent with a aneugenic 
Mode of Action, here pH3 signal exceeds the fold change cut off of being greater than 
Figure 5.18: Demonstrating multinucleated cells and location within DNA histogram with cell cycle gates and rare 
events generated by Crizotinib. Image Row 2 shows a binucleate cell with MN containing ɣH2AX signal. Image Row 
1 and 3 show a bi and tri nucleated cell with P53 sequestered to only one nucleus. 
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1.1 fold. P53 as associated as a marker for DNA damage and cell cycle maintenance 
increased presence is to be expected and does so proportionally with MN response 
(Bryce et al., 2007; Bryce et al., 2016; Audbert et al., 2016). P53 stabilization really drives 
home the activity of the cell at the various checkpoints. The highest response of P53 
being in G2/M implies this is where the chemical is having the most impact despite the 
percentage of cells in G2/M being of a smaller population than G1 at the 0.0010 µg/mL 
dose and lower. Up until 0.0008µg/mL cell cycle response (figure 5.10) was consistent 
with literature (Bryce et al., 2007). The increase in percentage cells found in G1 is in line 
with cells that have not quite received enough damage to arrest in G2M but have stalled 
in cell cycle progression at the G1 checkpoint. An overall decrease of percentage cells in 
S phase implies that the cells present in S phase whilst reduced are capable of continued 
cell cycle progress. Unlike Bryce et al., 2007 where cytotoxity was a limiting factor, 
concentrations up to 0.0020 µg/mL were able to be assessed. At the top dose the effect 
on the cell cycle observed is a large portion of cells in G2/M phase increasing and G1 
decreasing. As figure 5.12 demonstrates there is a fold increase of ɣH2AX at 
0.0020µg/mL, this increase corresponds with an overall decrease of cell population in 
the G1 phase. This increase of ɣH2AX signal could be indicative of cells entering 
apoptosis (figure 5.19) or the Vinblastine chemical at higher doses having a secondary 
clastogenic effect. It is interesting to note that the overall response of ɣH2AX not having 
an increase further demonstrates the importance of scrutinising cellular responses 
compared with one another rather than making sweeping assessments on general 





Though the biology behind ɣH2AX and pH3 is linked and established i.e., during mitosis 
there is a global phosphorylation of H3 and ɣH2AX and therefore in this context ɣH2AX 
cannot be relied upon as a marker for DNA damage. There is no reason to say that a 
change away from the “normal” healthy relationship of pH3 and ɣH2AX should not be 
considered a potential way to help indicate MoA as previously discussed. Vinblastine 
clearly demonstrates a dose response increase of abnormally mitotic cells (table 5.5a) 
suggesting mitosis is a key site of DNA damage activity. This reasoning is not 
unreasonable to suggest given Vinblastine exposure has been shown to induce 
chromosome lag and non-disjunction events (Zijno et al., 1996; Surrallés et al., 1995).  
Whilst there is a clear dose dependant statistically significant increase of pH3 signal the 
relative proportions of cells in prophase, metaphase and anaphase compared to control 
have not increased with any great effect, but rather decreased. This at first can seem 
counter intuitive, as surely there should be an increase at the metaphase stage as this is 
the main step of spindle interaction. However, understanding of the underlying biology 
explains this decrease of cells at the metaphase/anaphase cell stages. As Vinblastine is a 
spindle poison the cell essentially stalls before entering into "correct" metaphase so 
Figure 5.19: Shows the G1 gH2AX response for Vinblastine at the 0.002µg/mL dose and corresponding 
apoptotic cell image. The scatter point demonstrating apoptosis is in the ++ gate. This is the population 
of gH2AX being assessed for response metric. The cell image shows this cell is likely apoptotic with its 
blebbing nucleus.  
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there ends up being a build-up of cells ready to exit prophase/prometaphase but can not 
because of the damage to spindle assembly. Therefore, looking at the change 
proportionally from cells identified as prophase compared to cells in metaphase and 
anaphase a response can be identified, see figure 5.14, to potentially identify the 
arresting phase within mitosis i.e., prophase arrest. Whilst this is an interesting 
observation on the proportional effects of cells in prophase vs metaphase vs anaphase 
additional spindle poisons would need to be assessed. At this point in time the system as 
it is cannot explicitly identify the exact stage of influence of the compound past that of 
generically saying the "compound causes cell cycle arrest at the M phase of the cell 
cycle" without further assessment. 
5.4.4 - ARA-C  
ARA-C not only does it become incorporated into the DNA during synthesis which results 
in double strand breakage (Gerson et al., 2018) it also inhibits DNA damage repair 
through binding of polymerases resulting in inhibition of cell repair at checkpoints 
outside synthesis phase (Gerson et al., 2018). As ɣH2AX is a DSB biomarker a increase in 
ɣH2AX with a increase of DSB is expected. 
As the chemical mainly impacts the S phase of the cell cycle and inhibits polymerases 
(Momparler, 2013), as the data here suggests this prevents cells from passing into G2 
and passing the G2/M checkpoint there is a corresponding decrease of cells with H3 
phosphorylation. This suggests that the integrity of the DNA, due to integration of ARA-
C, results in a genomic instability that mitosis cannot support, this explains the decrease 
of cells in G1 population as shown in figure 5.17 
Whilst a effect at the lower doses on S phase would be expected initially the effect on 
the checkpoints and DNA repair mechanisms seem to be larger. This can be explained by 
cells not passing the G2/M checkpoint due to interferences with polymerase reactions. 
At the lower doses the repair pathway mechanisms and the inactivation of the chemical 
to ARA-U (uracil arabinoside) by cytidine deaminase initially helps protect the synthesis 
portion of the cell cycle (Momparler, 2013). At some point between 0.05 and 0.21µg/mL 
there is a overwhelming of the synthesis pathway protective mechanisms at which point 
the expected effect of cell cycle arrest at the s phase of the cell cycle is observed.  
As figure 5.16 shows P53 increases with ɣH2AX induction confirms true DNA damage is 
occurring. Inhibition of the DNA damage repair system at the G2M checkpoint explains 
this increase of G1 ɣH2AX signal and the increase of S phase ɣH2AX is also explained as 
the compound induces more double strand breakage as the compound becomes 
integrated into the DNA. The importance of the G2/M response is highlighted by P53, 
where at all doses ARA-C induces P53 response the most at the G2/M phase of the cell 






5.4.5 –  ISMN-me MoA Overview  
Data displayed above indicates the ISMN-me whilst flawed is able to identify differences 
between the various chemicals assessed. Based on the general consensus in the 
literature (Bryce et al., 2016; Bryce et al., 2017; Khoury et al., 2016; Dertinger et al., 
2018) induction of P53 response is indicative of DNA damage, pH3 increase indicates 
aneugenictity and ɣH2AX increase indicates clastogenicity and MN generation is 
proportional to genotoxic potential of a compound. In all instances the ISMN-me assay 
detected a increase in MN and P53 response. The chemicals MMS, ARA-C and Etoposide 
display features associated with clastogenicity (increase MN, P53, ɣH2AX and decrease 
in pH3). The chemicals Vinblastine, Carbendazim and Crizotinib display features 
associated with aneugenicity (increase MN, P53 pH3 and decrease ɣH2AX). Specific cell 
cycle biomarker assessment enabled further insights into cell cycle processing of DNA 
damage response markers. Whilst conclusive decisions cannot be made at this stage 
about the in depth cell cycle biomarker profile for chemicals of varying chemical classes 
a acknowledgement that differences of these cell cycle biomarker metrics generate 
different chemical profiles (even within known MoA groupings) can be detected, see 





Figure 5.20: Demonstrating qualitatively the overall visual differences of the different genotoxic chemicals 
assessed. Left panel is known clastogens and right panel known aneugens. Graphs show the plotted square root 
fold change of biomarkers as radar graphs. Different coloured lines are relative to the dose and points around the 
edge are metrics assessed excluding MN. Based on shape MMS and ARA-C work via clastogenic MoA. 
Carbendazim, Crizotinib and Vinblastine via a aneugenic MoA. Etoposide demonstrates features of both 
aneugenic and clastogenic MoA which has been identified in other studies (Hermine et al., 1997).  
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The high content nature of the assay allowed for the assessment of rare events such as 
MN containing P53 and or ɣH2AX signal. Whilst the meaning of these relationships has 
yet to be investigated fully the ability to assess these events because of microscopy 
image presences provides an addition angle for MoA assessment. Furthermore, features 
such as multinucleation in response to chemical presence was also identified as a 
potential avenue of investigation as demonstrated in figure 5.18. Image analysis also 
allowed confirmation of potential reasons for clastogenic marker increase in response at 
higher doses due to apoptotic induction, see figure 5.19. Ability for further data mining 
of rare cellular events such as P53 translocation to one nucleus in a multinucleated cell 























Chapter 6 – General Discussion 
6.1 – Thesis Overview 
Here I demonstrate a simple robust protocol for optimised staining of fixed human 
lymphoblast p53 proficient TK6 cells with the antibodies; Anti- ɣH2AX, Anti -P53 and Ant-
pH3S28 along with DRAQ5™ DNA staining in a whole cell multiplex system that is suitable 
for analysis via microscopy or imaging flow cytometry. Antibody penetration of the cell and 
nuclear membrane was demonstrated by qualitative assessment of confocal microscopy Z-
Stack imagery that allowed 3D visualisation of nuclear specific antibody binding. Use of the 
Amnis® FlowSight® and ImageStream X Mark II® platform provided a high content, high 
throughput acquisition platform with the sensitivity of flow cytometry and accuracy of 
image analysis. Using both optimal and suboptimal lasers for fluorophore excitation 
demonstrated that a multiplex system for DNA damage assessment including MN was 
possible in unlysed cells. IDEAS® 6.2 template generation allowed for batch processing of 
data samples extracting the following metrics: Cell Cycle, MN, ɣH2AX, P53, pH3, G1 ɣH2AX, 
G1 P53, S ɣH2AX, S P53, G2 ɣH2AX, G2/M P53, G2M Prophase pH3, G2M Metaphase pH3, 
G2M Anaphase pH3, Abnormal mitosis (H3+ve ɣH2AX-ve) and shifts in Prophase, Metaphase 
and Anaphase relationships along with some preliminary data on biomarker signal found 
within MN. The system found differences in the biomarker metric responses between the 
chemicals; MMS, Carbendazim, ARA-C, Vinblastine, Etoposide and Crizotinib suggesting 
potential for chemical MoA elucidation.  
6.1.1 – Template Generation and Batch Processing 
IDEAS® 6.2 is a intuitive software that is user friendly providing comparable data sets 
across FlowSight® and ImageStream X Mark II® machines. Template design and batch 
analysis of data sets filtered user bias while providing high data content outputs that 
were able to be mined for relevant responses linked with the biology of the antibodies 
and DNA stain used. However, limitations of this multiplex platform were mainly found 
in relation to the IDEAS® 6.2 software and masking features. Lack of a automated cell 
cycle assessment feature hindered the batch processing of data sets requiring manual 
placement of the cell cycle gates G1 S and G2/M to account for sample variability. On 
average the masking spot count feature for MN analysis was on only 57% accurate with 
a 45% miss rate which varied between chemical classes.  
6.1.2 – FlowSight®  and ImageStream X Mark II® 
I have begun to investigate the use of mechanistic markers alongside MN scoring to 
provide multiplex data analysis. From the data increases in micronucleus dose responses 
can be observed, alongside their corresponding respective responses within the 
mechanistic markers ɣH2AX P53 and pH3. The data appears to demonstrate the typical 
responses indicative of MMS acting via a clastogenic MoA and Carbendazim acting 
through an aneugenic MoA. Whilst the FlowSight® system did not allow for the four 
colour stain system to be used the dual marker response with regards to pH3 and ɣH2AX 
was consistent with the optimised assay response data. Both the FlowSight®  dual 
marker system and ISMN-me allowed MoA assessment to enable high throughput and 
189 
 
high content whole cell analysis, along with computer-based image scoring and 
archiving.  
For MMS there was a dose dependant increase of ɣH2AX and MN at the same doses 
where H3 signal decreasing. The relevant increase in ɣH2AX reflects an increase of cells 
with DNA strand breaks, at the same concentration as MN and P53 levels, along with 
there being a decrease of cells in mitosis as demonstrated by the reduction in pH3 
signal. From the results generated, MMS appears to cause MN through chromosome 
breaks, and this is displayed without the need for kinetochore labelling. By contrast the 
aneugen Carbendazim had the reverse ɣH2AX, H3 profile at the same concentrations as 
an increase in MN and P53 response. The decrease in strand breaks observed, could be 
linked with mitotic arrest, and the increase in H3 is in line with the response of known 
aneugens, particularly when happening at the same concentrations as the increase in 
MN. This suggests that MN are generated through aneuploidy dominant mechanism. 
Furthermore, the greater fold increase of P53 response of Carbendazim compared to 
MMS could be indicative of the fact MN generation via aneugenicity is more lethal than 
simply DSB generation.  
6.1.3 – ISMN-me Assay 
ISMN-me whilst flawed, i.e., accuracy of the MN mask, is able to identify differences 
between the various chemicals assessed. Based on the general consensus in the 
literature (Bryce et al., 2016; Bryce et al., 2017; Koury et al., 2016; Dertinger et al., 2019) 
induction of P53 response is indicative of DNA damage, pH3 increase indicates 
aneugenistity, ɣH2AX increase indicates clastogenicity and MN generation is 
proportional to genotoxic potential of a compound. In all instances the ISMN-me assay 
detected a increase in MN and P53 response. The chemicals MMS, ARA-C and Etoposide 
display features associated with clastogenicity (Increase MN, P53, ɣH2AX and decrease 
in pH3). The chemicals Vinblastine, Carbendazim and Crizotinib display features 
associated with aneugenisity (increase MN, P53 pH3 and decrease ɣH2AX). Specific cell 
cycle biomarker assessment enabled further insights into cell cycle processing of DNA 
damage response markers. Whilst conclusive decisions cannot be made at this stage 
about the in depth cell cycle biomarker profile for chemicals of varying chemical classes, 
an acknowledgement can be made that differences of these cell cycle biomarker metrics 
generate different chemical profiles (even within known MoA groupings) can be 
detected.  The main drawbacks of the system thus far are actually in relation to 
limitations of software and data mining to accurately and coherently unlock the 
available information collected in the data sets.  
6.1.4 – Position In Industry 
The principal advantage of this assay is the simultaneous detection of DNA damage 
Mode of Action whilst maintaining the morphological high content localisation 
information of microscopy, with the high throughput potential of flow cytometry. These 
qualities of the ISMN-me assay place the platform within industry safety assessment, 
specifically in genetic toxicology within the drug development pipeline filling a niche not 
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covered by current MoA genetic toxicology assays (Wilson et al., 2021; Dertinger et al., 
2018).  
Use of such a platform for understanding of MoA could result in less late stage attrition 
and reduction on the abandoning of promising candidates too early. For instance, 
compounds with a aneugenic MoA can have thresholds of carcinogenic risk established 
(Elhajouji et al., 2011). In terms of clastogens, due to their direct interaction with DNA, 
this thresholds approach is less accepted however with more in depth MoA data 
thresholds of safety could be established (Wills et al., 2017). Being able to analyse 
thousands of cells across multiple samples in mere seconds could provide the 
quantitative data needed to start making such decisions as well as providing 
opportunities to interrogate rare event generation as shown in figure 6.1 and potential 









Adverse Outcome Pathways refer to conceptual steps associated with stress factors that 
result in a molecular initiating event that can then progress through a series of key 
events that result in an adverse outcome. This framework of adverse outcome pathway 
generation relies on existing knowledge and empirical data between upstream and 
downstream toxicological pathways (Zeiger et al., 2015; Sasaki et al., 2020). AOP 
development requires the identification and detection of key events along the pathway, 
these frameworks can then be used to identify MoA. Thus, MoA’s of specific chemicals 
and their classes can be used to generate hypothetical MoA across compounds that are 
similar in action and structure. Elucidation of MoA’s, using assays such as the one 
described here, for a small subset of chemicals can potentially inform on a larger 
chemical space reducing time and resource (Zeiger et al., 2015; Derarfield et al., 2017; 
Sasaki et al., 2020). The high throughput, high content as well as miniaturisation and 
automation potential of the ISMN-me assay alongside Artificial Intelligence (AI) imaging 
classifiers and generation of AOPs could aid in the evolving landscape of next generation 
genetic toxicology testing strategy as reviewed by Dearfield et al 2017 providing a 
greater pool of information for assessing realistic risk in humans.  
 
Figure 6.1: Rare event identification. Row 1 shows a binucleated cell with MN containing ɣH2AX 
signal. Row 2 shows a tetra nucleated cell with P53 signal aggregated to one nucleus.  
Brightfield                 pH3                         P53                     ɣH2AX                    DRAQ5             Composite 








Having the ability to generate data on multiple DNA damage markers, as well as 
provides a template analysis approach for batch processing of acquired image files, the 
platform provides a reduction in time and resource required for compound assessment. 
As a result, it not only has the ability to reduce late stage attrition, but also could 
potentially be used as a screening assay for candidate selection optimisation. An 
extension of this is the determining of appropriate testing strategies to decrease animal 
usage, as well as off and on target interrogations. Whilst the IMN-me assay has the 
potential to be useful in the decision making process within the drug development 
pipeline, as demonstrated throughout chapters 3, 4 and 5 the complex profiles 
generated by the biomarkers and imagery information have posed a challenge in the 
presentation of the data. Use of tools such as Toxicological Prioritization Index (ToxPi) 
visualisation software for generation of a carcinogenicity scores could go a long way to 
making this barrage of information easier to digest and draw conclusions from in terms 
of determining MoA (Chapman et al., 2021; Wilde et al., 2018). Whilst promising, 
generation of clean cut ‘Yes/No’ decision making, that is often relied upon in genetic 
toxicology with regard to compound progression and regulatory submissions, specifically 
in relation to biomarker response and best approaches is a topic of debate (Chapman et 
al., 2021; Wheeldon et al., 2020; Bryce et al., 2018; Dertinger et al., 2019; Gollapudi et 
al., 2013; Wilson et al., 2021). 
6.2 – Conclusion 
ɣH2AX, pH3 and P53 use on the flow cytometry platform have become increasingly popular 
and the combination of Cell Cycle, MN ɣH2AX, pH3 and P53 signal results on the Amnis® 
FlowSight® (only pH3 and ɣH2AX) and ImageStream X Mark II® has proven consistent with 
current literature (Bryce et al., 2016; Khoury et al., 2016). Combined use of Cell Cycle, MN 
ɣH2AX, pH3 and P53 signal in a single sample containing unlysed cells allows for the direct 
comparison of DNA damage biomarkers MN and Cell cycle responses of chemicals that 
directly and indirectly result in DNA damage events. The system provides a reduction in 
experimental variability when compared to separate sample analysis, reduces time of 
sample preparation, number of samples needing to be assessed and amount of compound 
required for analysis. Adaptability for use using auto sampling and 96well plates generates 
not only a high content assay but a high through put one as well. 
Whilst the ISMN-me platform does not necessarily provide the same resolution and 
qualitative microscopy power of confocal microscopy. The system provides the high content 
power of flow cytometry with the spatial location of microscopy. Archival of thousands of 
images allows for continual mining of data sets as understanding of biology evolves and 
software programmes are updated. The ISMN-me assay is a novel approach to genetic 
toxicology assessment in the identification of Mode of Action and giving insights into the 
underlying mechanisms has potential for use as a chemical screening system in the 
pharmaceutical industry during the drug development pipeline.  
During 24hr exposures the ISMN-me system was able to identify differences between 
aneugenic MoA (inhibiting microtubule formation Vinblastine, microtubule destabilisation 
Carbendazim and tyrosine Kinase Inhibitor Crizotinib) Clastogen alkylating agent MMS, 
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nucleoside analogue ARA-C, topoII inhibitor Etoposide MoA. Whilst further work on these 
chemicals including 3hr exposures in presence and absence of metabolic activation (S9) and 
additional ECVAM chemical analysis is still needed to confirm the trends seen here, 
potential for the assay is promising. 
Use of this staining approach on the Amnis® Imaging flow cytometry platform allows for 
specific image analysis of individual cells. Combining the assessment of signal intensity per 
cell and cellular morphology offers additional MoA information alongside the MN assay. 
Within this body of work this approach allows for the direct comparison of P53, pH3 and 
ɣH2AX signals with direct respect to MN results, per cell, as well as direct biomarker cell 
cycle analysis. The 12 channel system of the platform, provides potential for further 
expansion of the multiplex assay to add in more mechanistic markers. This platform has the 
ability to reduce the subjectivity of traditional flow cytometry gating, due to the individual 
assessment of physical cellular images and additional features offered within the IDEAS® 
software such as pixel saturation, for each biomarker within each gate. Another significant 
advantage to this approach, is that it does not require cell lysis, therefore the histone foci 
and MN are maintained within the boundary of the cell cytoplasmic membrane. This could 
result in a reduction of misleading positives as providing MN localisation data ensures that 
each MN and cellular signal is associated with its own cell of origin. Furthermore, access to 
the cellular images provide additional morphological data which can be mined for additional 
information. This additional spatial information could aid further chemical categorisation 
based on mechanism of action in a fast, automated way. The ISMN-me assay has potential 
to be a powerful tool in helping elucidate chemical MoA.  
6.2.1 – Future Work and Developments 
ISMN-me assay is at the start of its journey and whilst the first initial steps of 
optimisation have been completed and feasibility of chemical MoA shown, more work is 
still required to identify the robustness of the assay and expand its usage into more 
specific DNA damage and high content image analysis assessment. As optimal machine 
setting, and gating strategies have been established re-analysis of Carbendazim and 
MMS need to be performed to confirm preliminary results. Repeats of experiments 
showing unexpected results i.e., Etoposide, need to be performed along with 
degradation experiments to identify the robustness of the assay. Having performed the 
initial 24 hour exposures of six chemicals an additional 3 hour exposure assay arm needs 
to be performed in the presence and absence of a metabolic activating system. Not only 
as part of the assay validation criteria, as suggested in the OECD guidelines, but also to 
assess potential biomarker and cell cycle nuances under a shorter exposure at higher 
concentrations. Further chemicals from the ECVAM list of model chemicals need to be 
tested to aid in elucidation of cell cycle biomarker related patterns for different chemical 
groups and assessment of the assays’ sensitivity and specificity in identification of true 
negative and positive compounds. Initial work has only been performed in the well 
defined TK6 cell line, assessment of the assay in other cell lines such as the metabolically 
active HepG2 cell line would further assess the robustness as well as flexibility and 
transferability of this assay.  
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Future developments of the assay lie in true miniaturisation of the assay i.e., culturing 
cells, compound treatments and staining all performed in 96 well plates to aid in assay 
automation. As the ImageStream has the capacity to accept up to 12 different 
fluorophores further expansion of the assay is possible. Potential avenues of additional 
biomarkers to explore could be: Use of an apoptotic marker such as a antibody against 
cleaved PARP or anti-cleaved caspase 3 for identification of cells that are triggered for 
cell death; Use of multiple phosphorylated P53 antibodies specific to different 
phosphorylation events for identification of particular DNA damage responses i.e., 
reactive oxygen species induced damage; biomarkers for specific DNA damage repair 
pathway assessment i.e., MGMT, OGG1. Further high content image analysis and re 
analysis of current data sets using the Deep Flow neural network, developed at Swansea 
University or IDEAS® 6.3 and Amnis AI software (Wills et al., 2021; Rodrigues, et al., 
2021) for data mining of biomarker metrics, MN responses and cell cycle analysis. 
Assessment of collected bi-nucleated ISMN-me files and compare analysis and 
biomarker responses to mononucleated data to assess the impact of Cyto-B on the 
biomarker responses.  
Use of the ISMN-me assay for chemical MoA assessment has barely begun and multiple 
avenues for further gains in efficiency and precision will come as software and 
understandings evolve. Suggestions above are just a small sampling of the plethora of 
possibilities for this platform.  
Here I have focused on the imaging flow cytometry platform, however the preparation 
and staining method of the samples has the adaptability to be moved into other 
microscopy based platforms allowing for further alignment with the more commonly 
used microscopy techniques within genetic toxicology. Adding to the tools in the genetic 
toxicology arsenal allows for the advent of more robust testing, allows for a greater 
understanding with less time and resource as well as help direct compounds into more 
appropriate drug projects i.e., oncology. Feed into in silico databases and generation of 
adverse outcome pathways to aid in animal use reduction. Whilst it is tempting to 
suggest with the variability of in vitro tests and the subjectivity of flow cytometry to 
simply abandon these Mode and Mechanism of action genetic toxicology assays and 
their development in favour of the exciting new world toxicogenomics. It is my opinion 
that advancements in safety science such as toxicogenomics should be used alongside 
the more traditional genotoxic end points and biomarkers to create a holistic view of the 
mode and mechanism minutia. Demonstrating the genetic effect and the physical 
biological response expanding our understanding. “Any fool can know. The point is to 
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